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Abstract
Background and aims: Increasing evidence suggests that epithelial to mesenchymal
transition (EMT) has a key role in breast cancer progression, underlying invasion,
metastatic dissemination and acquisition of therapeutic resistance. However, this role
is predominantly inferred from in vitro and animal studies and controversy regarding
EMT in human cancer remains. This thesis has two principle aims. Firstly, to clarify
the role of EMT in human breast cancer at the protein level. Secondly, to develop a
three-dimensional in vitro assay to investigate cell invasion.
Experimental Design: Two independent patient cohorts of high-grade, invasive
ductal breast cancer were interrogated for their expression of key EMT proteins
using quantitative immunofluorescence. This analysis was extended to paired lymph
node metastases for a subset of cases. EMT-related cell lines were selected based on
gene and protein expression data. These lines were investigated using light-
microscopy, immunohistochemistry and immunofluorescence in a three-dimensional
assay that models invasion across the basement membrane.
Results: Two transcriptionally-driven EMT programmes were identified. One
comprises vimentin, Snail and Slug and is uncoupled from E-cadherin down-
regulation. A second is characterised by up-regulation of WT1, Snail and Slug and
down-regulation of E-cadherin. Importantly, acquisition of this phenotype in lymph
node metastases predicts poor outcome. Some aspects of these programmes were
recapitulated in vitro.
Conclusions: These results suggest that EMT does occur in human breast cancer but
in a manner distinct to that seen in vitro. The examination of primary tumours with
their paired lymph node metastases may significantly contribute to understanding
EMT. Lastly, in vitro models can reflect aspects of tumour biology and may prove
invaluable in identifying clinically relevant, targetable pathways.
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Chapter 1: Introduction
Clinical challenges in breast cancer
Breast cancer is the leading cause of cancer-related deaths in women world-wide [1].
Over 40,000 new cases are diagnosed and over 12,000 women die each year in
England and Wales alone [2], Furthermore, the incidence of breast cancer in the UK
is rising, reflecting changes in population demographics, environmental factors and
increased diagnosis as a result of screening [3]. Nonetheless, breast cancer related
deaths have fallen by over 25% in the past two decades [4, 5], reflecting significant
improvements in management. Breast cancer related deaths are mainly due to the
currently incurable nature of metastatic spread of the disease. It is estimated that
-6% of women have metastatic disease at the time of their diagnosis whilst up to
50% will develop metastatic disease with time [6, 7]. The prognosis associated with
metastases is poor. Median survival is 18-24 months and 20% remain alive after 5
years [8]. Preceding metastatic spread, the development of treatment resistance or
recurrence is an important step in disease progression.
Systemic therapies in breast cancer
Surgery is the mainstay of treatment in early breast cancer across all age groups, in
combination with adjuvant radiotherapy for those patients who have had breast-
conserving surgery or those at high risk of local recurrence following mastectomy
[9], However, the use of systemic therapies, including endocrine, targeted and
chemotherapies, is also critically important and advances in the use of these
regimens is thought to be a major contributing factor to the observed decline in
breast cancer recurrence and associated mortality [10], The main aim of systemic
adjuvant treatment is to target micrometastatic disease thus reducing recurrence rates
and improving long-term overall survival. Some of these therapies are also used in
the neoadjuvant setting in order to downstage disease prior to breast conserving
surgery. In breast cancer, specific markers are routinely used in combination with
information regarding tumour size, grade, lympho-vascular invasion and nodal stage
to categorize patients into prognostic groups. Importantly, these markers are also
used to predict response to therapy and guide treatment planning [11],
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Oestrogen receptor status and endocrine treatments in breast cancer
Oestrogen receptor (ER) status is probably the most powerful predictor examined in
breast cancer. The majority of breast cancers, corresponding to -60% in women
under 50 years and -80% in women over 50 years, are ER positive [12]. Therefore,
inhibition of the ER receptor either directly (using weak oestrogen agonists such as
tamoxifen) or indirectly (by blocking the conversion of androgens to oestrogen using
aromatase inhibitors) is an important treatment option in both early and advanced
disease [13, 14].
The role of tamoxifen in reducing tumour recurrence and mortality in ER positive
tumours has been well established. Meta-analysis ofwomen with ER positive disease
treated with 5 years of tamoxifen has shown that annual recurrence rates are almost
halved (2.9% vs. 4.8%) whilst breast cancer mortality rates are reduced by a third
(19.3% vs. 27.1%). However, even with 5 years of treatment (which is superior to 1-
2 years), the 15-year recurrence and breast cancer mortality rates are still 33.2% and
25.6% respectively [15]. More recently several randomized clinical trials, including
the ATAC, BIG 1-98, TEAM, MA-17, NSABP B-33 and ABSCG-6 studies, have
examined the role of aromatase inhibitors (AI) in ER positive disease [16, 17]. These
studies have examined the effects of either AI versus tamoxifen or various sequential
approaches combining both agents. Although the most effective strategy remains to
be determined, these studies have found that incorporation of Als improves disease
free survival, especially in the poorer prognostic subgroups. Consequently,
postmenopausal women with ER positive disease are now treated with an AI for 5
years whilst patients treated with tamoxifen are either switched to an AI or receive a
period of extended treatment with an AI on completion of treatment with tamoxifen.
Tamoxifen remains the recommended treatment in pre- and perimenopausal women.
Progesterone receptor status
Progesterone (PR) is an oestrogen-regulated gene and consequently expression is
thought to indicate a functioning ER pathway and may assist in predicting response
to hormone therapy [11]. It has been shown that PR positive tumours are more likely
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to respond to tamoxifen in both early and advanced disease [18] but the significance
of PR expression in the absence ofER expression remains controversial [19, 20].
Human epidermal growth factor receptor 2 (HER2) status and targeted therapies
in breast cancer
The human epidermal growth factor receptor 2 oncogene (HER2, also known as
ERBB2) is a member of the epidermal growth factor receptor (EGFR) family of
tyrosine kinases. Amplification and overexpression of the HER2 glycoprotein is seen
in -20-30% of breast cancers [21] and is associated with high tumour grade, lymph
node involvement and increased rates of disease recurrence and mortality [22, 23].
HER2 status is predictive of response to targeted therapies, in particular trastuzumab
(Herceptin; Genentech, South San Francisco, CA, USA), a monoclonal antibody that
targets the HER2 extracellular domain. A key phase-Ill trial that compared
trastuzumab plus chemotherapy versus chemotherapy alone in HER2 positive
metastatic breast cancer demonstrated significant improvements in median time to
progression (7.4 vs. 4.6 months) and median overall survival (25 vs. 20 months) [24].
More recently, a series of prospective randomized clinical trials have shown that
trastuzumab also reduces recurrence and mortality rates in patients with early stage
disease [25-27], HER2 status may also be predictive of response to anthracycline-
and taxane-containing chemotherapy regimens [28, 29],
Novel targeted agents for use in HER positive breast cancer are currently being
developed with encouraging results [30], New antibody-based approaches against
HER2 include pertuzumab (Omnitarg, 2C4; Genentech), which targets a different
epitope on the HER2 extracellular domain [31]. Preclinical studies with pertuzumab
alone and in combination with trastuzumab demonstrate antitumour activity with
down-regulation of PI3K/Akt and MAPK signalling pathways [32], In addition, a
recent single-arm phase II trial of pertuzumab plus trastuzumab in 66 patients with
trastuzumab-refractory HER2 positive metastatic breast cancer demonstrated a
complete response in 5 patients (7.6%), partial response in 11 patients (16.7%) and
stable disease for at least 6 months in 17 patients (25.8%) [33]. Lapatinib (Tykerb;
GlaxoSmithKline, London, UK) is a small molecule inhibitor of HER2 and
EGFR/HER1 (an additional member of the EGFR family of tyrosine kinases) and is
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currently approved for use in metastatic breast cancer. A key phase-Ill trial
compared lapatinib plus capecitabine versus capecitabine alone in patients with
locally advanced or metastatic HER2 positive disease and reported a significant
improvement in median time to progression (8.4 vs. 4.4 months) [34], Updated
efficacy analyses have confirmed these findings, although no statistical difference in
overall survival is seen [35, 36], There is also emerging clinical evidence to support
the use of trastuzumab in combination with lapatinib in HER2 positive breast cancer
at various stages of disease [37, 38], Other strategies against HER2 are also being
developed and include anti-angiogenic therapies, heat shock protein 90 inhibitors,
PI3K and mammalian target of rapamycin inhibitors and IGF-1R inhibitors [30].
Chemotherapy in breast cancer
The combination of cyclophosphamide, methotrexate and fluorouracil (or CMF) has
been considered standard therapy for early breast cancer since the late 1970s [10].
Subsequently, a number of randomized clinical trials have examined the role of
anthracyclines and compared them with CMF regimens. A collaborative meta¬
analysis of many of these trials has shown that 6 months of anthracycline-based
polychemotherapy reduces annual breast cancer mortality by -38% in women less
than 50 years old and by -20% in women aged 50-69 years, irrespective of ER status
or other tumour characteristics. In addition, these regimens were significantly more
effective that CMF regimens [15]. The NEAT/SCTBG Br9601 trial is another
important study that demonstrated large and significant reductions in breast cancer
recurrence (30%) and mortality (36%) when CMF plus epirubicin was compared to
CMF alone [39], As a result of these and other studies [40, 41], anthracycline-based
regimens have replaced CMF as the mainstay of chemotherapy in women without
pre-existing heart disease.
Chemotherapy is of particular importance in ER negative disease where the option of
endocrine therapy is not available. A collaborative meta-analysis of -6000 patients
with ER-poor breast cancer treated with non-taxane-based polychemotherapy versus
no chemotherapy reported significant reductions in 10-year recurrence (33% vs. 45%
in women less than 50 years; 42% vs. 52% in women aged 50-69 years) and
mortality rates (24% vs. 32% in women less than 50 years; 36% vs. 42% in women
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aged 50-69 years) [42]. Despite substantial risk reductions, both recurrence and
mortality rates remain high in these patients and, as expected, tamoxifen had little
effect on recurrence or mortality in these patients.
Taxanes have also emerged as important chemotherapy agents in breast cancer.
Randomized trials comparing a taxane-containing regimen with a non-taxane-
containing regimen have shown significant improvements in disease free and overall
survival [43] and the use of anthracycline-taxane combinations is now an accepted
strategy, especially in high-risk patients [44], Furthermore, concerns regarding
cardiotoxicity and an increased incidence of leukaemia have led to the development
of regimens featuring a taxane without an anthracycline. Results from the US
Oncology 9735 and BCIRG 006 trials suggest equivalent efficiencies in taxane- and
anthracycline-comparator arms, with reduced side-effects seen in the taxane-based
regimens [45].
Whilst significant advances in chemotherapy treatments have been made, this is a
complex area with ongoing controversies. The use of anthracyclines and taxanes in
the adjuvant setting is also likely to pose a new challenge as an increasing number of
women present with metastatic disease having already been exposed to these agents.
Despite clear advances in the management of breast cancer, several important
clinical and scientific challenges remain. In part, these relate to understanding the
molecular and cellular basis of cancer progression, in particular the development of
resistance and ultimately metastatic spread [7, 46]. Flowever, this is complicated by
the fact that breast cancer is not a single disease but is highly heterogeneous at both
the molecular and clinical level.
Breast cancer is a heterogeneous disease defined by molecular subtypes
Global gene expression analyses of human breast cancers have identified distinct
tumour subgroups [47-49], Two subtypes are ER negative and include a subgroup
defined by increased expression of HER2 and a subgroup with characteristics of
basal/'myoepithelial cells. These tumours are associated with poor clinical outcomes.
A third subtype is ER positive and termed 'luminal' and can be genetically divided
into good outcome 'luminal A' tumours and poor outcome 'luminal B'. The fourth
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subgroup resembles normal breast. These studies indicated that breast cancer is not a
single disease with variable morphological features and biomarkers but rather a
group of molecularly distinct neoplastic disorders. It is not surprising that diagnosis
based on subtype adds significant prognostic and predictive information to standard
parameters for patients with breast cancer [50],
Importantly, comparisons between mouse mammary carcinoma models and human
breast tumours has led to the identification of an additional human molecular
subtype, termed claudin-low. These cancers are characterised by low expression of
genes involved in tight junctions and cell-cell adhesions, including claudins and E-
cadherin, and relatively high expression of mesenchymal markers including
vimentin. In addition, these are moderate-high grade invasive ductal carcinomas and
appear distinct to lobular carcinomas despite their low expression of E-cadherin [51].
Metaplastic breast cancers (MBC) are aggressive, triple-negative (ER, progesterone
(PR) and HER2 receptor negative) tumours [52], These tumours express some
markers associated with basal-like cancers and have been proposed to represent a
form of basal-like cancer [53], However, distinct clinical features such as
chemoresistance suggest that MBCs may represent a unique subtype [54], More
recently, transcriptional profding has shown that claudin-low cancers are related to
metaplastic breast cancers [55]. Both of these triple-negative subtypes are
characterised by low expression of genes responsible for cell-cell adhesion and high
expression of stem cell and epithelial to mesenchymal transition (EMT) related
genes.
Genetic and epigenetic events drive the initiation and progression of breast
cancer
The exact aetiology of breast cancer is unclear. However, a family history of breast
cancer remains one of the strongest predictors of risk. Mutations in high-penetrance
genes such as BRCA1, BRCA2 and TP53 are thought to underlie -25% of inherited
susceptibility [56] whilst mutations in moderate- and low-penetrance genes such as
FGFR2 (fibroblast growth factor receptor 2), CASP8 (caspase 8) and LSP1
(lymphocyte-specific protein 1) underlie the majority of cases [57-59], Nonetheless,
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the mechanisms by which these genetic abnormalities influence breast cancer
development remain to be fully understood.
In addition to genetic events, epigenetic changes are thought to contribute
significantly to cancer progression. These can be defined as stable molecular
alterations in the cellular phenotype of a cell which are heritable during somatic cell
divisions but do not involve changes in DNA sequence. In addition, epigenetic
changes occur more frequently than genetic changes, are potentially reversible and
occur at defined regions within a gene [60].
DNA methylation is an established epigenetic mechanism and hypermethylation of
gene promoter regions has been identified as a frequent mechanism of loss of gene
function in cancer [61]. DNA methylation is a post-replication modification that
occurs at the pyrimidine ring of cytosines that are located 5' to a guanosine [62].
During evolution, the number of CpG dinucleotides in the genome has been
selectively reduced due to the inherent mutagenicity of methylated cytosines [63].
However, CpG dinucleotides occur with a much higher frequency within CpG
islands, small stretches of DNA (-500-2000 bp) located in the 5'-regions of most
genes [64, 65], Whilst CpGs throughout the genome are generally methylated, CpGs
within CpG islands and in particular those associated with gene promoters are
usually unmethylated, allowing transcriptional activity to occur. In human cancers
including breast, CpG islands may become methylated resulting in the silencing of
gene expression [66], DNA methylation may be of particular relevance to a claudin-
low signature that comprises 9 down-regulated genes, previously known to be de
novo methylated in breast and other cancers (see Table 5.1). Figure 1.1 illustrates
how accumulated genetic and epigenetic alterations, combined with clonal expansion
and selection, result in the initiation and progression of breast cancer. Corresponding
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Figure 1.1. Breast cancer initiation and progression. A schematic illustration of
normal, in situ, invasive and metastatic carcinoma is shown. Normal breast ducts are
composed of a layer of luminal epithelial cells, myoepithelial cells and basement
membrane. A number of cells exist within the surrounding stroma including
fibroblasts, leukocytes, myofibroblasts and endothelial cells. As genetic and
epigenetic alterations accumulate, epithelial cells acquire the ability to invade the
basement membrane and ultimately invade to distant sites within the body.
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Grade I invasive Grade III invasive Nodal metastasis
ductal carcinoma ductal carcinoma
Normal TDLU
comedo necrosis
Figure 1.2. Histological changes in cancer progression. The normal architecture of
the terminal duct lobular unit (TDLU) is shown. Luminal epithelial cells surround a
hollow lumen and in turn are surrounded by a layer ofmyoepithelial cells that lie in
direct contact with the basement membrane. Ductal carcinoma in situ (DCIS), where
changes are contained by basement membrane, is a pre-invasive lesion with several
architectural subtypes. Solid sheets of highly atypical, pleomorphic cells with
intraluminal necrosis characterize comedo DCIS. Invasive ductal carcinoma is the
commonest type of human breast cancer, accounting for -70% of cases. The images
shown are 4x, lOx and 20x magnification (top panel, left to right) and lOx, 20x and
4x magnification (bottom panel, left to right). Reproduced with kind permission from
Dr. J. Thomas, Consultant Pathologist, Western General Hospital, Edinburgh.
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Epithelial to mesenchymal transition, cell-cell contacts and mesenchymal markers
The trans-differentiation of cells from an epithelial to a mesenchymal phenotype,
defined as EMT, is essential in embryogenesis and normal development [67].
Increasing evidence supports a role for EMT in the progression ofmany cancer types
including breast, with critical roles in invasion and metastatic dissemination [68, 69]
(Figure 1.3). EMT involves loss of cell-cell contacts and re-organisation of the actin
cytoskeleton, resulting in loss of apical-basal polarity and acquisition of a spindle¬
like mesenchymal morphology [70]. EMT is associated with decreased expression of
epithelial-specific proteins, including E-cadherin. This is possibly one of the most
important consequences of EMT that results in the changed behaviour of tumour
cells [71, 72], Various mechanisms regulate the expression of E-cadherin in breast
cancer. Somatic mutations of E-cadherin have been reported, although exclusively in
the lobular subtype [73], Hypermethylation of the CpG islands in the promoter
region of CDH1 has also been reported, occurring in all breast cancer types and
associated with poorer clinical outcome [74, 75], However, the most frequently
described mechanism of E-cadherin loss is transcriptional repression [71]. Specific
repressors which belong to a family of zinc finger binding proteins have been
identified and include Snail, Slug, Zebl, Zeb2 and Twist [76],
Cell-cell contacts are important in determining the normal structure and function of
many epithelial tissues. These consist of three main adhesive structures: tight
junctions (TJs), adherens junctions (AJs) and desmosomes [77]. TJs have two
principle roles. Firstly, they regulate paracellular permeability, a function which
relies on the ability of claudin proteins to form size and charge-selective pores [78],
Secondly, TJs form a physical barrier that prevents the intramembranous movement
of lipids and proteins and contributes to the development of apico-basal polarity [79].
Apico-basal polarity underlies terminal differentiation of epithelial structures by
orientating the trans-Golgi apparatus. This in turn sorts proteins to either the apical or
basolateral membrane, ultimately allowing appropriate electrochemical gradients to
be established [80], E-cadherin is the main transmembrane protein of the AJ and
initiates intercellular contacts by binding to cadherins on opposing cells (Figure 3.1)
[81]. Cadherins also bind directly and indirectly to many cytoplasmic proteins, in
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particular to members of the catenin family. The catenins in turn regulate
organisation of the actin cytoskeleton, cadherin stability and intracellular signalling
pathways that control gene transcription [82], The functions and protein components
of TJs and AJs make these particularly relevant to EMT and dysregulated cell-cell
contact are increasingly implicated in the progression of various cancer types [83,
84],
In many epithelial cancers, loss of E-cadherin is accompanied by increased
expression of N-cadherin and other mesenchymal cadherins, and is referred to as a
'cadherin switch' [85, 86], This is thought to result in a significant change in the
adhesive properties of cancer cells, so that they lose their affinity for epithelial
neighbours and gain affinity for stromal cells [87]. In addition, the cadherin switch is
associated with increased cell motility, matrix metalloproteinase (MMP) secretion,
invasiveness, and poor prognosis [88, 89], This is thought to result, at least in part,
from the interaction of N-cadherin with fibroblast growth factor receptors, which
results in sustained mitogen-activated protein kinase (MAPK) pathway activity [85,
90]. Importantly, transcriptional repressors of E-cadherin, including Snail, Slug and
Zeb2 can also induce N-cadherin, suggesting that the cadherin switch is part of a
transcriptionally driven reprogramming of cancer cells [91]. Vimentin and the
extracellular matrix component fibronectin are two other mesenchymal proteins
commonly expressed by cancer cells following EMT. Expression of vimentin is
associated with changes in cell shape and cytoskeletal arrangement as well as
changes in motility and adhesion [92-94]. The changes in extracellular matrix
function and composition associated with cancer development are in part due to
increased production of fibronectin [95], by both stromal and tumour cells. This is
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Figure 1.3. EMT is a dynamic process that reflects epithelial plasticity. Cells
undergoing EMT during tumour progression are characterised by loss of cell-cell
adhesion and polarity, cytoskeletal rearrangements, increased motility and increased
invasive capacity. This is accompanied by a change in morphology. Cells that
undergo EMT may revert to an epithelial phenotype by mesenchymal to epithelial
transition (MET), and stable MET may occur at established distant metastases.
Adapted from [76],
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Important signalling pathways in EMT
Transforming growth factor-^ (TGF-P) is an important inducer of EMT during
development [97] and is also over expressed in many cancers where it is thought to
drive EMT [98, 99], However, tumour suppressor roles have also been described
such that the role of TGF-P in cancer and its ability to induce EMT appears to be
context dependent [100, 101]. TGF-(3 is known to co-operate with a number of
signalling pathways including Wnt [102, 103], Ras/receptor tyrosine kinases [104,
105], Hedgehog [106] and Notch [107] to induce a complete EMT. These pathways
also have roles in the renewal and proliferation of stem cells [108, 109].
Consequently, it is hypothesized that co-activation of these pathways may modify the
cellular response to TGF-P, either promoting or inhibiting EMT [110]. This
hypothesis is also in keeping with the emerging links between EMT and the
acquisition of stem cell characteristics [111].
Binding of TGF-P to its receptors results in the formation of a heterotetrameric
signalling complex involving type 1 and type II receptors, resulting in the activation
of Smads- intracellular transcription factors and transducers of TGF-P signalling
[112]. The receptor-activated Smad2 and Smad3 proteins associate with cytoplasmic
Smad4 and translocate to the nucleus to regulate gene transcription [100], However,
Smads have a low affinity for DNA and interact with transcriptional cofactors to
improve their affinity for target genes. In addition, the availability and activity of
cofactors in the nucleus determines the cellular response to TGF-p and whether
target genes are activated or repressed [100],
Recent studies have shown that many EMT promoting transcriptional factors
including Snail, Zebl/2, Twist and P-catentin can act as Smad cofactors [113-116],
Interaction between these transcription factors and Smads results in the formation of
EMT promoting Smad complexes (EPSC) which drive EMT by repressing epithelial
genes including E-cadherin and up-regulating mesenchymal genes including
vimentin [110]. This is an important finding as EMT promoting transcriptional
factors are of significant and current interest as drivers of EMT (discussed further in
chapter 3) and the formation of EPSC represents a point of convergence between a
number of signalling pathways (Figure 1.4). In addition, Wnt, Ras and TGF-P
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signalling pathways can cooperate to activate and stabilize Snail, Zebl/2, P-catentin
and other EMT promoting transcriptional factors. For example, the up-regulation of
Snail by TGF-p is mediated by transcriptional cooperation between Smads and the
high-mobility group A protein 2 (HMGA2) [117], itself a transcriptional target of
Ras signalling [118]. Growth factor mediated activation of Ras also cooperates with
TGF-P to regulate Snail expression [119]. Snail is also directly targeted by Wnt
signalling, and indirectly, through glycogen synthase kinase-3beta (GSK-3P)
mediated phosphorylation and degradation [120, 121].
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Figure 1.4. Transcriptional crosstalk between key signalling pathways in EMT. The
binding of TGF-(3 to its receptor results in the phosphorylation and nuclear
translocation of Smad proteins where they interact with cofactors to regulate gene
transcription. Cofactors include EMT promoting transcription factors (including
epithelial repressors (EpR) such as Snail, Zeb and Twist, and mesenchymal
activators (MeA) such as P-catenin). Interaction between Smads and these cofactors
results in the formation ofEMT promoting Smad complexes (EPSC) which drive
EMT. The Wnt, Ras and TGF-P signalling pathways also cooperate to activate EMT
promoting transcription factors such that the formation ofEPSC represents an
important point of convergence between them. The availability of Smad cofactors, as
influenced by the above pathways, may determine whether EPSC are formed and
whether or not EMT results. GSK-3P is an important nodal protein whose activity is
regulated by Wnt and Ras pathways and which in turn negatively regulates Snail and
P-catentin stability. Adapted from [110].
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Evidence for epithelial to mesenchymal transition in human breast cancer
Until recently, insufficient evidence for EMT in clinical samples has contributed to
the ongoing controversy regarding the relevance ofEMT in human cancer [122-124].
Furthermore, the role of EMT in human cancer has predominantly been inferred
from in vitro studies using cell type-specific markers [125-127], This makes tracing
the actual origin of tumour associated mesenchymal cells difficult as, having
undergone EMT, tumour epithelial cells will be phenotypically similar to normal
stromal cells.
The description of small aggregates of tumour cells detaching from the invasive front
of colorectal carcinomas has provided morphological evidence for the existence of
EMT in human cancer [128]. Importantly, these morphological changes have been
associated with loss of E-cadherin expression and deregulated Wnt signalling [129].
In breast, a recent immunohistochemical analysis of invasive ductal carcinomas
reported significant associations between nuclear expression of Slug and loss of
membranous E-cadherin protein expression [130]. In a second immunohistochemical
study comprising 479 invasive human breast carcinomas, unsupervised hierarchical
clustering identified up-regulation of additional EMT markers in a subset of cancers.
Similarly, this correlated with loss of E-cadherin protein expression [131]. However,
whilst these studies examined clinical specimens for evidence of EMT, neither
formally investigated the relationship between morphology and the observed changes
in protein expression.
In order to directly visualize EMT in cancer progression in vivo, stromal- and
epithelial-specific cre-transgenic mice have been developed [132]. This genetic
system allows epithelial and stromal cells to be tracked independently, without
relying on cell type-specific markers. Three oncogene-driven (myc, neu and PyMT)
breast cancer models, reflecting different molecular and cellular aspects of breast
cancer, were selected. Investigation of these models using stromal- and epithelial-
specific cre-transgenic mice showed that EMT was common in myc-induced tumours
but rare in neu- and PyMT-initiated tumours. Interestingly, EMT was not a pre¬
requisite for invasiveness and metastases in this model as mice with neu- and PyMT-
induced cancers had significant amounts of lung metastases. Conservation of gene
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expression between tumour epithelial and stromal cells has been used as a marker of
the likelihood of a common progenitor between these populations. Using this
approach, Trimboli and colleagues subsequently showed that the incidence of EMT
in invasive human breast cancers is rare (although when it occurs it is associated with
amplification ofMYC) [132], A similar study that evaluated nuclear polymorphisms
between tumour epithelial and stromal populations also suggested that mesenchymal
cells within the stroma infrequently originate from an epithelial lineage [133]. Taken
together, these studies suggest that EMT is a relevant phenomenon in at least a
proportion of human cancers.
EMT and chemoresistance
There is increasing evidence in a variety of cancer types to suggest a molecular and
phenotypic link between EMT and chemoresistance. Oxaliplatin resistance in
colorectal cancer cell lines was associated with spindle morphology and expression
of EMT markers [134], Similar changes were seen in paclitaxel resistant ovarian
carcinoma cells [135]. Another study found that up-regulation of the transcription
factor Twist in breast cancer cell lines is associated with EMT and resistance to
paclitaxel [136], A second study in breast cancer cell lines found that multidrug
resistance following adriamycin-induced EMT was partially reversed by depletion of
Twist. In addition, Twist RNA interference improved the efficiency of adriamycin
treatment in relation to tumour volume, development of metastases and survival in a
mouse model of breast cancer [137], Similarly, a study in resistant pancreatic cancer
cell lines has shown that silencing of an additional EMT-related transcriptional
repressor, Zebl, increases the expression of epithelial markers and restores drug
sensitivity [138], These results support the need to target specific cancer
subpopulations including those undergoing EMT in the prevention of recurrence.
Cancer stem cells in breast cancer
The role of stem cells in embryogenesis and in the renewal and maintenance of adult
tissues has led to the exciting concept that similar 'cancer' stem cells (CSC) might
play an important role in cancer development and progression [139],
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General aspects ofembryonic and somatic stem cells
As the concept of CSCs is derived from the general model of stem cells, embryonic
(ESC) and adult or somatic stem cells (SCC) will be briefly considered first.
Regardless of their source, stem cells are characterised by general properties- i) self-
renewal; ii) asymmetric division to produce either a copy of themselves or a
hierarchy of progressively more differentiated daughter cells and iii) homeostatic
control [140]. However, whilst ESC can generate all three germ layers and ultimately
all differentiated cells in the body, SCC have a more restricted potential and typically
generate cell types of the tissue in which they reside [141]. In addition, ESC and
SCC utilize different signalling pathways for their maintenance [142],
Cancer stem cells- identification and uncertainties
The CSC hypothesis proposes that there is a small subpopulation of cells within a
tumour capable of initiating and sustaining tumour growth. These cells have been
interchangeably described as CSCs or 'tumourigenic' or 'tumour initiating cells'
[143], These cells may play a key role in resistance to treatment in breast cancer (see
subsequent section). Whilst increasingly accepted it is important to note that the CSC
hypothesis is an area of ongoing controversy in terms of how to define CSCs, their
origin (including their relation to SCCs) and even in terms of the validity of the
CSCs hypothesis [144, 145],
CSCs have been isolated based on the presence of cell surface markers (using flow
cytometry), with further characterization using sphere culture assays and
transplantation into immune-compromised mice [146]. Sphere culture assays make
use of an in vitro culture system where single cells are grown in suspension. Some
stem or progenitor cells cultured in this way will form spherical colonies termed
spheroids (or mammospheres in the context of breast), the self-renewal capacity of
which is then tested by evaluating the ability of spheroid-derived cells to form new
spheres containing multipotent cells [147]. The first convincing evidence for the
existence of CSCs was found in acute myloid leukaemia (AML) [148], In this study
a rare subpopulation (0.2-100 cells per 106) of cells expressing the cell surface
markers CD34+CD38" were isolated. 5000 of these cells were sufficient to induce
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leukaemic transformation in immune-compromised mice whilst much greater
numbers of CD34+CD38+ cells could not. Subsequently, Al-Hajj and colleagues
demonstrated evidence for the existence of CSCs in breast cancer [149]. In this
study, a subpopulation of highly tumourigenic CD44+CD24"/low cells was identified
from metastatic pleural effusions associated with breast cancer. These cells formed
multi-lineage mammospheres in vitro and as few as 100 CD44+CD24"/low cells were
sufficient to induce tumour formation in immune-compromised mice whilst again
much larger numbers of non-CSCs could not. More recently, other groups have
identified putative CSC populations in a variety of solid cancers including brain
[150], colon [151], hepatocellular [152] and prostate cancer [153]. CSCs and SCCs
both demonstrate shared characteristics (i.e. a capacity for self-renewal and the
generation of heterogeneous progeny) whilst others including asymmetry and rates of
cell division, the necessity for a specific microenvironment to maintain an
undifferentiated state [140] and homeostatic control are not so clearly shared [154].
Whilst distinct, the similarity of roles and the similarity of surface marker expression
between some CSCs (for example leukaemia and brain CSCs [155]) and their normal
counterparts supports the hypothesis that CSCs can originate form SCCs [156, 157].
There is also evidence for shared signalling pathways between some SCCs and CSSs
[158, 159], The origin of CSCs remains an area of debate and is discussed in further
detail subsequently.
The role of cell surface markers in the identification of CSCs is well established.
Several biomarkers have been identified, some of which are common to different
cancer types [155]. If these biomarkers characterize a unique and homogenous
population, then this population should demonstrate all the characteristics of CSCs
without further refinement. However, this is generally not the case. For example, in
pancreatic cancer, distinct CSC populations appear to confer tumour growth and
metastatic activity [160]. In addition, the expression of biomarkers is often much
more prevalent than would be expected given that they are postulated to represent a
'rare' subpopulation. For example, the CD44+CD24"/low population identified by Al-
Hajj and colleagues represents 11-35% of the total population examined [149].
Furthermore, subsequent examination of these cells suggests that only 10-20% have
self-renewal capacity [161]. Whilst improved biomarker specificity is required it
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seems unlikely that CSC populations represent a single, homogenous population. In
support of this, single CSCs have not been shown capable of tumour initiation whilst
a single stem cell can repopulate the normal mammary gland in mice [162], The
difficulties in identifying and defining CSC populations must be considered when
interpreting data from these studies.
Cancer stem cells underlie intrinsic resistance
Patients may relapse with time for various reasons. Firstly, multiple subpopulations
of cancer cells within a tumour may gradually acquire resistance. In this situation,
the relative proportions of subpopulations of cancer cells in residual tumours should
be unchanged before and after treatment. Alternatively, a specific subpopulation may
be intrinsically resistant to treatment, in which case the relative proportion of this
subpopulation should increase after treatment (Figure 1.4). In support of the second
hypothesis, it has been shown that the gene expression pattern of residual tumour
cells after docetaxel is different to that of the initial tumour [163], These findings
provide the beginning of an explanation for the relative failures of conventional
chemotherapies and even the observed enhancement of tumour progression seen in
some settings [164],
Gene expression signatures based on CD44+CD24"/low surface marker expression
have already been used as independent prognostic predictors in breast and other
cancers [165]. More recently, the role of CD44+CD24"/Imv cells in human breast
cancer resistance has been examined [166], "Neoadjuvant chemotherapy in HER2-
negative patients significantly increased the proportion of CD44+CD24"/low cells and
was associated with increased mammosphere forming efficiency (MSFE) in vitro. In
addition, cells from residual tumours were associated with increased tumour
outgrowth when implanted into immunocompromised mice. These data provide
clinical evidence for the existence of a subpopulation of intrinsically resistant CSCs
in breast cancer. In the same study, lapatinib treatment of patients with FIER2-
positive tumours was associated with a decrease in the proportion of CD44+CD24"/ltm
cells and their MSFE. Lapatinib is an EGFR (epidermal growth factor
receptor)/HER2 tyrosine kinase inhibitor and EGFR signalling has been shown to
play a role in self-renewal [167], These data may partially explain the significant
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survival benefit seen when trastuzumab (which also targets EGFR/HER2 signalling)
is given in conjunction with chemotherapy in comparison with chemotherapy alone
[168]. In addition, lapatinib given in combination with chemotherapy has been
shown to improve progression-free survival in women with HER2 positive metastatic
disease [34]. These data suggest that the use of specific pathway inhibitors in
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Figure 1.5. Acquired versus intrinsic resistance. There are two broad, although not
exclusive, explanations for treatment resistance and clinical recurrence.
Subpopulations of cancer cells may be equally susceptible to treatment but continued
exposure results in the acquisition of resistance by some populations (top panel).
Alternatively, a relatively rare, tumourigenic subpopulation may be intrinsically
resistant to treatment. In this case, the relative proportions of cells in residual
tumours with tumourigenic properties would be expected to increase with treatment
(bottom panel).
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Further attempts to understand the regulatory pathways underlying subpopulations of
residual tumour cells after conventional treatments have been made [169], A gene
signature common to both CD44+CD24"/low and mammosphere-forming (MS) cells
was found to be predominantly expressed in tumours of the recently identified
claudin-low subtype. In addition, both this signature and a previously defined
claudin-low signature [51] were up-regulated in residual tumours after treatment with
endocrine- (letrozole) or chemo-therapy (docetaxel). Importantly, the claudin-low
subtype is characterised by the expression of many EMT associated genes. The
increased expression of EMT markers in post-treatment tumours, including vimentin,
Snail and MMP2, was confirmed. EMT has been increasingly implicated in cancer
progression (discussed in detail below) and may contribute to treatment resistance.
These data suggest that subpopulations of residual tumour cells after conventional
treatments display not only CSC features but also evidence of EMT. Therefore,
targeting EMT related pathways may provide an additional therapeutic strategy
against recurrence. The full clinical significance of this work remains to be seen as
there is no report on the long-term outcome of those patients with up-regulated
expression of both the CD44+CD24~/low-MS-forming and claudin-low signatures. In
addition, correlations between the claudin-low subtype and outcome have yet to be
described by other groups. However, other studies support the link between EMT
and CSCs. In one study, circulating tumour cells were isolated from breast cancer
patients treated with chemotherapy and classified as responders versus non-
responders. The non-responders were found to express both EMT and CSC
signatures [170], In addition, claudin-low tumours are related at the gene expression
level to MBCs, which are associated with chemoresistance and poor outcome [55].
The association between EMT and chemoresistance has been briefly discussed.
Taking these associations further, a study in ovarian cancer cells has shown that
induction of EMT mediates radio- and chemo-resistance through the induction of
stem cell promoting genes [171].
The clinical relevance of these studies is accumulating and the use of multiplex
assays that identify markers of 'sternness' and EMT with prognostic and predictive
value is likely to become increasingly apparent. In a recent study, co-expression of
the stem cell markers ALDH1 and CD44 was found to significantly correlate with
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poor clinical outcome in human breast cancer, independently of other established
prognostic markers [172],
EMT and CSCs: two closely linked phenomena
In addition to the emerging link between EMT and chemoresistance, recent evidence
suggests a direct link between EMT and the acquisition of stem cell-like properties.
Mani and colleagues clearly demonstrated this in their series of recent experiments
where they showed that immortalized human mammary epithelial cells (HMECs)
that have undergone EMT also express stem-cell markers and increased MSFE [111].
In addition, stem cell-like cells isolated from human reduction mammoplasties and
breast carcinomas were shown to express markers of EMT whilst transformed
HMECs that had undergone EMT formed both mammospheres and tumours with
greater efficiency. A subsequent study aimed to determine specifically the origin of
tumourigenic CD44+CD24~/low cells [173]. This study showed that CD44+CD24"/lovv
cells can originate from primary CD44lowCD24+ HMECs following their neoplastic
transformation. Similar findings were seen with the untransformed breast epithelial
cell line MCF10A. Importantly, in both HMECs and MCF10A cells, acquisition of
the CD24" phenotype was associated with a mesenchymal morphology and
expression ofEMT markers. This study supports the findings ofMani and colleagues
and shows that CSCs can originate in the absence of normal stem cells. An additional
study provides further evidence that EMT can generate CSCs, and found that these
cells demonstrate enhanced resistance to drugs and radiation [174],
A recent study uses normal human mammary epithelial hierarchy as a framework for
understanding the cellular origins of the molecular subtypes of breast cancer [175],
Gene signatures characterising the hierarchal subpopulations in normal breast were
compared to those characterising the molecular subtypes of breast cancer.
Interestingly, a 'stem cell signature' was enriched in the EMT-related claudin-low
subtype, further supporting a link between sternness and EMT. Clearly, therapeutic
strategies that target CSCs are required. In a key study, Gupta and colleagues exploit
the ability of EMT to enrich populations for CSCs in order to implement high-
throughput screening for selective CSC inhibitors [72], They demonstrate for the first
time that CSCs exhibiting features of EMT can be selectively targeted.
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miRNA expression profiles suggest that CSCs can originate from their normal
counterparts
An area of ongoing controversy surrounding CSCs regards their origin [176], Mani
and colleagues have shown a clear link between EMT and the generation of stem
cell-like cells and Morel and colleagues have shown that these cells can originate
from transformed, differentiated cells of CD44lowCD24+ lineage [111, 173], This
implies that there is no prerequisite for transformation of normal stem cells.
Nonetheless, normal stem cells have been implicated in the origin of CSCs. This is
based on the following observations. Firstly, CSCs and normal stem cells share many
properties. Secondly, the long lifespan and multiple mitoses undergone by normal
stem cells would appear to make them potential targets for malignant transformation
[177],
Comparison of microRNA (miRNA) expression in breast stem cell populations has
led to the identification of shared regulators between normal and CSCs [178].
miRNAs are small noncoding RNAs that regulate the translation of messenger RNA
(mRNA), either inhibiting or degrading the target mRNA [179]. In addition,
miRNAs are critical regulators of self-renewal and differentiation [180, 181] and
expression profiles correlate with clinical outcomes including tumour stage and
prognosis [182]. Shimono and colleagues have identified three miRNA clusters,
miR-200c-141, miR-200b-200a-429 and miR-183-96-182, which are down-regulated
in both human breast CSCs and normal stem cells. Importantly, expression of miR-
200c inhibited the formation of differentiated mammary structures by normal stem
cells and tumour formation by CSCs in vivo [178]. This identification of molecular
and functional links between normal and CSCs may be interpreted as evidence that
CSCs can originate from their normal counterparts.
miRNA expression profiles strengthen the emerging links between EMT, CSCs and
cancer progression
The findings of Shimono and colleagues [178] strengthen the emerging link between
EMT and CSCs as the miR-200 family has recently been shown to prevent EMT by
suppressing the expression of Zebl and Zeb2, two transcriptional repressors of E-
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cadherin [183, 184], In addition, re-expression of miR200c in ovarian cancer cell
lines has been shown to restore E-cadherin expression and sensitivity to microtubule-
targeting chemotherapy [185].
Other miRNAs with links to EMT pathways have been identified as promoters of
metastases in breast cancer. miR-9 is up-regulated in human breast cancer and can
directly target CDH1. In addition, overexpression of miR-9 promotes the formation
of pulmonary metastases in mice and correlates with grade and metastatic status in
human cancers [186]. Similarly, miR-lOb, whose expression is induced by Twist, is
highly expressed in metastatic human breast cancer [187], Silencing miR-lOb using
specific antagomirs (modified anti-miRNA oligonucleotides) significantly suppresses
the formation of metastases in a mouse model and demonstrates an additional
potential therapeutic strategy for targeting metastases [188].
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Aims
Increasingly, links are being established between EMT, CSCs and important clinical
events, namely recurrence of disease and metastatic spread (Figure 1.5). In addition,
therapeutic strategies that target EMT pathways and CSCs are beginning to emerge
and precise, multiplex assays that identify markers related to these biological events
with correlations to clinical outcomes are envisaged for the future. However, if EMT
and its related processes are to be successfully targeted, their roles as well as their
underlying mechanisms in human cancer need to be fully understood.
Therefore, the aims of this thesis are:
• To clarify the role of EMT in human breast cancer at the protein level. This
will involve an analysis of the expression of key protein markers of EMT in
primary tumours (Chapter 3), and, for a subset of these, in paired LN
metastases (Chapter 4).
• To develop an in vitro assay for the investigation of a series of EMT-related
breast cancer cell lines, with a particular focus on the mechanisms underlying






Figure 1.6. EMT and 'sternness' are two important biological processes that closely
underlie clinical resistance and metastatic spread. The exact links between these
processes remain to be fully clarified.
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Chapter 2: Materials and Methods
Patient cohort selection for tissue microarray
Invasive ductal carcinomas of no special type (1DC-NST) were examined as these
are the commonest form of breast cancer. The first patient cohort (set 1) was
enriched for HER2 positive invasive breast cancers [189], therefore minimising the
number of invasive lobular carcinomas (ILC) [190]. This is important as down-
regulation of E-cadherin is much more common in ILC than 1DC-NST [191-193], In
addition, hierarchical cluster analysis has clearly demonstrated that ILC and IDC-
NST are molecularly distinct [194] and therefore down-regulation of E-cadherin is
likely to occur through distinct mechanisms. Set 1 consisted of 122 patients with
primary breast cancer who were subsequently treated with trastuzumab in the
Edinburgh Breast Unit as previously described [189].
The second patient cohort (set 2) was enriched for large, high-grade cancers that had
already given rise to lymph node (LN) metastases. The presence of these poor
prognostic features [195] maximises the identification of EMT events as EMT is
believed to contribute to invasion and metastatic dissemination [68], This study
population was derived from an original population of 521 patients with primary
breast carcinomas treated in the Edinburgh Breast Unit from 1999 to 2002,
previously described [196]. All received axillary LN dissections as part of surgery
for large or high-grade invasive breast carcinomas, in the absence of known distant
metastases. Out of these 521 cases, 156 had paired LN metastases and were selected
for tissue micro-array (TMA) construction. Exclusion of 13 cases with insufficient
tumour left 143 primary carcinomas with paired LNs for inclusion in the TMA.
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Table 2.1. Available patient characteristics for set 1. Median follow-up was 21.6
months. The Nottingham Prognostic Index (NPI) is based on tumour size, LN status
and histological grade. 3 prognostic categories may be derived accordingly: NPI <























Node stage at diagnosis












Anthracycline containing 66 (54.1)
Taxane containing 53 (43.4)
NK 3 (2.5)
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<20 (Tl) 49 (34.3)
21-50 (T2) 84 (58.7)
> 50 (T3) 9 (6.3)
NK 1 (0.7)













Breast cancer tissue microarray construction
The characteristics of the patient cohorts used to construct the two TMA sets in this
study are summarised in Tables 2.1 (set 1) and 2.2 (set 2). Construction of these sets
was approved by the Lothian Research Ethics Committee (08/S1101/41). Tumour
areas were selected for TMA construction on H&E slides and 0.6 mm cores were
placed into three separate TMA replicates for each sample, as previously described
[198]. H&E slides for both TMA sets were subsequently re-examined and
phenotyped by a senior pathologist (Dr. J. Thomas) to ensure that only IDC-NST
were included in the analysis.
Immunofluorescence
AQUA (Automated Quantitative Analysis) methodology has been described
elsewhere [189, 199, 200]. Briefly, antigen retrieval for all epitopes was carried out
using heat treatment under pressure in a microwave oven for 5 min in citrate buffer
(82ml 0.01 M sodium citrate: 18ml 0.01M citric acid) pH 6.0. Slides were incubated
with primary antibodies for 1 hour at room temperature. Details of primary
antibodies are summarized in Table 2.3. Rabbit primary antibodies were incubated
overnight with mouse anti-pancytokeratin (Invitrogen, #18-0059, 1:25) to visualise
epithelial cells. Mouse primary antibodies were incubated overnight with rabbit anti-
pancytokeratin (Dako, #Z0622, 1:150) and rabbit anti-pancadherin (Cell Signalling,
#4068, 1:50). The epithelial compartment was then visualised with Cy3 (Invitrogen,
anti-rabbit #A21422; anti-mouse #A21428, both used at 1:25). DAPI (4',6-
diamidino-2-phenylindole) counterstain (Invitrogen, #P36931) was used to identify
nuclei and Cy-5-tyramide (HistoRx, #AQ-EMM 1-0001, 1:50) was used to detect
protein 'targets'.
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Table 2.3. Details of antibodies used for immunofluorescence and western blotting.





E-cadherin BD 610181 Mouse 1:1500 1:2500 120 KDa
Claudin7 Abeam Ab75347 Rabbit n/a 1:1000 23 KDa
N-cadherin BD 610921 Mouse 1:300 1:3000 130 KDa
Vimentin Sigma V 6630 Mouse 1:400 1:1000 58 KDa
Fibronectin Abeam ab2413 Rabbit 1:10000 1:5000 262 KDa
Zebl D. Darling [201] Rabbit 1:1000 n/a n/a
Slug LifeSpan Bio LS-C30318 Rabbit 1:1000 1:4000 34 KDa
Snail Abeam ab17732 Rabbit 1:700 1:4000 29 KDa
(I-catenin (total) BD 610153 Mouse 1:500 1:2000 92 KDa
P-catenin (active) Millipore 05-665 Mouse n/a 1:1000 92 KDa
pan-WTl Genetex GTX15249 Rabbit 1:100 n/a n/a
Tubulin Abeam Ab7291 Mouse n/a 1:6000 50 KDa
AQUA automated image analysis
Monochromatic images of each TMA core were captured at 20x magnification using
an Olympus AX-51 epifluorescence microscope. These high-resolution, digital
images were individually, manually quality checked to crop aberrant imaging
artefacts and exclude them from analysis. All areas of normal mammary duct and
DCIS were also cropped to ensure that only invasive cancer was included in the
analysis. Checked images were then analysed using AQUA software [199], Briefly, a
binary epithelial mask was created from the cytokeratin image of each TMA core. If
the epithelium comprised <5% of total core area, the core was excluded from
analysis. Similar binary masks were created for cytoplasmic and nuclear
compartments based on DAPI staining of nuclei. Target protein expression was
quantified by calculating the Cy5 fluorescent signal intensity on a scale of 0 to 255
within each image pixel. The AQUA score was generated by dividing the sum of
Cy5 signal within the epithelial mask by the area of the cytoplasmic compartment.
Cytokeratin, DAPI, 'protein target' and 'composite signal' AQUA images are
illustrated in Figure 2.1. Quantitative analysis of ER, PR and HER2 expression using
AQUA correlates well with traditional immunohistochemistry (IHC) techniques
(Allred and HercepTest). Furthermore, AQUA demonstrates a particularly dynamic
range of scores at higher IHC scores as shown in Figure 2.2 [196].
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Figure 2.1. AQUA quantitative image analysis for compartmentalised analysis of
tissue sections, (a) DAPI counterstain was used to identify nuclei, (b) anti-
pancytokeratin was used to identify infiltrating tumour cells and normal epithelium
and (c) Cy-5-tyramide was used to identify target proteins. Cytokeratin = green;
DAPI = blue; E-cadherin = red. Bars = 100 pm.
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Figure 2.2. Quantitative receptor expression analysis using AQUA compared with
IHC. (a) ER, (b) PR and (c) HER2. There is a continuous distribution of AQUA
scores with a wide dynamic range of expression at high-intensity staining. AQUA
scores for ER, PR and HER2 show good correlation with IHC (Pearson regression
coefficients, r = 0.66, 0.68 and 0.50 respectively). Reproduced with kind permission
from Dr. D. Faratian, Consultant Pathologist, Western General Hospital, Edinburgh
[196],
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Statistical analysis methods for AQUA data
An arbitrary cut-off of < 50% available AQUA scores was selected for the exclusion
of cases with insufficient data prior to analysis. Cases with special type carcinomas
were also excluded from analysis. AQUAsition data was matched to TMA maps,
facilitating the investigation of correlations between EMT markers and clinical
parameters. AQUA scores for each array were log2 transformed and mean centred.
The mean of the three replicates for each protein target was used for further analysis.
As a consequence of this averaging process, zero no longer represents the mean of
the data that is shown graphically.
Associations between variables were calculated using Pearson's correlation
coefficients and differences in means with one-way ANOVA using SPSS software
vl4. Overall survival was subsequently assessed by Kaplan-Meier analysis with log-
rank testing to determine statistical significance. Deriving cutpoints in Kaplan-Meier
analysis using minimum P statistics can introduce a type I statistical error through
multiple testing [202]. X-Tile, a bio-informatics tool that allows optimal cutpoints to
be derived whilst correcting for the use of minimum P statistics [203], was used in
order to reduce this type I error. The two statistical corrections used were the Monte-
Carlo P value and the Miller-Siegmund minimal P correction [202], Pairwise
comparisons of change in phenotype between primary tumours and paired UN
metastases were made using the Chi-squared test.
Retrospective power calculations were carried out using online formulas available at
www.stattools.net/SSizSurvival_Pgm.php and
www.dssresearch.com/KnowledgeCenter/tooIkitcalculators/samplesizecalculators.as
px to determine the required population sizes to establish whether observed
associations in Chapter 4 were real.
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Cell lines and culture conditions for use in invasion assays
Table 2.4, amended from [204], gives details of all claudin-low/EMT-like cell lines
as well as MCF1 OA cells.





Culture media Culture conditions
HBL100 BaB - ["] N DMEM, 10% FCS 37°C, 5% CO,
SUM1315 BaB - ["] IDC (skin
metastasis)
Ham's F12, 5%-IE 37°C, 5% C02
SUM159PT BaB [-1 [-] AnCar Ham's F12, 5%-IH 37°C, 5% CO,
BT549 BaB - [-] IDC, pap RPMI, 10% FCS 37°C, 5% C02
MDAMB436 BaB [-1 [-] IDC LI5, 10% FCS 37°C, no CO,
MDAMB157 BaB ["] MC DMEM, 10% FCS 37°C, 5% CO,
MDAMB231 BaB - [-] AC DMEM, 10% FCS 37°C, 5% CO,
HS578T BaB - [-] IDC DMEM, 10% FCS 37°C, 5% CO,
MCF 1 OA BaB - [-] F DMEM/F12* 37°C, 5% C02
AC, adenocarcinoma; AnCar, anaplastic carcinoma; BaB, Basal B (the basal-like
cluster was found to comprise of two major subdivision termed 'A' and 'B'); F,
fibrocystic disease; IDC, invasive ductal carcinoma; MC, metaplastic carcinoma; N,
normal; pap, papillary. Expression data for ER and PR are derived from mRNA and
protein levels, square brackets indicate that levels are inferred from mRNA levels
alone. Media conditions: FCS, foetal calf serum (Harlan, #S-0001AE); I, insulin
O.Olmg/ml (Sigma, #19278); H, hydrocortisone 500ng/ml (Sigma, #H0888); E, EGF
20ng/ml (Sigma, #E9644); DMEM, Dulbecco's Modified Eagle medium, G1BCO
#31885-023; RPMI, RPM1 medium 1640, GIBCO #21875-034; Ham's F12, D-12
nutrient mixture (Ham), GIBCO #21765-029; DMEM/F12, Dulbecco's modified
Eagle's medium: Nutrient mix F-12 (D-MEM/F-12), GIBCO #31330-038; L15,
Leibovitz's L-15 medium, GIBCO #11415-049. For MCF10A, supplement
DMEM/F12 media with 5% horse serum (Invitrogen, #16050-122), 20ng/ml EGF,
lOOng/ml cholera toxin (Sigma, #C8052), O.Olmg/ml insulin and 500ng/ml
hydrocortisone.
All cell lines obtained from ATCC (American Type Culture Collection;
www.atcc.org) apart from SUM1315 and SUM159PT which were obtained from Dr.
A. Orimo, University ofManchester.
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Primary cell isolation for tissue culture
Normal fresh breast tissue cores were incubated for 1 hour at room temperature in
tissue mix consisting of DMEM/F12, 1% fungizone (Invitrogen, #15290018), 1%
penicillin/streptomycin (G1BCO, #15140, 10,000U/ml penicillin, 10,000ug/ml
streptomycin), lOug/ml insulin and 10% FCS. Tissue cores were then finely chopped
(~lml pieces) and put in a tissue mix/Collagenase I solution (GIBCO, #17100-017,
made up with 200uL of 200U/ml Collagenase I to 20ml tissue mix) for digestion (2
hours at 37°C, 200 rpm). The digested tissue was then spun for 4 minutes at 60g. The
resulting pellet was plated with fibroblast media (DMEM supplemented with 10%
FCS, 50 U/ml penicillin and 50 mg/ml streptomycin) and the supernatant spun for a
further 4 minutes at 600g, 4 times. The resulting second pellet was plated with
HMEC media (CnT-22 (CELLNTEC, #CnT-22.BM) supplemented with 5% FCS).
The same protocol was used to isolate epithelial cells and fibroblasts from fresh
breast cancer specimens.
Rat tail collagen I preparation for use in invasion assay
Fresh rat tails were collected and frozen. Prior to harvesting these were placed in
70% ethanol. Tendons were stripped from the tails and returned to 70% ethanol to
sterilise. The collected tendons were weighed and transferred to the appropriate
volume of pre-cooled acetic acid (lg tendon to 250ml 0.5M acetic acid) and gently
stirred for 48 hours at 4°C. The tendon/acetic acid mix was then centrifuged at
10,000g for 30 minutes and the pellet discarded. The remaining supernatant was
measured and an equal volume of 10% (w/v) NaCl added. This mix was allowed to
stand overnight at 4°C. The collagen-rich, insoluble 'bottom layer' was taken and
collected by further centrifugation (10,000g for 30 minutes). The collagen-rich
material was resuspended in 0.25M acetic acid at 4°C and dialysed against 1:1000
acetic acid at 4°C for 3 days, changing the dialysis buffer twice daily. The collagen
solution was then sterilised by centrifugation (20,000g for 2 hours) and stored at 4°C.
Collagen was diluted as required by the addition of sterile 1:1000 acetic acid to a
stock concentration of 1.2mg/ml.
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Collagen based 'on top' invasion assays
This assay was used to investigate invasion following the expression of C35 protein.
Methodology for this assay has been previously described [205, 206]. 3ml of rat tail
collagen I solution was prepared (25% Collagen stock, 55% sterile 1:1000 acetic
acid, 10% DMEM, -10% 0.22M NaOH (Sigma, #S2770), and 10% FCS to give a
10% excess) with 0.1 x 106 normal human breast fibroblasts per gel. This mix was
transferred to a 35mm Petri dish and allowed to contract in fibroblast media over a
period of 4-7 days. Sufficient contraction was judged as a ~4-fold reduction in size.
When this was achieved, gels were carefully transferred to a 24 well plate and 0.3 x
106 H16N-2 cells from the desired lines seeded on top. H16N-2 cells were obtained
as a kind gift from Dr. V. Band, Band and Sanger, 1991. These were then incubated
as submerged cultures for 3-4 days in H16N-2 media (MEGM supplemented with
5% FCS (Lonza, #CC-3150). To induce invasion, the gels were raised to the
air/liquid interface and incubated for a further 7 days. This was done by transferring
the gels onto a raised mesh within a 50mm Petri dish. At this stage, the gels were
fixed in 10% phosphate buffered formalin and wax embedded (Figure 2.3a). Details
of transfections ofH16N-2 with C35 protein are fully described elsewhere [206],
Matrigel based 'plug' invasion assays
This assay was used to investigate the invasion of cells across basement membrane.
200uL cell-collagen plugs and 75uL cell-Matrigel plugs were made in a u-shaped 96
well plate, with the aim of achieving comparable size after a 24hr incubation (day -
1). A cell concentration of 1 x 106 was used for all plugs. Details of all lines used in
this assay are shown in Table 2.4. Rat tail collagen I, for both plugs and subsequent
embedding, was prepared as per the 'on top' assays. Growth factor reduced Matrigel
was obtained from BD (#354230, 9.4mg/ml) and used at a 5mg/ml. Matrigel matrix
is a soluble basement membrane extract of the Engelbreth-Holm-Swarm tumour that
gels at room temperature to form a reconstituted basement membrane. The major
components are laminin, collagen IV, entactin and heparin sulphate membrane. After
the 24 hour incubation, cell plugs were carefully removed from their 96 well plate
and embedded in 1ml of collagen in a 24 well plate (taken as day 0), with or without
fibroblasts (used at 10,000/ml). These cultures were incubated for a further hour and
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then carefully freed from the edges of the well (to allow contraction of the collagen)
and supplemented with 0.5ml of cell-specific media. The cultures were then left to
invade. Media was changed weekly. Gels were fixed at either 1 or 2 weeks in 10%
phosphate buffered formalin and wax embedded (Figure 2.3b). This assay is similar
to that of Sabeh and colleagues [207].
Haematoxylin and eosin staining
Slides were de-waxed and re-hydrated, stained and then de-hydrated and cover-
slipped according to a standard protocol detailed below. The Haematoxylin used was
Shandon's ready-made Harris Haematoxylin. This must be filtered before use and
discarded after every 200 slides. Eosin is supplied by Shandon as EosinY.
De-waxing and Rehydration:
De-wax- Xylene solution 1 5 minutes
De-wax- Xylene solution 2 5 minutes
De-wax- Xylene solution 3 5 minutes
Rehydration- 100% Alcohol solution 1 2 minutes
Rehydration- 100% Alcohol solution 2 2 minutes
Rehydration- 80% Alcohol 2 minutes
Rehydration- 50% Alcohol 2 minutes
Wash in running water 2 minutes
Staining:
• Haematoxylin
• Wash in running water
• Scott's tap water substitute
• EosinY
• Wash in running water
5 minutes






Dehydration-50% Alcohol 30 seconds
Dehydration-80% Alcohol 30 seconds
Dehydration-100% Alcohol solution 1 2 minutes
Dehydration-100% Alcohol solution 2 2 minutes
Clearing-Xylene solution 1 5 minutes
Clearing-Xylene solution 2 5 minutes
Clearing-Xylene solution 3 5 minutes
Collagen based 'on top' assay







day -1 day 0
96 well plate:
200uL cell-collagen 'plug'











Figure 2.3. Schematic illustration of the 'on-top' and 'plug-based' invasion assays,
(a) In the on-top assay, a contracted collagen gel containing fibroblasts is seeded
with epithelial cells. These gels are then incubated as submerged cultures such that
the epithelial cells invade down into the gel along a nutrient gradient, (b) In the plug-
based assay, a collagen- or matrigel-based epithelial plug is generated in a 96 well
plate. This plug is then embedded in additional collagen, which may or may not
contain fibroblasts as required. With time, the epithelial cells invade out of the plug




Protein lysates (50ug/well, as determined by MicroBCA protein assay) were resolved
by SDS-PAGE after being denatured for 1 hour at 60°C. The resolving gel (7.5% w/v
acrylamide, 0.37M TRIS pH8.85, 0.1% SDS, 0.02% AMPS, 0.25% TEMED) was set
between glass plates using a Bio-Rad kit. Once the resolving gel had set, a stacking
gel (3.6% w/v acrylamide, 0.12M TRIS pH6.8, 0.1% SDS, 0.03% AMPS, 0.33%
TEMED) was layered and a comb used to create wells for sample loading. The
loaded samples were electro-separated under constant current (100-200mA) using
electrophoresis buffer (25mM Trizma Base, 0.19M Glycine, 10% SDS). Electro-
transfer onto immobilon transfer membrane (Millipore, #IPVH304F0) was
performed using transfer buffer (25mM Trizma Base, 0.19M Glycine) using a Bio-
Rad kit, under constant electrical potential (~30mV for at least 2 hours). All
chemicals used here and for western blotting came from Sigma unless otherwise
stated.
Western Blotting
Nonspecific binding was blocked with Li-Cor Odyssey Blocking Buffer (Li-Cor,
#927-40000), diluted 50:50 in PBS, for 1 hour at room temperature. Primary
antibodies were diluted in Li-Cor Odyssey Blocking Buffer (see Table 2.3 for
details), diluted 50:50 in 0.1% PBS-Tween20, and incubated with the blot overnight
at 4°C. Blots were washed 3 times for 5 minutes with PBS-T before incubation with
appropriate fluorescent secondary antibodies (Li-Cor, anti-rabbit 680nm, #926-
32221; anti-rabbit 800nm, #926-32211; anti-mouse 680nm, #926-32220; anti-mouse
800nm, #926-32210), diluted 1:10,000 in Li-Cor Odyssey Blocking Buffer, diluted
50:50 in 0.1% PBS-Tween20, for 45 minutes at room temperature. Exposure to light
was avoided. Subsequently, membranes were washed, dried and scanned on the Li-
Cor Odyssey scanner. All washes/incubations were carried out under constant
agitation.
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RNA extraction, gene expression micro-array construction and analysis, and qRT-
PCR (quantitative real time polymerase chain reaction)
RNA was extracted from the collagen invasion assays using an RNeasy Mini kit
(Qiagen, #74104) and from cell lines cultured on plastic using an AllPrep DNA/RNA
Mini kit (Qiagen, #80204). Quality and concentration was evaluated using an Agilent
Bioanalyser and Agilent RNA 6000 Nano kit (Agilent Technologies, #5067-1511)
and Nanodrop. An RNA Integrity Number (RIN) of >9 was required before
proceeding as low quality, fragmented RNA may compromise qRT-PCR or micro-
array analysis.
RNA from the collagen invasion assays was labelled using an Illumina TotalPrep
RNA amplification kit (Ambion, #AMIL1791) according to manufacturer's
instructions. Triplicate samples from invasion assays (1500ng cDNA per assay) were
hybridised to Illumina BeadChips and whole genome gene expression analysis
performed using the Illumina HumanRef-8 v3 Expression BeadChip and BeadArray
Reader. Microarray data was analysed using packages within Bioconductor [208]
(http://www.bioconductor.org) that implement R statistical programming. Gene
expression data was normalised using quantile normalisation within the BeadArray
package [209] and differential gene expression assessed using Significance Analysis
of Microarrays (SAM) [210] and the siggenes package. The dataset from
Hershkowitz and colleagues [51] was downloaded from the UNC Microarray
Database (https://genome.unc.edu/). Microarrays were constructed by Dr Katz and
Dr Larionov and analysed by Dr Sims (all are part of the Breakthrough Breast
Cancer Research Unit, Western General Hospital).
RNA from cell lines cultured on plastic was converted to cDNA prior to PCR using a
QuantiTect Reverse Transcription kit (Qiagen, #205311). Gene expression patterns
for invasion assays (biological triplicates) and cell lines cultured on plastic (technical
triplicates) were examined using the QuantiTect SYBR Green PCR kit (Qiagen,
#204145) and a Corbett RotoGene 3000. Primers for CDH1 were: forward 5'-
CGGAGAAGAGGACCAGGACT-3', reverse 5'-GGTCAGTATCAGCCGCTTTC-
3'; for CLDN7: forward 5'-AAAATGTACGACTCGGTGCTC-3\ reverse 5'-
AGACCTGCCACGATGAAAAT; for TBP: forward 5'-
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GGGGAGCTGTGATGTGAAGT-3reverse 5'-
CCAGGAAATAACTCTGGCTCA-3'; for ACTB: forward 5'-
CCTTCCTGGGCATGGAGTCCT-3', reverse 5'-
GGAGCAATGATCTTGATCTT-3'. QuantiTect Primer Assays (Qiagen) were used
for KRT8, CRB3, MARVELD3, IRF6, MAL2, TACSTD1 and SPINT2. PCR
programme was identical for all genes: 95°C, 15 minutes; (94°C, 15 seconds; 56°C,
30 seconds; 72°C, 30 seconds) x 50 cycles; 72°C, 5 minutes. Standard reference
human cDNA was from Clontech (#639654), random primed. ~50ng RNA equiv/mL
was used for quantification ofmRNA expression. Final normalisation was performed
against the geometrical mean ofACTB and TBP levels.
Gene promoter analysis
Using the presumptive promoter region for the 9 relevant genes (a 2kb region
upstream of the presumptive transcription start site determined using Ensembl 52,
Jan2009, based on NCBI 36 assembly), over-represented 6- and 7-mer oligos were
identified using oligo-analysis [211] from the RSAT-tools package
(http://rsat.scmbb.ulb.ac.be/rsatA [212], This program counts all oligonucleotide
occurrences within the sequence set and estimates their statistical significance. A
calibration is done using the entire genome promoter regions as a background model
(Ensembl 52, Jan2009, based on the NCBI 36 assembly). The best 7-mer candidates
were identified and their sequences compared to the entire collection of consensus
binding sites available from Transfac professional [213] (release 2010.1) using the
compare-pattern script (RSAT-tools) and the associated binding-factors identified.
The analysis was performed by Dr. P. Gautier, MRC Human Genetics Unit
Bioinformatics Service, Western General Hospital.
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Chapter 3: The down-regulation of E-cadherin is uncoupled from an EMT
programme in high-grade invasive ductal breast cancers
Introduction
Transcriptional repression is a key mediator of EMT
Increasing evidence suggests that EMT has a key role in cancer progression,
underlying invasion, metastatic dissemination and acquisition of resistance. This role
has predominantly been inferred from in vitro and animal studies and controversy
regarding the precise role of EMT in human cancer remains. A decrease in E-
cadherin expression is possibly one of the most important consequences of EMT
resulting in the changed behaviour of tumour cells [12]. Various mechanisms may
down-regulate E-cadherin expression in cancer but transcriptional repression is
thought to be particularly important. A number of zinc finger-containing repressors,
capable of interacting with E-boxes within the CDH1 promoter, have been identified.
These include Snail, Slug (Snail2), Zebl, Zeb2 and Twist [76],
Following investigation in a series of human carcinoma cell lines, Snail was the first
of these transcription factors to be characterised as a repressor of E-cadherin and
inducer of EMT [214, 215]. Subsequently, Snail expression has been reported in
various human tumours, including breast, where expression correlates with LN and
distant metastases [126, 216, 217], The expression of Slug is similarly associated
with poor clinico-pathological outcomes in breast cancer [217, 218], However, Slug
expression has been found to correlate with a partially differentiated phenotype,
suggesting that Snail and Slug may play different roles in the progression of breast
cancer [219], Zebl expression has predominantly been studied in colorectal and
uterine cancers, where expression correlates with poor outcome [220, 221]. In the
context of breast, Zeb2 expression has been reported in pleural effusions (although
not predictive of outcome) [217], and both Zebl and Zeb2 are associated with
repression of E-cadherin and EMT in transformed MCF10A cells [222]. The ability
of Twist to induce EMT and the development of metastases was originally described
in a mouse model. In addition, the same study reported an inverse relationship
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between the expression of E-cadherin and Twist in lobular carcinomas of the breast
[223]. However, further studies have shown expression of Twist to be a feature of
high-grade breast carcinomas of various types [224]. Despite similarities between
these transcription factors, the complexity of their individual roles in processes such
as EMT remains to be fully understood.
Canonical Wnt signalling is an alternative EMT mechanism
p-catenin is a multifunctional protein. At the plasma membrane, it is an important
component of the adherens junction, facilitating cell-cell adhesion by linking E-
cadherin, in conjunction with a-catenin, to the actin cytoskeleton [82], In addition,
P-catenin is the main effector of canonical Wnt signalling. Normally, free
cytoplasmic P-catenin is rapidly degraded by means of a degradation complex
consisting of the serine and threonine kinases CK1 and GSK3P, the scaffold protein
axin and the adenomatous polyposis coli protein APC. Binding of P-catenin to this
complex results in P-catenin phosphorylation and subsequent proteosomal
breakdown [225], Binding of Wnt ligands to a coreceptor complex consisting of a
seven, transmembrane domain Frizzled receptor and LDL receptor-related proteins
LRP5 or LRP6 inhibits GSK3P [226]. Consequently, P-catenin accumulates in the
cytoplasm and translocates to the nucleus. Here, it interacts with members of the T-
cell-specific transcription factor/1ymphoid enhancer binding factor (TCF/LEF)





















Figure 3.1. Canonical Wnt signalling. In the absence of Wnt signals {left panel), p-
catenin (P) is localized in adherens junctions at the plasma membrane, contributing
to cell-cell adhesion in conjunction with E-cadherin (E) and a-catenin (a).
Cytoplasmic p-catenin is targeted for proteasomal breakdown by a multiprotein
degradation complex that includes APC, CK1, axin and GSK3p. Binding of Wnt
molecules to frizzled receptors {right panel) inhibits the degradation complex and
allows P-catenin to accumulate and translocate to the nucleus where specific
transcriptional programmes are activated. Frizzled receptor mediated recruitment of
the cytoplasmic protein dishevelled (DVL) is an important step in this signalling
pathway [228]. Loss of membranous E-cadherin can also liberate P-catenin and drive
its nuclear translocation. Adapted from [71].
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The canonical Wnt signalling pathway is known to regulate EMT-programmes in the
developing mammary gland and increasing evidence suggests that this pathway may
be up-regulated in various cancers, including breast [229-231], A study has shown
that Wnt signalling, through a p-catenin-TCF/LEF complex, is capable of driving
EMT by up-regulating Snail in human breast cancer cell lines [232], In addition, loss
of E-cadherin-p-catenin junctions at the cell membrane can independently drive
EMT by allowing freed P-catenin to translocate to the nucleus [186, 233, 234], These
studies, carried out in vitro and in animal models, support the nuclear translocation
of P-catenin as a key event driving EMT and poor outcome [235], Additional studies
indicate that there are multiple reciprocal interactions between E-cadherin, P-catenin
and EMT-inducing transcriptional repressors [71]. Illustrating some of this
complexity, Stemmer and colleagues [236] have demonstrated positive feedback
stimulation of Wnt signalling by Snail that is independent of its repressor activity
and independent of loss of E-cadherin.
A number of immunohistochemical studies have investigated P-catenin expression
patterns and correlation with clinical outcome with mixed results [237-239],
However, Rimm and colleagues, who were the first to utilise an automated,
quantitative immunohistochemical analysis of protein expression using the AQUA
system, report a significant correlation between loss of cytoplasmic p-catenin and
poor outcome [240], However, this study does not support a translocation
mechanism as almost no nuclear expression of p-catenin (<10/600 cases) was
observed. Consequently, the role of p-catenin as a mechanism of EMT in human
breast cancer warrants further investigation. A recent study using a TCF/LEF
reporter has shown that canonical Wnt signalling activity is a marker of CSCs in
colon cancer [241], The evidence suggesting a link between EMT and sternness has
already been discussed above. This additional evidence in the context of Wnt
signalling makes the investigation of P-catenin in breast cancer particularly relevant.
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Aims
To clarify the role of EMT in human breast cancer at the protein level we selected
two patient cohorts that maximised the likelihood of identifying EMT-related events.
As the most common form of the disease [242], only invasive ductal carcinomas of
no special type (1DC-NST) were examined. The expression of key EMT-related
proteins, including P-catenin and transcriptional repressors of E-cadherin, were
examined using automated, quantitative, immunofluorescence analysis.
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Results
Human breast cancer has a wide range of E-cadherin expression, highly correlated
with p-catenin
To determine whether down-regulation of E-cadherin is evident in human IDC-NST,
quantitative immunofluorescence analysis of E-cadherin protein expression was
performed. Scores for immunofluorescence imaging were given by the AQUA
system and were allocated as membrane/cytoplasmic and nuclear as appropriate.
These scores are relative values and are based on expression within the whole
tumour cohort.
A continuous range of E-cadherin expression was seen in both sets (Figure 3.2a). In
set 1, an 18-fold change in the expression of E-cadherin was seen. A corresponding
11-fold change was seen in set 2. No correlation between E-cadherin expression and
ER or HER2 receptor status was observed (Figure 3.2b). Qualitative assessment of
immunofluorescence images showed that E-cadherin staining remains membranous
across all breast tumours (Figure 3.2c). This is an important observation as tumours
with non-functional, cytoplasmic E-cadherin (potentially indicative of EMT) would
not be allocated distinctly low AQUA scores. Quantitative analysis of P-catenin
expression was performed to determine the relationship with E-cadherin expression.
Tumours with high cytoplasmic P-catenin expression were identified (Figure 3.3a).
Nuclear P-catenin expression, although less distinct, was also observed and
positively correlated with cytoplasmic expression (Table 3.1). Importantly, a positive
correlation between E-cadherin and P-catenin expression was seen in both patient
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Figure 3.2. Human breast cancer has a wide range of E-cadherin expression, (a)
Comparable, wide ranges of E-cadherin expression are seen in both TMA sets.
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AQUA scores for each array were log2 transformed and mean centred (0 represents
the adjusted mean for each individual TMA slide). The mean of three TMA
replicates is shown, (b) E-cadherin protein expression distribution by ER and HER2
receptor status in both TMA sets, (c) Representative immunofluorescence images
illustrating varying E-cadherin protein expression (left panels, with pan-cytokeratin
mask; right panels, without pan-cytokeratin). Note the membranous staining of E-
cadherin throughout. Normalised AQUA scores are given (arbitrary units). Bar = 50







































Figure 3.3. E-cadherin and p-catenin protein expression are highly correlated in
human breast cancer, (a) Representative immunofluorescence images illustrating
tumours with high (left panel) and low (right panel) expression of P-catenin. Inset
shows nuclear staining in individual cells (arrows). Bar = 50 pm. Cytokeratin =
green; DAPI = blue; P-catenin = red. (b) Plots comparing membrane/cytoplasmic and
nuclear P-catenin expression levels to E-cadherin in both TMA sets (all p<0.0l by
Pearson's correlation, see Table 3.1).
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High expression of N-cadherin and other mesenchymal markers is found in human
breast cancer
Having identified tumours with relatively low E-cadherin expression, we
hypothesised that some of these might be undergoing EMT and should therefore
show evidence of a 'cadherin switch'. Tumours with high N-cadherin expression
(Figure 3.4a) were identified. A weak negative correlation with E-cadherin
expression was observed in set 1 (Pearson's correlation, r=-0.204, p<0.05; Figure 3.5
and Table 3.2), the set enriched for HER2 expression. No such correlation was found
in set 2 (Figure 3.5 and Table 3.2). Vimentin and fibronectin are two other
established mesenchymal markers that are up-regulated in EMT in the context of
breast and other cancers [243]. As with N-cadherin, tumours with relatively high
vimentin and fibronectin expression were identified (Figure 3.4b-c), but no
correlation with E-cadherin expression observed (Figure 3.5, Table 3.2).
Immunofluorescence images show stromal and epithelial staining for these markers
as expected. Interestingly, fibronectin was expressed focally and not evenly in high
expressing tumours (Figure 3.4c). No correlation was observed between N-cadherin,
vimentin and fibronectin expression in these tumours (Table 3.2). These findings
suggest that up-regulation of mesenchymal markers is an uncommon event and that
tumours that up-regulate one protein marker do not necessarily up-regulate others.
Mesenchymal protein up-regulation is uncoupled from E-cadherin down-regulation
in the breast cancers examined.
64
E-cadherin = 0.26
N-cadherin = -0.88 E-cadherin = -0.63N-cadherin = 2.03 E-cadherin = 0.55
Fibronectin = -1.41
Figure 3.4. High expression of mesenchymal proteins is found in human breast
cancer. Representative immunofluorescence images illustrating tumours with high
(left panels) and low (right panels) expression of (a) N-cadherin, (b) vimentin and (c)
fibronectin. Corresponding E-cadherin expression is shown in each case. Note the
stromal (short arrow) as well as epithelial (long arrow) expression of vimentin and
fibronectin. Bar = 50 pm. Cytokeratin = green; DAPI = blue; N-
cadherin/vimentin/fibronectin = red.
Vimentin = 1.57 E-cadherin = 0.73
Fibronectin = 0.75
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Figure 3.5. Correlations between mesenchymal proteins and E-cadherin. Plots
comparing N-cadherin, vimentin and fibronectin protein expression levels to E-
cadherin are shown for both sets.
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High expression of Snail and Slug in human breast cancer
Quantitative analysis of transcription repressors was performed to determine their
correlation with E-cadherin expression and other EMT markers. Tumours with
relatively high Snail and Slug expression were identified (Figure 3.6), but no
correlation with E-cadherin expression was observed (Figure 3.7, Table 3.2). In
addition, protein expression of Slug and Snail did not differ significantly in relation
to ER status (not shown), as previously reported using immunohistochemical
methods [244]. Interestingly, immunofluorescence images show that Snail
expression is predominantly nuclear, whilst Slug expression is predominantly
cytoplasmic (Figure 3.6a-b). Cytoplasmic expression of EMT transcription
repressors including Slug has been reported but the functional significance of this
remains unknown [219]. Twist expression could not be reliably reported due to the
poor specificity of commercially available antibodies. In addition, Zebl expression
was purely stromal in set 1 and therefore not investigated in set 2 (Figure 3.8). These
findings strengthen the observation that EMT events are relatively uncommon, do
not occur uniformly and are uncoupled from E-cadherin loss.
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Snail = 0.66 E-cadherin = 0.57 Snail = -2.14 E-cadherin = -0.50
Slug = 0.67 E-cadherin = 0.44 Slug = -1.12 E-cadherin = 0.04
Figure 3.6. High expression of Snail and Slug in human breast cancer.
Representative immunofluorescence images illustrating tumours with high (left
panels) and low {right panels) expression of (a) Snail and (b) Slug. Corresponding E-
cadherin expression is shown in each case. Note the clear nuclear expression of Snail
whilst Slug is predominantly cytoplasmic. Bar = 50 pm. Cytokeratin = green; DAPI
= blue; Snail/Slug = red
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Figure 3.7. Correlations between transcriptional repressors and E-cadherin. Plots
comparing Snail and Slug protein expression levels to E-cadherin are shown for both
sets.
Zebl
Figure 3.8. Zebl staining. Representative immunofluorescence image illustrating
stromal staining of Zebl (arrows).
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Correlations between markers of EMT support two distinct programmes in human
breast cancer
Protein markers of EMT with reproducible, significant correlations across both
patient sets are shown in Table 3.1. Univariate analysis showed no reproducibly
significant correlations between the markers of EMT investigated in this study and
patient survival (Table 3.3). The expression of E-cadherin significantly correlates
with p-catenin, which in turn correlates with N-cadherin. The expression of vimentin
correlates with Snail, which in turn correlates with Slug (Figure 3.9, Table 3.1).
These correlations may represent two distinct programmes that are expressed in
human breast cancers. These programmes appear related, but not identical, to EMT



































Figure 3.9. Correlations between protein markers of EMT suggest a transcriptionally
driven programme in human breast cancers. Plots illustrating the reproducible
correlations between vimentin, Snail and Slug as identified in Table 3.1. Correlation
coefficients, significant at the 0.01 level, are shown alongside each graph. Both sets
are shown with linear regression.
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Table 3.1. Significant correlations between protein markers of EMT. Significant
correlations, reproducible across both TMA sets, are seen between some protein
markers of EMT. Upper row = set 1; bottom row = set 2. * Correlation is significant
at the 0.05 level (2-tailed); ** Correlation is significant at the 0.01 level (2-tailed).
Cyto = cytoplasmic; nuc = nuclear.
E-cadherin 0.476** p-catenin (cyto)
0.749**
E-cadherin 0.501** P-catenin (nuc)
0.724**
N-cadherin 0.274** P-catenin (cyto)
0.247**
N-cadherin 0.262** P-catenin (nuc)
0.193*























































































































































































Table 3.3. Markers of EMT and patient survival. Univariate analysis showed no
reproducible, significant correlations between markers ofEMT and patient survival.
Two statistical correction (Miller-Siegmund and Monte-Carlo) were used to correct
type 1 statistical error that results from multiple testing for cutpoints in Kaplan-
Meirer survival analysis. Upper row = set 1; bottom row = set 2.
Target P, uncorrected P, corrected MonteCarlo corrected
E-cadherin 0.03 0.38 0.35
0.06 0.53 0.54














Snail 0.02 0.23 0.18
0.01 0.21 0.22
Slug 0.13 1 0.79
0.18 1 0.81
Vimentin 0.05 0.46 0.40
0.07 0.61 0.64
Fibronectin 0.05 0.46 0.39
0.11 1 0.64
Zebl 0.23 1 0.93
n/a n/a n/a
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Chapter 4: The acquisition of a WTl-related EMT phenotype in LN metastases
correlates with poor clinical outcome in human breast cancer
Introduction
WT1 in human breast carcinoma
WT1 (Wilms' tumour 1) encodes a transcriptional regulatory protein involved in the
normal development of multiple tissues including the kidneys, spleen and heart
[245], Whilst several transcriptional modifications can occur, WT1 mRNA is subject
to two alternative splicing events involving exon 5 (a 17 amino acid sequence) and
KTS (a three amino acid sequence found between the third and fourth zinc finger
domains). Alternative splicing at these two sites results in the expression of four
predominant isoforms, including or excluding exon 5 and KTS respectively [246]
(Figure 4.1). WT1 was originally described as a tumour suppressor in the relatively
rare paediatric kidney malignancy Wilms' tumour, following the identification of
WT1 mutations in 15% of sporadic cases [247], However, overexpression of the
wild-type WT1 has been reported in a variety of human cancers, including a
proportion of Wilms' tumour cases, leading to the hypothesis that WT1 can function
as a tumour suppressor or oncogene in a context dependent manner [248].
Current clinical trials have shown that WT1 is a potential molecular target for cancer
immunotherapy [249], A phase I trial reported clinical responses, defined as a
decrease in tumour size or tumour marker expression, in 2/2 patients with advanced
breast cancer [250]. Similar responses have been seen in lung and kidney [251, 252].
Therefore, understanding the role of WT1 and its expression patterns in cancer
subtypes is clinically relevant. Whilst mutations in WT1 do not appear to be a feature





ZF1 ZF2 ZF3 ZF4
Dimerisation domain (1-180) Exon 5 (150-266)
^ Zinc-finger domain (323-449)^
... DNAand RNA binding
Repression domain (84-124)
Putative RRI\^ (11-72) Activatior) domainjl81-250)
Figure 4.1. A schematic representation of the WT1 protein. The N-terminal
comprises various domains: a dimerisation domain; a transcriptional activation and
repression domain and a putative RNA recognition motif (RRM). Alternative
splicing events involving exon 5 (a 17 amino acid sequence shown as 17AA) and
KTS (a three amino acid sequence between the 3rd and 4th zinc finger domains ZF3
and ZF4 shown in red) generates the four predominant WT1 isoforms. Adapted from
[254],
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Using immunohistochemical methods, an early study examining WT1 expression in
human breast tissues reported WT1 expression in normal breast. The complex
expression patterns observed, with WT1 more strongly expressed in epithelial cells
with characteristics of less differentiated cells, were consistent with a role for WT1
in developmental regulation. In addition, 15/21 breast tumours examined were
classified as WT1 negative (although it is important to note that negativity was
defined as less than 50% of cells staining for WT1) [255]. These findings were
interpreted as indicating that WT1 has a tumour suppressor role in breast cancer and
were supported by the subsequent finding that WT1 suppresses the growth of the
breast cancer cell line MDA-MB-231 in vitro [256], However, another group
reported absent expression of WT1 in normal breast epithelium (19/20) and over
expression in breast cancer (27/31) using RT-PCR [257], Subsequently, WT1
expression was shown to correlate with poor clinical outcome in human breast cancer
[258] and rates of proliferation in additional breast cancer cell lines [259], WT1
expression according to breast carcinoma subtype has not been extensively
examined. However, taken together, these studies support an oncogenic role for WT1
in breast cancer.
WT1 is a potential novel regulator of EMT
Multiple WT1 isoforms are variably expressed in individual cancers [257] and could
explain, at least in part, the conflicting reports regarding the role of WT1. To
examine this possibility, an additional study examined the effects of expressing
distinct WT1 isoforms in a non-transformed mammary epithelial cell line [260].
Interestingly, expression of an isoform containing both exon 5 and the KTS insert
(+Ex5/+KTS) induced morphological changes consistent with EMT. This was
accompanied by a redistribution of E-cadherin from the cell membrane to the
cytoplasm and up-regulation of vimentin. In contrast, an isoform lacking both these
sequences (~Ex5/-KTS) was associated with impaired proliferation and induction of
G2-cell cycle arrest. These results suggest that the ratio of expression of different
isoforms may be critical in determining the role of WT1 in cancer progression.
Importantly, this study also raises the possibility that WT1 may be a regulator of
EMT. An association between WT1 and EMT has been described in additional
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studies [261, 262]. The transcription factors Slug and Snail have an established role
in EMT [76]. Genome-wide expression profiling has identified Slug as a direct target
of WT1. In addition, Slug and WT1 co-express in the embryonic kidney [261]. A
second study showed that WT1 directly regulates Snail and E-cadherin, and possibly
Slug, in cardiovascular progenitor and embryonic stem cells [262].
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Aims
Quantitative immunofluorescence was used to examine the expression of WT1 in a
cohort of breast IDC-NST. The relationship ofWT1 with the EMT-related proteins
E-cadherin and P-catenin was examined. In addition, the hypothesis that WT1 might
regulate an EMT programme in breast cancer involving the transcriptional repressors




Human breast cancer has a wide range of WT1 expression
There is some controversy regarding WT1 expression patterns in human breast
cancer. However, increasing evidence suggests that WT1 is over expressed in at least
a proportion of these and correlates with poor clinical outcome [255, 257, 258].
Therefore, WT1 expression was examined in a cohort of 1DC-NST by quantitative
analysis. This analysis concentrated on the previously described set 2, a cohort
enriched for large, high-grade cancers that are associated with LN metastases. An 11-
fold change in WT1 expression was observed in primary tumours (Figure 4.2a). A
similar range of expression was observed in LN metastases (Figure 4.2b).
Interestingly, qualitative assessment of immunofluorescence images showed that
WT1 staining is mostly uniform and not focal, as seen in normal development [263]
(Figure 4.2c).
ER and HER2 are important clinical biomarkers in breast cancer and may correlate
with WT1 expression. Higher expression of WT1 in ER negative cancers has been
reported [255] and WT1 expression has been shown to induce ER-independent
growth in ER positive breast cancer cell lines [264]. HER2 expression has also been
associated with WT1 expression in breast cancer cell lines [265], Therefore, the
relationships between WT1, ER and HER2 were examined in primary tumours. No
correlation was observed between WT1 expression and HER2 receptor status (Figure
4.2d). A trend demonstrating higher WT1 expression in ER positive tumours was
observed (two-tailed t-test, p=0.0528; Figure 4.2e). However, a retrospective power
calculation assuming 95% confidence intervals suggests that the sample size is











Figure 4.2. A wide range ofWTl expression is seen in both primary breast cancers
and LN metastases, (a) A wide range of WTl expression is seen in primary breast
cancers. AQUA scores for each array were log? transformed and mean centred (0
represents the adjusted mean for each individual TMA slide). The mean of three
TMA replicates is shown, (b) A similar range of WTl expression is seen in LN
metastases, (c) Representative immunofluorescence images illustrating varying WTl
protein expression. Normalised AQUA scores are given (arbitrary units). Bar = 50
pm. Cytokeratin = green; DAPI = blue; WTl = red. (d) WTl protein expression
distribution by HER2 and (e) ER receptor status.
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WT1 expression is independent of E-cadherin and p-catenin in primary tumours
The relationship between WT1, E-cadherin and P-catenin is of potential interest.
WT1 is emerging as a novel regulator of EMT [261, 262]. In addition, the cell
junction protein E-cadherin, whose down-regulation is a key event in EMT, has been
identified as a potential direct target of WT1 [266], The nuclear translocation of P-
catenin is an established, alternative regulator of EMT [71]. Importantly, WT1 has
been shown to down-regulate P-catenin/TCF signalling in breast cancer cell lines
[256]. Therefore, these relationships were examined in primary tumours. However,
no significant correlation was seen between WT1 and E-cadherin expression (Figure
4.3a). Immunofluorescence images illustrate the co-expression of these markers in
some tumours (Figure 4.3b). Similarly, no correlation was seen between WT1 and P*
catenin expression (Figure 4.3c) and WT1 -expressing tumours with maintained P-
catenin expression at cellular junctions are seen (Figure 4.3d). Importantly,
examination of correlations between WT1 and the EMT markers examined in
Chapter 3 showed significant correlations with only fibronectin (Pearson's
correlation = -0.319, p<0.01) and Slug (Pearson's correlation = 0.193, p<0.05).
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E-cadherin

















Figure 4.3. Correlations between WT1, E-cadherin and P-catenin protein expression
in human breast cancer. Plots comparing E-cadherin and p-catenin protein
expression to that of WT1 in primary tumours are shown in (a) and (c).
Representative immunofluorescence images illustrating tumours with high
expression of WT1 are shown in (b) and (d). Corresponding expression of E-
cadherin and p-catenin is shown. Bar = 50 pm. Cytokeratin = green; DAPI = blue;
WTl/E-cadherin/p-catenin = red.
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A WTl-related EMT phenotype comprising Snail and Slug is seen in human breast
cancer
Recent studies suggest that WT1 may regulate an EMT programme involving Snail
and Slug [261, 262]. To test this hypothesis in human breast cancer, protein
expression levels of WT1, E-cadherin, Snail and Slug were measured in primary
tumours. Elnsupervised hierarchical clustering of protein expression data from
primary tumours revealed two principle clusters. Cluster 1 (shown in red) was
characterised by down-regulated expression of E-cadherin and predominantly up-
regulated expression of WT1, Snail and Slug. Cluster 2 (shown in blue) was
characterised by high expression of E-cadherin and low/mixed expression of WT1,
Snail and Slug (Figure 4.4a). The pattern of protein expression seen in cluster 1 is
highly suggestive of an EMT phenotype whilst that seen in cluster 2 suggests an
epithelial phenotype.
As the expression of protein markers is known to alter between primary and LN
metastases in breast cancer with clinical and biological implications [196], paired LN
metastases were similarly examined. Interestingly, similar pattern of protein
expression was seen in paired LN metastases with an equivalent cluster 1 and cluster
2 (Figure 4.5a). However, in both primary and LN tissues, separation according to
cluster showed no correlation with clinical outcome (Figure 4.4b and 4.5b).
However, retrospective power calculations (assuming 95% confidence intervals)
show that this data is significantly underpowered. Estimated total sample sizes of
1146 and 1019 cases would be required to determine whether the trends seen in
Figures 4.4b and 4.5b are real (www.stattools.net/SSizSurvival_Pgm.php). Mean
survival times by cluster for primary tumours and LN metastases are given in the
respective figure legends.
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Figure 4.4. Unsupervised hierarchical clustering of protein expression data in
primary breast tumours identifies a WTl-related EMT phenotype. (a) Two main
clusters are identified. Down-regulated expression of E-cadherin and predominantly
up-regulated expression of WT1, Snail and Slug characterises cluster 1 (outlined in
red). High expression of E-cadherin and low/mixed expression of WT1, Snail and
Slug characterises cluster 2 (outlined in blue). Cluster 1 has a mean survival of 90.7
months (confidence interval (79.7-101.7)) versus 82.5 months for cluster 2
(confidence interval (72.9-92.1)). Relative up-regulation of protein expression =
yellow; relative down-regulation of protein expression = blue, (b) Separation








Figure 4.5. Unsupervised hierarchical clustering of protein expression data in paired
LN metastases identifies a WT1-related EMT phenotype. (a) As in primary tumours,
two main clusters are identified. Down-regulated expression of E-cadherin and
predominantly up-regulated expression ofWTl, Snail and Slug characterises cluster
1 (outlined in red). High expression of E-cadherin and low/mixed expression of
WTl, Snail and Slug characterises cluster 2 (outlined in blue). Cluster 1 has a mean
survival of 77.5 months (confidence interval (64.3-90.7)) versus 85.5 months for
cluster 2 (confidence interval (75.4-95.6)). Relative up-regulation of protein
expression = yellow; relative down-regulation of protein expression = blue, (b)
Separation according to cluster is not correlated with clinical outcome.
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Acquisition of a WTl-related EMT phenotype in LN metastases predicts poor
clinical outcome
EMT is a dynamic process and reversion to an epithelial phenotype (mesenchymal to
epithelial transition or MET) is a feature of both normal development and cancer
progression [68], The observation that distant metastases are mainly composed of
cells with an epithelial phenotype closely resembling that of the primary tumour
supports this [129, 144, 267], Therefore, an ability to move between EMT and MET
phenotypes depending on the microenvironment may play a role in determining the
aggressiveness of tumour cells. Consequently, the change in cluster expression
between primary tumours and paired LN metastases and correlation with outcome
was examined.
Within the framework of the clusters identified here, four possibilities exist.
Tumours may remain in the same cluster type, either maintaining an EMT phenotype
(those that remain in cluster 1) or maintaining an epithelial phenotype (those that
remain in cluster 2). Alternatively, tumours may change cluster as they invade
locoregional LNs, either acquiring an EMT phenotype (those that change from
cluster 2 to cluster 1) or reverting to an epithelial phenotype which can be equated
with MET (those that change from cluster 1 to cluster 2). Importantly, tumours that
acquired an EMT phenotype had the worst prognosis (Figure 4.6) and were close to
statistical significance when compared with tumours that maintained the same
phenotype, either EMT (p = 0.058) or epithelial (p = 0.059) (see Tables 4.1 and 4.2).
Tumours that acquired an EMT phenotype also had a worse prognosis than those
undergoing MET but this did not reach significance. It is important to note that
patient numbers in this study are limited and retrospective power calculation
(assuming 95% confidence intervals) suggests that a total sample size of at least 206
cases would be required to determine whether the trend shown in Figure 4.6 is real
(www.stattools.net/SSizSurvival_Pgm.php). When those tumours that maintained the
same phenotype are combined and then compared to those that acquired an EMT
phenotype, a clearly significant difference in prognosis is seen (p = 0.024; Tables 4.3
and 4.4). These results suggest that acquisition of an EMT phenotype as tumour cells
invade locoregional LNs confers the greatest aggressiveness to tumour cells.
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Importantly, univariate analysis of individual markers expressed in LN metastases
was not predictive of outcome (Table 4.5). In addition, change in cluster showed no
relation to tumour grade, size, number of positive nodes and ER or HER2 receptor
status (not shown).
Immunofluorescence images illustrating the change in expression in E-cadherin,
WT1, Snail and Slug in a tumour that acquires this phenotype are shown (Figure
4.7). H&E stains for paired primary and LN tissues were examined by two
pathologists (Dr. J. Thomas and Dr. D. Faratian) but no clear morphological












Figure 4.6. Change in cluster expression between primary tumours and paired LN
metastases correlates with clinical outcome. The change in cluster expression
between primary tumours and paired LN metastases is correlated with outcome.





Figure 4.7. A subgroup of human breast tumours acquire an EMT phenotype as they
invade locoregional LNs. Immunofluorescent staining is shown for E-cadherin,
WT1, Snail and Slug protein expression (left panels, primary tumour; right panels,
LN metastases). Note the down-regulation of E-cadherin expression and the up-
regulation of WT1, Snail and Slug as this tumour invades locoregional LNs. Cell
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Figure 4.8. H&E stains according to change in cluster. A primary tumour (top panel)
with its paired LN metastases (bottom panel) is shown for each change in cluster.
Bars = 100 pm.
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Table 4.1. Pairwise comparisons according to change in phenotype.





Table 4.2. Means and medians for survival time according to change in phenotype.


















1>1 90.07 9.09 72.26 107.88 - - - -
2>2 86.00 6.51 73.24 98.76 - - - -
1>2 81.19 7.84 65.80 96.54 - - - -
2>1 65.64 9.05 47.90 83.37 66.10 17.01 32.76 99.44
Overall 82.85 4.23 74.57 91.14 - - - -
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Table 4.3. Pairwise comparisons according to change in phenotype when tumours
maintaining the same phenotype are combined.
Change in cluster 2>1
Chi-Square Significance
1>1 and 2>2 5.091 0.024
1>2 2.039 0.153
Table 4.4. Means and medians for survival time according to change in phenotype
when tumours maintaining the same phenotype are combined, (a) Estimation is


















1>1 and 2>2 88.51 5.40 77.93 99.09 - - - -
1>2 81.19 7.84 65.80 96.54 - - - -
2>1 65.64 9.05 47.90 83.37 66.10 17.01 32.76 99.44
Overall 82.85 4.23 74.57 91.14 - - - -
Table 4.5. Markers ofEMT in LN metastases and patient survival. Univariate
analysis showed no significant correlations between markers of EMT in LN
metastases and patient survival.
Target P, uncorrected P, corrected MonteCarlo corrected
E-cadherin 0.023 0.303 0.300
Snail 0.054 0.517 0.450
Slug 0.0049 0.93 0.09
WT1 0.038 0.414 0.370
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Chapter 5: Developing a three-dimensional (3D) model for the investigation of
invasion
Introduction
The acquisition of an invasive phenotype and the ability to breach the basement
membrane is a prerequisite for metastasis
Breast cancer related deaths are primarily due to metastatic progression [8].
Understanding the mechanisms that underlie this multistep process is essential to
improving clinical outcome. The transformation of normal breast epithelial cells to
metastatic cancer is the result of multiple epigenetic and genetic changes, in the
context of deregulated interactions with the microenvironment. During this process,
control of proliferation, cell survival, migration and differentiation is lost. The
acquisition of an invasive phenotype, and in particular the ability to breach the
basement membrane, is a critical event in cancer progression and a prerequisite for
metastasis. In addition, the acquisition of an invasive phenotype is closely associated
with EMT [68]. Having breached the basement membrane, cells may then access the
circulation and lymphatics and attempt to establish distant tumour foci [268-270].
Cell culture models and cell lines for the investigation of invasion
Culture models of human breast cells provide an opportunity to investigate
metastatic progression and in particular, migration and invasion. In addition, they
allow new, targeted therapies to be tested in a pre-clinical setting. Although closely
related to the tissue of origin, primary cells from human tissues have limited use in
vitro. These cells do not divide indefinitely in culture and are not easily manipulated
at the gene expression level. In addition, heterogeneity between samples from
different individuals raises issues around interpretation of results and reproducibility
[271]. Consequently, a large series of breast cancer cell lines have been developed
for use in culture, resolving many of these issues. However, it is important to be
aware that multiple variants of a single line can develop, making comparison
between studies potentially difficult [272],
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The value of cell culture models depends on a high degree of similarity between cell
lines and human cancers. A number of studies have compared the genomic and
transcriptional profiles of breast cancer cell lines with those of primary cancers [204,
273, 274], In the largest of these studies Neve and colleagues compared a panel of 51
cell lines to 145 primary cancers [204]. Importantly, most genomic and
transcriptional abnormalities characteristic of primary cancers were identified in cell
lines. In addition, this study showed that a panel of cell lines can be used to identify
molecular markers that predict response to targeted treatment. However, some
differences between cell lines and primary cancers were also apparent. The genome
copy number abnormalities seen between luminal and basal-subtype tumours were
not present in corresponding cell lines and not all cancer subtypes were represented
by the cell line panel. Importantly, luminal subtypes A and B, associated with
distinct prognoses, were not distinguished. These studies suggest that cell lines are
valuable tools in cell culture but results may not always be directly applicable to
human cancers.
Normal breast architecture can be recapitulated in 3D culture
Many studies, including the important work of Neve and colleagues, have been
carried out using cell lines cultured on plastic [204, 273, 275]. These two-
dimensional (2D) cultures lack exposure to physiological substratum and fail to
recapitulate 3D tissue architecture [276, 277], In contrast, culture of normal breast
epithelial cells in 3D laminin-rich extracellular matrix, also known as Matrigel,
results in a well-characterised morphogenesis process that closely resembles normal
breast. These cells undergo a limited number of divisions, after which they organise
into polarised, growth-arrested colonies. Similar 3D culture of cancer cells results in
unlimited proliferation, absence of tissue polarity and disorganised architecture
(Figure 5.1) [278, 279]. In addition, signalling pathways are known to be
differentially regulated in 2D versus 3D culture [280], Nonetheless, comparison of
the gene expression profiles of cell lines cultured in 2D versus 3D has shown that
individual cell lines still cluster together, independently of culture conditions.
Although this indicates that 3D culture does not induce a global change in gene
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expression, a group of genes encoding signal transduction proteins significantly
correlated with 3D culture [281].
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Aims
Taken together, these studies suggest that 3D culture is closer to the in vivo situation.
A significant amount of work has been done in this field and models that
demonstrate accelerated invasion or make use of increasingly physiological matrices
have been developed [282, 283]. In addition, cell lines with increased invasive
potential have been developed in order to study the transition to an invasive
phenotype [284], The movement of cells across basement membrane has also been
examined with important findings regarding the role of Snail and MMPs in cancer
progression [285], However, a model that examines cells before, during and after
they cross the basement membrane has not been described. Therefore, we identified
and characterised a series of potentially invasive, EMT-like cell lines and developed
an in vitro model that allows cells to be followed and examined as they cross the
basement membrane.
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Cells in monolayer on
tissue culture plastic
b
Figure 5.1. Three-dimensional culture recapitulates normal tissue architecture, (a)
Two-dimensional (2D) cultures grown on plastic are exposed to a non-physiological
substratum that lacks the normal components of the extracellular matrix in vivo.
These cultures lack heterotypic cell-cell contacts and fail to recapitulate three-
dimensional (3D) tissue architecture, (b) The morphology and behaviour of non-
transformed epithelial cells in 3D culture more accurately mimics breast structure
and function. These cells undergo a morphogenesis process similar to that seen in
vivo in normal breast, (c) When breast cancer cell lines are grown in 3D culture, they
fail to growth arrest, lack polarity, display abnormal architecture and may become
invasive. Whilst this is similar to what is observed in vivo, not all changes occur at













Identification of a 9-gene claudin-low/ EMT signature derived from breast cancer
models
Claudin-low breast cancers are a novel molecular subtype, identified following
comparisons between mouse models of breast cancer and human cancers [51]. This
subtype appears closely related to EMT, as well as to intrinsic resistance to common
therapies [169], Recent in vitro work has shown a clear overlap between the claudin-
low phenotype and a C35-expressiong cell line system [206]. C35 (also known as
C17orf37 or MGC14832) is a 12KDa membrane-anchored protein found on the
HER2 amplicon and is overexpressed in ~11% of breast cancers [286], Importantly,
expression of C35 in vitro can induce mammary epithelial cell transformation
associated with acquisition of an EMT phenotype. Increased expression of C35 was
associated with increased invasion in 3D culture, down-regulation of E-cadherin
expression and up-regulation of the transcription repressor Twist (Figure 5.2a-c)
[206], Corresponding AQUA scores for C35 and E-caderin protein expression are
shown (Figure 5.2d). These results suggest that invading C35-expressing cells may
consitute a good model for the investigation ofEMT and the claudin-low phenotype.
Consequently, genes correlating with C35 expression (and consequently EMT) and
those identifying the claudin-low phenotype were compared using gene expression
micro-array data. The top 100 illumina probes most differentially expressed between
C35 and parental cells were identified. Of these, 57 corresponded to genes examined
in the work of Flerschkowitz and colleagues [51]. These 57 genes were sufficient to
cluster together the 13 claudin-low tumours identified and 9 of these 57 genes were
shared with a 34 gene claudin-low cluster (Figure 5.3). In addition, all of the genes
on the illumina array representing the 34 gene claudin-low cluster (of which there
were 25) were significantly down-regulated in C35-expressing cells compared with
o
parental cells (p < 1x10" ).
The 9 genes commonly expressed between claudin-low tumours and C35-expressing
cells can be grouped into functional clusters: polarity and cell-cell contact (CDH1,
CLDN7, CRB3, KRT8. TACSTD1), protein trafficking (MAL2, MARVELD3) and
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protease-related (1RF6, SPINT2) (Table 5.1). Some of these genes (CDH1, CLDN7,
TACST1, CRB3 and KRT8) have previously been reported to be down-regulated in
either claudin-low cancers or in the context of EMT in vitro [287-291], In addition,
SPINT2 (hepatocyte growth factor activator inhibitor-2 or HAI-2) has been shown to
regulate the HGF-induced invasion of breast cancer cells in vitro [292],
Importantly, all 9 genes were down-regulated in both claudin-low tumours and C35-
expressing cells, suggesting that a common repressive mechanism underlies this
phenotype. Therefore, oligo-analysis was carried out to determine whether these
genes share common regulatory elements in their promoter regions and identified a
shared 7-mer (CAGGTGC/GCACCTG) [293], This binding motif is targeted by E-
box transcription repressors including members of the Snail and Zeb families. These
findings raise the possibility that transcriptional repression regulates the expression
of these EMT-related genes both in vitro and in vivo. Other regulatory mechanisms,
such as DNA methylation, may also regulate this phenotype and evidence that these







Figure 5.2. C35-expression leads to an invasive phenotype, associated with EMT.
H16N-2 cells were retrovirally transfected with C35 protein. Colonies expressing i)
empty vector (null, left panels), ii) variable levels of C35, termed C35-pool (C35,
middle panels) and iii) high levels of C35 protein (C35hl, right panel) were stained
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by immunohistochemistry for C35 (a), E-cadherin (b) and Twist (c). Specific areas of
E-cadherin loss are observed in the C35 pool (arrows) whilst a more general loss is
observed in the C35hl- expressing cells. Importantly, this is accompanied by up-
regulation of Twist expression. Bar =100 pm. (d) Quantification of C35 and E-
cadherin by AQUA. Expression of C35 protein is inversely correlated to that of E-
cadherin. The mean of three replicates is shown in all cases.
102





Figure 5.3. Comparison of genes correlating with C35 expression and those
identifying the claudin-low phenotype identifies a 9-gene EMT signature. The top
100 illumina probes most differentially expressed between C35 and parental cells
were identified, 57 of which correspond to genes examined in the Herschkowitz
dataset [51]. These 57 genes were able to cluster together the 13 claudin-low tumours
identified by Herschkowitz and colleagues and 9/57 are shared with a 34-gene
claudin-low cluster. In addition, these 34 claudin-low genes are able to cluster
together parental and C35-expressing cells. The 9 genes comprising this signature are
shown in Table 5.1. For full gene lists refer to [293].
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Validation of the 9-gene signature by qRT-PCR and identification of representative
cell lines
The identification of a concise gene signature that reflects invasion and EMT
provides a means of identifying candidate cell lines for the in vitro study of these
processes. Quantitative RT-PCR was performed to validate the observed down-
regulated expression of the 9-gene signature in the C35 model. High C35 expression
was associated with the clear down-regulation of eight of these genes in comparison
with parental cells (Figure 5.4). This is observed when epithelial cells are seeded on
plastic and on contracted collagen lattices, on which they have the opportunity to
invade. Marveld3 could not be assessed due to particularly low levels of expression.
Varied expression levels are seen in the C35 pool (which contains clones with
variable expression levels of C35) although expression tended to be similar to that of
parental cells.
Having validated the 9-gene signature in the C35 model, a series of eight claudin-
low/EMT cell lines were identified from the large set characterised by Neve and
colleagues by means of gene expression micro-array data [204] (for details of these
lines including culture conditions see Materials and Methods). The clear
mesenchymal or spindle-shaped morphology of these cells when cultured on plastic
is shown (Figure 5.5). These cells contact neighbouring cells only focally. This is in
contrast to the cobblestone appearance ofMCF10A cells which, in addition, maintain
close contact with their neighbours. As with the C35 model, the down-regulation of
the 9-gene signature in these cell lines, excluding Marveld3, was confirmed by
quantitative RT-PCR (Figure 5.6). Normal HMECs were used for comparison.
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SPINT2 MAL2
on plastic invading on plastic invading
Figure 5.4. Genes down-regulated in the C35-induced, transformed phenotype. C35-
induced down-regulation of CDH1, CLDN7, CRB3, KRT8, TACSTD1, IRF6,
SPINT2 and MAL2 was confirmed by qRT-PCR. This is found both in cells grown
on plastic and in cells grown on contracted collagen lattices with the opportunity to
invade. MARVELD3 could not be assessed due to particularly low levels of
expression. Biological triplicate mRNA expression data is shown for the empty
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Figure 5.5. Claudin-low/EMT cell lines exhibit a mesenchymal morphology. Eight
potential claudin-low/EMT cell lines were identified. Representative live microscopy
images of these lines cultured on plastic are shown. Note the predominant
mesenchymal morphology of these cells. The non-transformed cell line, MCF10A,
shows a contrasting cobblestone morphology. Insets illustrate the contrasting
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Figure 5.6. Genes down-regulated in the claudin-low/EMT cell lines. Low
expression of CDH1, CLDN7, CRB3, KRT8, TACSTD1, IRF6, SPINT2 and MAL2
was confirmed by qRT-PCR in a panel of 8 cell lines. As before, MARVELD3 could
not be assessed due to particularly low levels of expression. HMECs are shown for
comparison and express significantly higher levels of mRNA for each gene
examined. Technical triplicate mRNA expression data is shown for each line.
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Claudin-low/EMT cell lines show up-regulation of key transcriptional drivers of
EMT
Several transcription repressors have been identified as important drivers of EMT,
both in development and in cancer progression. These include Snail, Slug, Zebl,
Zeb2 and Twist [76], Importantly, examination of gene expression micro-array data
suggests that the selected claudin-low/EMT cell lines have elevated expression of
Slug, Zebl and Twist (Figure 5.7a). Western blots were carried out in order to
investigate the expression of these and other transcription repressors at the protein
level. The expression of other EMT-related proteins was also examined in order to
further characterise the cell lines (Figure 5.7b). All claudin-low cell lines show low
levels of E-cadherin and Claudin-7 in comparison to normal mammary epithelial
cells. Most cell lines have detectable levels of Snail whilst Slug is absent only in
MDA MB231 cells. Interestingly, strong expression of active p-catenin is seen in
normal mammary epithelial cells. Whilst these blots are derived from cell lines
cultured in 2D, this may reflect the positive correlation between p-catenin and E-
cadherin seen in human tumours (Chapter 3). However, western blot gives no
information about the cellular localization of these proteins, which is key to
understanding their function. Most claudin-low lines variably express the
mesenchymal markers N-cadherin, vimentin and fibronectin. Normal mammary
epithelial cells express strong levels of fibronectin and the exact reason for this is not
clear. Twist antibodies were non-specific for western blot and blots are therefore not
shown. A suitable Zebl antibody for use in western blot also could not be found.
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Figure 5.7. Claudin-low/EMT cell lines express key markers of EMT. (a)
Examination of gene-expression micro-array data suggests that claudin-low/EMT
cell lines have elevated expression of the transcriptional repressors Slug (Snail2),
Zebl and Twist [204]. (b) Western blots examine the expression of these and other
EMT-related markers at the protein level. HMECs are shown for comparison. As
expected, these cells show high levels of E-cadherin and claudin-7.
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A novel 3D invasion assay mimics invasion across the basement membrane
The acquisition of an invasive phenotype, and in particular the ability to breach the
basement membrane, is a critical event in cancer progression. A 3D model that
attempts to mimic this process was developed. Epithelial cells were embedded in
laminin-rich, basement membrane-like Matrigel to generate a cell 'plug' which was
subsequently embedded in collagen to mimic surrounding extracellular matrix
(Figure 5.8). This model potentially generates a three-stage assay that allows
investigation of cells i) contained by basement membrane, ii) as they invade across
basement membrane and iii) as they invade more distally into surrounding
collagen/ECM. In addition, the movement of cells in a horizontal plane can be easily
followed by light microscopy, in contrast to the movement of cells in a vertical plane
that occurs with the collagen-based 'on top' assay [206],
Three claudin-low/EMT lines (HBL100, HS578T and SUM 159PT) demonstrated
clear and reproducible invasion in this novel assay. Importantly, all three lines adopt
a round morphology when embedded in Matrigel (day 0), versus the predominantly
elongated morphology that is seen in collagen. By day 7, the HBL100 and HS578T
cells have reverted to an elongated morphology, indistinguishable from that seen in
collagen, and are invading across basement membrane and into surrounding
collagen. In contrast, many SUM159PT cells retain a round morphology,
accompanied by delayed invasion. By day 14, SUM159PT cells appear to have
overcome this inhibition and many elongated cells are now seen leaving the Matrigel
plug (Figure 5.9). H&E staining confirms these morphological observations (Figure
5.10). MCF10A cells (an untransformed line) were also investigated in this assay and
show no invasion. As expected, MCF10A cells appear to form polarised, growth
arrested structures. These observations suggest that this model may allow the
investigation of cells as they invade across the basement membrane. Importantly,
SUM159PT cells are the most affected by Matrigel in terms of morphology and
invasive capacity, and were therefore selected for further investigation.
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Figure 5.8. A novel 3D invasion assay. Epithelial cells are embedded in basement
membrane-like Matrigel to generate a cell plug. This plug is subsequently embedded
in collagen to mimic surrounding extracellular matrix. Epithelial cells are then






















Figure 5.9. Morphological changes suggestive of spontaneous transitions between
MET and EMT states are observed by light microscopy, (a) Cell-collagen plugs were
made with HBL100, EIS578T and SUM159PT cell lines. These exhibit a
predominantly elongated morphology at day 0. Clear invasion into surrounding
collagen is seen by day 7 in all three lines (arrows), (b) Cell-matrigel plugs made
with the same lines exhibit a marked rounded morphology on day 0, contrasting with
that seen with cell-collagen plugs. By day 7, HBL100 and HS578T cells have
reverted to an elongated morphology and are invading into surrounding collagen. In
contrast, SUM159PT cells retain a rounded morphology accompanied by delayed
invasion (day 7) although this appears to be overcome by day 14. Dotted lines
represent the original plug edge. Bar = 100 pm.
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Figure 5.10. H&E staining confirms the observations made by light microscopy.
Only assays using SUM159PT cells are shown here. Cell-collagen (top panel) and
cell-matrigel (bottom panel) plugs were fixed at day 14 following a period of
invasion. Images of the whole plugs (4x magnification; bars = 100 pm), plug cores
and plug edges are shown (both 40x magnification; bars = 100 pm). Note the
organised, rounded morphology in matrigel (bottom panel) in contrast to the
elongated morphology as cells invade into surrounding collagen, suggestive ofEMT.
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Stromal fibroblasts have been shown to play critical roles in some models of
invasion, remodelling the ECM and generating tracks along which epithelial cells
can follow [299], The role of normal and cancer-associated fibroblasts (CAFs) was
therefore investigated here. No difference in invasion was evident with both normal
fibroblasts and CAFs and this lack of effect on invasion was seen when epithelial cell
plugs were made with both collagen and Matrigel (Figure 5.11). H&E staining at





























Figure 5.11. Fibroblasts have no obvious effect on the invasion of SUM159PT cells.
Comparable invasion is seen by light microscopy with no, normal and cancer-
associated fibroblasts at days 3, 6 and 10. This is observed both in collagen-based
{top panel) and matrigel-based {bottom panel) cell plugs. As previously observed,
SUM159PT cells exhibit a rounded morphology in matrigel and delayed invasion.
Bar = 100 pm.
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Figure 5.12. H&E staining confirms the comparable invasion of SUM159PT cells
regardless of the presence or type of fibroblasts in the surrounding collagen.
Comparable invasion of SUM159PT cells is seen with no, normal and cancer-
associated fibroblasts. This is seen at both 6 (top panel) and 10 days (bottom panel)
and is independent of the epithelial plug type. Bar = 100 pm.
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The expression of EMT markers changes as cells invade across basement
membrane
What mechanisms underlie the invasion of cells across the basement membrane as
observed here? To begin to answer this question the expression of E-cadherin and N-
cadherin, both important markers in EMT, was examined using immunofluorescence.
As HBL100 and HS578T appear to rapidly overcome the influence of Matrigel,
SUM159PT cells were again selected for comparison with MCF10A cells.
MCF10A cells show uniform, membranous expression of E-cadherin and no
expression of N-cadherin. In contrast, SUM159PT cells show no membranal E-
cadherin expression. Instead, E-cadherin expression appears to be nuclear, the
significance of which is not clear but may reflect a non-functional E-cadherin.
SUM 159PT cells show membranal N-cadherin expression throughout the core of the
plug whilst N-cadherin expression appears to be lost in the elongated, invading cells
at the periphery (Figure 5.13 and 5.14). Therefore, two important observations are
made: i) despite similar, round morphology within the plug, the pattern of E-cadherin
expression in MCF10A cells is comparable to that of N-cadherin in SUM159PT
cells; ii) perhaps surprisingly, SUM159PT cells demonstrate loss of N-cadherin as
they invade. These findings may explain the lack of a cadherin switch that was










Figure 5.13. Immunofluorescent images illustrate expression patterns of E-cadherin
and N-cadherin in MCF10A cells. MCFIOA cells show membranous E-cadherin
expression throughout the cell plug (top 2 panels). No expression of N-cadherin is
seen (bottom 2 panels). In addition, MCFIOA cells shown no evidence of invasion
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Figure 5.14. Immunofluorescent images illustrate expression patterns of E-cadherin
and N-cadherin in SUM159PT cells. SUM159PT cells appear to express nuclear E-
cadherin (top 2 panels). Despite the rounded morphology of cells within the plug,
membranal N-cadherin expression is observed. In addition, N-cadherin expression is
lost in the elongated, mesenchymal cells that invade out of the plug (bottom 2
panels). Dotted lines represent the plug edge. Bar = 50 pm.
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Table 5.1. Comparison of genes correlating with C35 expression/EMT and claudin-
low tumours identifies a 9-gene signature.
Gene Protein Name Function Evidence of Promoter
Methylation
CDH1 E-cadherin Adherens junctions Breast and other
cancers
CLDN7 Claudin-7 Tight junctions Breast
CRB3 Crumbs Polarity complex Not available
IRF6 Binds to maspin Not available
KRT8 Keratin-8 Intermediate filaments MCF7 cells
MAL2 Protein trafficking Not available
MARVELD3 Related to MAL2 Not available
SPINT2 HAI-2 HGF activation Liver cancer
TACSTD1 EpCAM Cell-cell contact Various cell lines
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Chapter 6: Discussion
EMT is believed to be a mechanism that allows cells to acquire an invasive
phenotype critical for cancer progression [68]. However, most of the evidence
supporting this function in cancer is based on in vitro experimental systems using
cell lines. This thesis had two broad aims. Firstly, to clarify the role of EMT in
human breast cancer by examining the expression of key protein markers of EMT in
primary tumours and, for a subset of these, in paired LN metastases. Secondly, this
thesis aimed to develop a 3D in vitro model for the investigation of invasion and in
particular the mechanisms underlying EMT as cells invade into collagen.
Evidence for transcriptionally driven EMT programmes is identified in human
breast cancer
An EMTprogramme comprising vimentin, Snail and Slug
The expression of, and correlations between, a wide range of EMT markers was
examined to determine whether relationships identified in vitro are maintained in
human breast cancer. This led to the identification of significant correlations between
vimentin, Snail and Slug, suggesting that a transcriptionally driven programme may
be in place in human breast cancer. Although not predictive of clinical outcome, this
programme was reproducible across two independent patient cohorts.
Snail and Slug are known transcriptional repressors of E-cadherin protein expression
in vitro [76], However, whilst strongly expressed in some tumours, these repressors
showed no correlation with E-cadherin in both patient cohorts. Similar results were
found for vimentin expression. These findings suggest that the programme identified
here is uncoupled from down-regulation of E-cadherin and supports the hypothesis
that EMT does occur in vivo but in a manner distinct to that suggested by in vitro
studies. Up-regulation of some EMT markers with associated down-regulation of E-
cadherin has been reported in a subset of human breast cancers [131]. However, this
study used immunohistochemical methods which are less quantitative and objective
than AQUA analysis. In addition, the arbitrary division of protein expression as
positive or negative is unlikely to accurately reflect the biology of biomarker
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expression [240], Comparison between this study and the results presented here is
further limited as only E-cadherin, N-cadherin and vimentin expression were
examined in both cases.
A number of studies have reported expression of vimentin, Snail and Slug that is at
least partially uncoupled from down-regulation of E-cadherin. Come and colleagues
have examined the expression of Snail, Slug and E-cadherin mRNA in a series of
transformed cell lines and breast carcinomas [219], In accordance with other studies
they found that Slug and Snail negatively correlated with E-cadherin in cell lines
[300, 301], However, in normal HMECs and in a large panel of breast tumour
samples, E-cadherin was found to co-express with Snail and Slug. Cell line models
have shown that Snail and Slug can target E-boxes in the E-cadherin promoter to
repress E-cadherin transcription [300, 301] and the persistent co-expression of these
markers in tumours suggests that other regulatory elements are involved in vivo [302,
303]. Another study examined the expression of E-cadherin, vimentin and Snail as
well as migratory potential in a series of cell lines exposed to hypoxia [304], Despite
an increase in Snail expression across all lines examined the observed EMTs were
described as partial as E-cadherin expression and migratory potential were variably
effected. Chao and colleagues have examined the expression of epithelial and
mesenchymal markers in paired breast primary and metastatic tumours [305]. They
describe a significantly increased expression of E-cadherin in metastases but
unchanged expression of mesenchymal markers including vimentin. This persistence
ofmesenchymal markers suggests that subsequent EMTs at the metastatic site might
be important for disease progression (discussed subsequently) but also supports our
finding that vimentin expression can be uncoupled from E-cadherin expression.
Candidate up-stream regulators of an EMT programme comprising vimentin, Snail
and Slug in breast cancer may already have been described. Ladybird homeobox 1
(LBX1), a developmentally regulated homeobox gene, has been shown to regulate
Snail in the context of breast cancer [306], Down-stream targets of Snail and Slug, in
the context of breast cancer, also need to be identified and may include members of
the MMP gene family. These MMPs are up-regulated in many tumour types
including breast [307]. One study identified a correlation between Slug mRNA
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expression and MMP2 in ovarian carcinomas. This correlation was not seen in breast
carcinomas although numbers in this part of the study were limited [217], More
recently, Weiss and colleagues reported that Snail can induce a basement membrane
transmigration programme which is dependent on the membrane-anchored
metalloproteinases, MT1-MMP and MT2-MMP. Silencing of these MMPs inhibited
the ability of Snail to drive basement membrane invasion, angiogenesis and
intravasation in vitro in breast cancer cell lines [285]. In addition, MMP1, MMP2
and MT1-MMP, are up-regulated by Snail in the context of hepatocellular carcinoma
cell lines [308]. Both MMP1 and MMP2 are found in primary breast carcinomas and
their expression is significantly higher in those primary tumours associated with
distant metastases [309], It has been recently shown in vitro that elongation of
invadopodia, the specialized protrusions used by invasive cells to breach basement
membrane, is dependent on an intact vimentin filament network. This is evidence
that vimentin also has a functional role in MMP-mediated EMT [93],
A WTl-related EMT programme is identified, and acquisition in LN metastases
predicts poor clinical outcome
As a result of recent studies, focus was directed to WT1 and its relationship with E-
cadherin, Snail and Slug [261, 262], In addition, due to the emerging importance of
LNs as a source of biological information [196], analysis of these markers was
extended to paired LN metastases. This modified approach resulted in the
identification of a novel, WTl-related EMT programme in human breast cancer. This
programme is evident in both primary tumours and LN metastases and is
characterised by up-regulation of WT1, Snail and Slug and, importantly, down-
regulation of E-cadherin. Expression of a WTl-related EMT programme is not
predictive of poor clinical outcome in both primary tumours and LN metastases.
However, the concept of examining marker expression in combination rather than
independently is an attractive one. A recent study in gastric cancer found that
combined altered expression of E-cadherin, vimentin, Snail and the stem cell marker
CD44 (specifically loss of E-cadherin and gain of mesenchymal proteins or CD44)
was significantly associated with aggressive clinical features and shortened disease
free survival [310],
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A key finding is that acquisition of this WT1-related EMT programme by cells
invading locoregional LNs predicts worst clinical outcome. The effect on survival is
significant in comparison with tumours that maintain their phenotype (i.e. maintain
expression of either an EMT or a non-EMT programme) whilst tumours that appear
to undergo MET form an intermediate group. These findings suggest that whilst an
EMT programme may be advantageous for invasion, an ability to move between
EMT and MET states in accordance with a changing microenvironment reflects
greater adaptability and therefore aggressiveness [76], These findings are thought to
reflect the complexity of the metastatic process and the fact that a breast tumour must
pass through cycles of invasion and tumour regeneration at new sites (i.e. LNs) in an
effort to establish distant metastases. The role of an MET in enabling metastatic
colonization has been proposed by a number of studies [68]. In addition, a recent
study in prostate cancer has shown that E-cadherin expression in metastatic deposits
is inversely correlated with the size of the metastasis [305]. This suggests that EMT
states in metastatic deposits are associated with more aggressive disease and that
sustained phenotypic plasticity beyond the primary tumour is important. Whilst
reversion to an epithelial phenotype may facilitate the survival of tumour cells in the
foreign environment of the metastatic site, it does not explain the generation of a
macrometastasis or the generation of metastatic deposits at other sites. However, the
increasingly supported concept that EMT confers many of the properties of stem
cells including self-renewal [111, 173, 174] provides an attractive mechanism by
which tumour cells can repopulate the metastatic site. Other studies support the role
of Snail and Slug in disease progression in the context of breast cancer. Snail and
Slug are significantly over expressed in tumours with associated LN metastases,
although no comparison with paired primary tumours is reported [219], Snail
expression in metastatic pleural effusions has also been shown to be negatively
predictive of disease free and overall survival in breast carcinoma [217],
We recently reported a similar, WT1-related programme in ovarian carcinoma
(Faratian et al., unpublished observation). In contrast to the situation in breast,
expression of this programme in primary tumours was associated with a significantly
worse prognosis. In addition, multivariate analysis with stage and histological type
showed that expression of this phenotype is an independent poor prognostic factor.
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However, expression of the WT1-related programme was not enriched by and did
not predict response to chemotherapy. This is in contrast to recent findings in breast
[166, 169], The differing predictive role of this EMT programme in ovarian and
breast may reflect the features of ovarian cancer spread that distinguish it from other
epithelial tumours. Ovarian carcinoma can spread by direct extension into adjacent
organs and, whilst lymphatic dissemination occurs, spread through the vasculature is
uncommon [311, 312], In contrast, breast carcinoma cells must acquire an ability to
invade locally, travel through the vasculature and lymphatics and finally establish
distant metastases in a foreign microenvironment [268]. More recently, the protein
expression of E-cadherin, Snail and Slug has been explored in renal cell carcinoma
[313]. 14/61 patients were found to express an EMT signature comprising high E-
cadherin and low Snail and Slug expression but this showed no correlation with
clinical outcome.
The results presented here support a role for EMT-promoting transcription factors, in
particular Snail and Slug, in cancer progression. As previously discussed, these
factors can act as cofactors for Smads resulting in the formation of EMT promoting
Smad complexes (EPSC) which represent a point of convergence between a number
of signalling pathways [110]. In Chapter 5 a 9-gene claudin-low/EMT signature was
identified [293], Interestingly, transcriptional repressors are not part of this signature
although they are broadly expressed in claudin-low cell lines. In addition, analysis of
the promoter regions of the 9 genes shows that they have the potential to be targeted
by E-box repressors including members of the Snail and Zeb families. Evidence that
some of these genes are targeted by Snail and Slug is present in the literature [289,
301, 314-316], but further work is required to fully understand the role of these
proteins in human breast cancer.
The results presented here also suggest that quantitative analysis of molecular
markers between primary and nodal disease may hold important biological
information. In support of this, a recent study showed that a significant number of
patients show discordant expression of ER, PR or HER2 receptor status between
primary and nodal disease [196]. These observations have clinical implications as
adjuvant therapy decisions are founded on the molecular pathology of the diagnostic
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core biopsy or primary resection specimen. Consequently, current treatment failures
may, at least in part, reflect a changing biology as tumour cells leave the primary
site.
EMT in vivo is distinct from the EMT observed in vitro
Examination of the expression of EMT markers, and in particular their relationship
to E-cadherin, suggests that many of the relationships reported in vitro are not
maintained in human breast cancer. The relationship between E-cadherin and
transcriptional repressors has already been discussed. In addition, no reproducible,
negative correlation with N-cadherin was observed, indicating that human breast
cancers as a whole do not demonstrate a cadherin switch as observed in vitro [86].
The nuclear translocation of P-catenin, resulting from either Wnt signalling of loss of
E-cadherin-P-catenin junctions, has been identified as a driver ofEMT in in vitro and
animal studies [186, 232], Therefore, the relationship between E-cadherin and P-
catenin was examined here. Importantly, a significant and reproducible correlation
between E-cadherin and P-catenin protein expression was seen, suggesting that p-
catenin does not drive EMT in human breast cancer. Rather, this suggests that the co-
localization of E-cadherin and P-catenin at cellular junctions, as seen in normal
epithelial tissues, is maintained [82], In addition, univariate analysis showed no
correlation between P-catenin expression and clinical outcome. These findings are in
contrast to those of Rimm and colleagues who reported a significant correlation
between loss of cytoplasmic P-catenin and poor clinical outcome using AQUA [240].
However, positive correlations between E-cadherin and P-catenin in human breast
cancer, with no correlation to outcome, have recently been described using
immunohistochemical methods [317], Other immunohistochemical studies have
investigated p-catenin expression patterns and correlation with clinical outcome with
mixed results [238, 239].
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Examination of EMT markers in primary tumours and their metastases may be key
to understanding EMT in human breast cancer
Two, transcriptionally-driven, EMT programmes, both comprising Snail and Slug,
have been identified here. Importantly, one programme appears uncoupled from E-
cadherin down-regulation whilst the other includes it. In both cases, unsupervised
clustering shows that these programmes are variably expressed in different tumours.
These findings are not surprising given the accumulating evidence that EMT need
not comprise a single, conserved programme. Partial or incomplete EMT
phenotypes, where advanced carcinomas display some mesenchymal features whilst
retaining characteristics of well-differentiated epithelial cells, have been described in
several studies [318]. In a recent review, Klymkowsky and Savagner categorized
various EMT-like phenotypes identified in a series of human carcinomas, based on
features seen in vitro, into corresponding EMT-like 'stages' [122], In addition, the
examination of additional markers, in spite of the comprehensive analysis carried out
here, may reveal more complete or consistently expressed EMT programmes.
Importantly, examination of LN metastases has shown that the acquisition of the
WT1-related programme in the transition from primary tumour to LN metastases is
predictive of clinical outcome. In contrast, no single marker examined here, both in
primary tumour and in LN metastases, correlated with outcome. This suggests that
understanding the role of EMT markers may depend on investigating how their
expression changes as the tumour progresses.
A novel, 3D in vitro model of invasion demonstrates spontaneous EMT
A novel, 3D in vitro model that allows cells to be investigated as they migrate into
collagen and undergo spontaneous EMT has been developed. A number of
preliminary but key observations have been made. Claudin-low/EMT cell lines lose
their mesenchymal morphology and acquire a rounded, organised morphology when
contained within Matrigel. This morphology is very similar to that of the
untransformed MCF10A cell line within the same assay and is consistent with a
more benign phenotype [281, 319], Importantly, claudin-low cell lines appear to
undergo spontaneous EMT, re-acquiring a mesenchymal morphology, as they invade
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into collagen. These morphological changes were particularly marked in SUM159PT
cells which maintain a rounded morphology for longest and consequently exhibit the
greatest delay in invasion. Importantly, immunofluorescent staining showed that
despite a similar rounded morphology within Matrigel, MCF10A cells express
membranal E-cadherin whilst SUM159PT cells express membranal N-cadherin and a
presumed non-functional nuclear E-cadherin. A number of studies have shown that
internalization of E-cadherin is a mechanism by which cells can disrupt E-cadherin
function, supporting this hypothesis [320, 321]. In addition, SUM159PT cells loose
N-cadherin expression as they undergo a supposed EMT and invade. These findings
raise questions regarding the role of these proteins, and in particular the role of a
cadherin switch, in regulating cell morphology and behaviour. Maeda and colleagues
have made some interesting observations regarding the timescale of events when
untransformed mouse mammary epithelial cells undergo EMT [322], They found
that E-cadherin expression was maintained until day 3 whilst morphological change
and up-regulation of N-cadherin occurred within 1 day, suggesting that induction of
N-cadherin rather than down-regulation of E-cadherin is important for morphological
EMT. However, knock-down of N-cadherin did not prevent these cells from
undergoing morphological EMT and N-cadherin over expression did not induce any
loss of epithelial morphology. These findings support our suggestion that
morphological change and N-cadherin up-regulation are independent events. The
loss of N-cadherin by invading SUM159PT cells observed in our Matrigel based
model is reminiscent of the absence of a cadherin switch observed in human tumours
in Chapter 3 and raises further questions about the role of a cadherin switch in vivo
[323]. Other studies report discrepancies between morphology and behaviour in
EMT. For example, down-regulation of E-cadherin in HCT116 colorectal carcinoma
cell lines is associated with up-regulation of vimentin and mesenchymal morphology
but these cells fail to invade in a 3D matrix [324]. Equally, silencing of Snail in an
ovarian cancer cell line impairs invasion although a mesenchymal morphology is
retained [325]. In keeping with the observations made here, these findings emphasise
the complexity of EMT and suggest that key features of EMT may be differentially
regulated. This may have implications when relying on a single feature (i.e.
morphological change) as indicative ofEMT.
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Our findings suggest that we have developed a model that may closely reflect some
aspects of EMT biology as it occurs in human tumours. A next step will be to
examine whether transcriptionally driven EMT programmes, as seen in human
tumours, are reproduced in this model, and whether they can be manipulated to
prevent or reverse EMT and invasion. Targetable pathways identified in this way
may by clinically relevant. In addition, manipulation of EMT markers within this
model may allow relationships between markers to be better understood and
separated from simple associations.
Future directions
In addition to continuing the investigation of EMT markers in paired LN metastases
and the mechanisms underlying EMT in our in vitro assay, other areas for future
investigation are evident. Methylation and suppression by miRNAs are alternative
mechanisms believed to regulate E-cadherin expression and EMT in breast cancer
[74, 75, 186]. However, the use of historical, paraffin embedded tissues in our study,
with potentially compromised preservation of nucleic acids, has limited investigation
to the protein level. Teasing out the role of different mechanism of E-cadherin down-
regulation is likely to be important in identifying and understanding EMT. For
example, the down-regulation of E-cadherin by methylation but not mutation is
related to EMT in cell lines [326], Similarly, despite shared down-regulation of E-
cadherin, ILCs are molecularly and clinically distinct to IDC-NST [194], Future
studies examining alternative mechanisms of E-cadherin loss in fresh frozen tissues,
in parallel to immunofluorescence analysis, are envisaged. The combination of
altered biomarker expression and morphological change as markers of EMT is also
envisaged as a means of capturing more 'complete' EMTs.
This study has examined the expression of protein markers of EMT at the whole
tumour level. Whilst many studies do not quantify changes in protein expression
according to tumour edge and tumour core, a number of studies suggest that EMT
primarily occurs at the tumour invading edge [327, 328]. Importantly, a study in
human squamous cell carcinoma found that changes in the expression of two out of
three EMT markers identified at the invasive edge where maintained at the whole
tumour level [329]. Therefore, whilst examination at the whole tumour level is likely
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to yield important biological information, a careful comparison to changes at the
invading edge is needed.
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A gene on the HER2 amplicon, C35, is an oncogene in breast
cancer whose actions are prevented by inhibition of Syk
E Katz*'1, S Dubois-Marshall1, AH Sims', D Faratian1, J Li2, ES Smith2, JA Quinn3, M Edward3, RR Meehan1'4,
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background: C35 is a l2kDa membrane-anchored protein endogenously over-expressed in many invasive breast cancers. C35
(CI7orf37) is located on the HER2 amplicon, between HER.2 and GR87. The function of over-expressed C35 in invasive breast
cancer is unknown.
methods: Tissue microarrays containing 122 primary human breast cancer specimens were used to examine the association of C35
with HER2 expression. Cell lines over-expressing C35 were generated and tested for evidence of cell transformation in vitro.
results: In primary breast cancers high levels of C35 mRNA expression were associated with HER2 gene amplification. High levels of
C35 protein expression were associated with hallmarks of transformation, such as, colony growth in soft agar, invasion into collagen
matrix and formation of large acinar structures in three-dimensional (3D) cell cultures. The transformed phenotype was also
associated with characteristics of epithelial to mesenchymal transition, such as adoption of spindle cell morphology and
down-regulation of epithelial markers, such as E-cadherin and keratin-8. Furthermore, C35-induced transformation in 3D cell cultures
was dependent on Syk kinase, a downstream mediator of signalling from the immunoreceptor tyrosine-based activation motif, which
is present in C35.
conclusion: C35 functions as an oncogene in breast cancer cell lines. Drug targeting of C35 or Syk kinase might be helpful in treating
a subset of patients with HER2-amplified breast cancers.
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The gene C35 (C17orf37) is located within the smallest region of
amplification of the HER2 amplicon, between HER2 and GRB7. It is
a 12kDa membrane-anchored protein over-expressed in 40-50%
of invasive breast cancers (Evans et al, 2006). C35 has recently
been implicated in conferring invasive potential in prostate
cancer cell lines (Dasgupta et al, 2009). It contains a canonical
immunoreceptor tyrosine-based activation motif (ITAM; Evans
et al, 2006), a motif common in receptors of the immune system
(Underhill and Goodridge, 2007), which has been associated with
cell transformation through the activation of downstream Syk
signalling. This raises the possibility that C35 can function as a
transforming oncogene. The ability of ITAM-containing proteins
to transform non-haematopoietic cells was previously shown using
viral glycoproteins, such as the murine mammary tumour virus
envelope protein (MMTV Env; Katz et al, 2005). Other examples of
non-haematopoietic transformation by ITAM-containing proteins
include latent membrane protein 2A of Epstein-Barr virus in skin
keratinocytes (Lu et al, 2006) and K1 protein of Kaposi's sarcoma-
associated herpes virus in endothelial cells (Wang et al, 2006).
^Correspondence: Dr E Katz; E-mail: elad.katz@ed.ac.uk
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Particularly relevant were the observations that ITAM-containing
proteins contribute to mammary epithelial cell (MEC) transforma¬
tion and development of mammary carcinomas (Katz et al, 2005;
Grande et al, 2006; Ross et al, 2006).
Using the ITAM-containing envelope protein ofMMTV Env and
a chimeric B-cell receptor protein, many researchers have made
several key observations (Katz et al, 2005; Grande et al, 2006; Ross
et al, 2006): (1) ITAM-containing protein expression can transform
immortalised normal MECs in three-dimensional (3D) culture;
(2) ITAM-induced transformation is dependent on its tyrosine
phosphorylation and is associated with downstream Src and Syk
kinase activation and (3) mutation of the ITAM tyrosines reduces
tumour induction markedly by MMTV in vivo and influences its
genomic integration. Therefore, ITAM-containing protein expres¬
sion can switch on an intrinsic transformation programme in
MECs. This programme is closely associated with epithelial to
mesenchymal transition (EMT). Whereas epithelial markers such
as E-cadherin and keratin-18 are down-regulated, mesenchymal
markers such as N-cadherin and vimentin are up-regulated
(Katz et al, 2005; Grande et al, 2006).
In this study, we determined the co-expression of C35 and HER2
proteins in human breast cancers. High levels of C35 expression
were shown to induce invasion mediated by EMT in vitro 3D
C35 in breast cancer
E Katz et al
)2
cultures using cell lines. Mutation of ITAM of C35 (or downstream
Syk inhibition) was sufficient for the reversal of C35-induced
transformation. Syk inhibition in combination with anti-HER2
therapy was shown to be effective in BT474 cell line model, offering
a possible therapeutic approach to treat HER2 1 tumours.
MATERIALS AND METHODS
Tissue microarray construction and AQUA analysis
The population characteristics of the trastuzumab-treated cohort
are summarised in Supplementary Table SI. HER2 gene amplifica¬
tion status was confirmed by fluorescence in situ hybridisation
(FISH) according to the manufacturer's recommendations (HER2
FISH PharmDx; Dako, Ely, Cambridge, UK). The use of this cohort
was approved by the Lothian Research Ethics Committee
(08/S1101/41). After H&E sectioning of representative tumour
blocks, tumour areas were marked for TMA construction and
0.6 mm2 cores were placed into three separate TMA replicates for
each sample, as previously described (Kononen et al, 1998).
Immunofluorescence was carried out using methods previously
described (Camp et al, 2002). Pan-cytokeratin antibody was used
to identify infiltrating tumour cells and normal epithelial cells,
DAPI counterstain to identify nuclei and Cy-5-tyramide detection
for target (C35, 1:500 dilution; Vaccinex, Rochester, NY, USA) for
compartmentalised (tissue and subcellular) analysis of tissue
sections. Monochromatic images of each TMA core were captured
at x 20 objective using an Olympus AX-51 epifluorescence
microscope (Olympus, Southend-on-Sea, UK), and high-resolution
digital images analysed by the AQUAnalysis software (HistoRx
Ltd., Branford, CT, USA). Briefly, a binary epithelial mask was
created from the cytokeratin image of each TMA core. Similar
binary masks were created for cytoplasmic and nuclear compart¬
ments on the basis of DAPI staining of nuclei. C35 expression was
quantified by calculating the Cy5 fluorescent signal intensity on a
scale of 0-255 within each image pixel, and the AQUA score was
computed by dividing the sum of Cy5 signal within the epithelial
mask by the area of the cytoplasmic compartment.
AQUA scores were averaged from replicate cores. If the tumour
epithelium comprised <5% of total core area, the core was
excluded from analysis. To determine the cut-point value for C35
expression in Kaplan-Meier analysis (Altman et al, 1994), we used
X-Tile (Yale University New Haven, CT, USA), which allows
determination of an optimal cut point while correcting for the use
of minimum P statistic (Camp et al, 2004). Overall survival was
subsequently assessed by Kaplan-Meier analysis with log-rank for
determining statistical significance. Comparison of differences in
means of C35 according to HER2 status was carried out using the
Student's f-test. All calculations and analyses were two tailed where
appropriate using SPSS 14.0 for Windows (SPSS Inc., Chicago,
IL, USA).
Immunohistochemistry
The following antibodies were used: C35, an affinity-purified
rabbit polyclonal antibody 78.2 (Vaccinex) at 0.42 //gml"1;
cytokeratins 5/6 (CK5/6), rabbit polyclonal antibody (Dako) at
1:50 dilution; E-cadherin, mouse monoclonal (BD Biosciences,
Oxford, UK) at 1:450 dilution; Twist, mouse monoclonal (Abeam,
Cambridge, UK) at 1:100 dilution and claudin-7, rabbit polyclonal
(Abeam) at 1:100 dilution.
Antigen retrieval for C35, E-cadherin and claudin-7 was carried
out using sodium citrate buffer (18 /<m citric acid, 82 /<m sodium
citrate, pH 6.0). Antigen retrieval for Twist was carried out using
Tris/EDTA buffer (imm EDTA, 10mM Tris-HCl base, pH 8.0).
Standard immunohistochemistry protocol was carried out using
the REAL EnVision mouse/rabbit kit (Dako), according to the
manufacturer's instructions. For C35, comparative staining
showed that automated AQUA immunofluorescence and manual
immunohistochemistry scores correlated as follows: <100:0;
100-200:1+ ; 201-300:2+ and >300:3 + .
HER2 immunohistochemistry was carried out using HercepTest
(Dako), according to the manufacturer's instructions; with antigen
retrieval at 96°C for 40min. Staining was carried out on
Autostainer (Dako). HER2 assessment was carried out according
to the ASCO/CAP guidelines (Wolff et al, 2007). HER2 tumours
were defined as positive only when the immunohistological score
was 3 + and HER2 amplification was subsequently verified
by FISH.
Cell lines, transfection and foci formation
The BT474, T47D, MBA-MD-231 and SKBr3 cell lines were
obtained from the American Type Culture Collection. BT474,
MBA-MD-231 and SKBr3 cells were cultured in RPMI 1640
(Invitrogen, Paisley, UK) supplemented with 10% donor bovine
serum, 50Uml-1 penicillin and 50mgml-1 streptomycin. T47D
cells were cultured in DMEM (Invitrogen) supplemented with 10%
donor bovine serum, 50 Uml 1 penicillin and 50mgml-1 strepto¬
mycin.
H16N-2 is an immortalised cell line derived from normal breast
epithelium that does not over-express C35 (a kind gift from
Dr V Band; Band and Sager, 1991). H16N-2 cells were cultured in
DFCI media (Evans et al, 2006) or commercial MEGM (Lonza,
Slough, UK) supplemented with 5% serum. The culture media were
supplemented with 0.5mgml-1 G418 for vector selection. For
detection of foci formation, we stained confluent monolayers with
crystal violet (0.1% crystal violet, 20% ethanol) for 5min, followed
by de-stain rinse with water.
C35 and ITAM mutants through transfection
The coding region for human C35 protein was cloned into plasmid
vector pIRESneo3 (Clontech, Mountain View, CA) at BsiWl and
BamHI restriction sites. Plasmid DNA encoding wild-type (wt),
Y39F/Y50F ITAM mutant or empty vector was transfected into
host cells using Lipofectamine 2000 (Invitrogen) in OptiMem
transfection medium following the manufacturer's protocol.
Transfection medium was replaced with growth medium after
6h. Transfectants were selected on G418, 48 h after transfection.
Bulk transfected lines were cloned using cloning discs.
C35 recombinant cells by retroviral transduction
The coding region for human C35 protein (Evans et al, 2006) was
cloned into retroviral vector pLXSN. To make a stable retrovirus
producing line, we transfected pLXSN encoding wt C35 or empty
vector into PA317 cells. Viral supernatants were collected, filter
sterilised (0.45 /im) and titrated in the range of approximately 105
PFU per ml. H16N-2 were seeded at 3- to 5 x 106 cells in a T75 flask
and incubated with 3 ml of viral supernatant and 2/tgml-1
polybrene at 37°C for 6h. Infection media were replaced with
DFCI growth media and 0.5/(gml-1 G418 was added at 48 h after
infection. Bulk transduced lines were cloned by limiting dilution.
Cell lines were assessed for C35 expression by western blot and/or
immunofluorescence staining with C35 mouse monoclonal anti¬
body (clone 1F2.4.1; Vaccinex) on fixed and permeabilised cells.
Soft agar colony formation assays
Triplicate wells of a six-well plate were seeded with uniform
H16N-2 or MDA-MB-231 cell suspension diluted in DFCI, 0.33%
agar (4 x 103 cells per well), which was layered over a bottom layer
containing 0.625% agar. Plates were incubated up to 5 weeks at
37°C, fresh media were added to each well every week to replenish
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nutrients and moisture. Presence of colonies was detected under
light microscope and visual inspection, at which point
colonies were stained with P-iodonitrotetrazolium violet dye
(Sigma-Aldrich, Gillingham, UK). Iodonitrotetrazolium violet
stock (dissolved in 95% ethanol at 20mgml~1) was diluted to
lmgml-1 in PBS and 0.25ml was added to each well. After
overnight incubation at 37°C, visible colonies were counted in each
well; counts from three wells were averaged. The number of
colonies was normalised by multiplying the average number of soft
agar colonies by the ratio of attached growth colonies normal to
attached growth colonies transfectant. The attached growth assay
was carried out at the same time as the soft agar assay, where 1/100
of each soft agar dilution was seeded into 100 mm dish. At 10-12
days after seeding, the dishes were stained with crystal violet and
colonies were counted (Foos et al, 1998). Similar results were
obtained in three independent experiments.
Collagen invasion assays
To characterise the mode of invasion of C35-expressing cells, we
carried out collagen invasion assays essentially as previously
described (Amjad et al, 2007). These assays are different from
traditional Boyden chambers in several aspects: (1) the material
used is a mixture of collagen and fibroblasts, generating a lattice of
stroma-like substance; (2) the presence of live fibroblasts allows
for continuing interaction with the epithelial cells; (3) importantly,
the cells are examined as they invade the collagen lattice, not only
measuring the number that have invaded right through the
material.
Briefly, rat collagen I solution was mixed with 105 human breast
fibroblasts (obtained from reduction mammoplasty, referenced in
Amjad et al, 2007) per lattice and left to contract in fibroblast
media (DMEM (Invitrogen) supplemented with 10% serum,
50Uml_1 penicillin and 50mgmU' streptomycin) for 4-7 days.
When the lattices were of the required size (approximately four¬
fold contraction), 3 x 105 H16N-2 cells from the desired lines were
seeded on top of the lattices and incubated as submerged cultures
for 3-4 days in H16N-2 media. To induce invasion, we raised the
lattices to the air/liquid interface and incubated for further 7 days
before the they were fixed in 10% phosphate-buffered formalin and
embedded in wax.
RNA extraction and RT - PCR
RNA was extracted by RNeasy Mini kit (Qiagen, Crawley, UK),
evaluated on Agilent (South Queensferry, UK) Bioanalyzer
(RIN>9.5) and labelled using Illumina TotalPrep RNA amplifica¬
tion kit (Applied Biosystems/Ambion, Austin, TX, USA) according
to the manufacturers' instructions. Triplicate samples from whole
invasion assays (1500 ng cRNA each) were hybridised to Illumina
BeadChips, according to the manufacturer's instructions. Whole-
genome gene expression analysis was performed using Illumina
HumanRef-8 v3 Expression BeadChip and BeadArray Reader.
Microarray data were analysed using packages within Bioconductor
(Gentleman et al, 2004; http://www.bioconductor.org) implemen¬
ted in the R statistical programming language (http://www.
r-project.org/). The gene expression data were normalised using
quantile normalisation within the bead array package (Dunning
et al, 2007) and differential gene expression was assessed using
significance analysis of microarrays (SAM; Tusher et al, 2001)
using the siggenes package. The data set of Herschkowitz et al
(2007) was downloaded from the UNC Microarray Database
(https://www.genome.unc.edu/).
Confirmation of gene expression patterns from biological
triplicates of invasion assays was carried out using the QuantiTect
SYBR Green kit (Corbett/Qiagen, Crawley, UK) on a Corbett
Rotor-Gene 3000. Primers for CDH1 were: forward 5'-CGGAGAA
GAGGACCAGGACT-3', reverse 5'-GGTCAGTATCAGCCGCTTTC-3';
for CLDN7: forward 5'-AAAATGTACGACTCGGTGCTC-3', reverse
5'-AGACCTGCCACGATGAAAAT; for TBP: forward 5'-GGGGA
GCTGTGATGTGAAGT-3', reverse 5'-CCAGGAAATAACTCTGG
CTCA-3'; for ACTB: forward 5'-CCTTCCTGGGCATGGAGTCCT-
3', reverse 5'-GGAGCAATGATCTTGATCTT-3'. QuantiTect Primer
Assays (Qiagen) were used for KRT8, MAL2, TACSTD1 and
SPINT2. PCR programme was identical for all genes: 95°C, 15min
(94°C, 15 s; 56°C, 30 s; 72°C, 30 s) x 50 cycles; 72°C, 5min.
Standard reference human cDNA was from Clontech (catalogue
no. 639654), random primed, ~ 50 ng RNA equivalent per pi was
used for quantification of mRNA expression. Final normalisation
as shown in Figure 4 was performed against the geometrical mean
of ACTB and TBP levels.
Flow cytometry
shRNA constructs were cloned into Open Biosystems/Thermo-
Fisher, Huntsville, AL) lentiviral inducible system; cell lines
generated using non-silencing and shRNA-598 (agagagacactctc
catgaaca) were evaluated for both C35 and Fler2 expression. FACS
analysis: cells were cultured in complete medium in the presence or
absence of 0.5pgml_1 doxcycline for at least 7 days, collected with
trypsin and re-suspended in FACS buffer (PBS (pH 7.2), 1% BSA).
For F1ER2 staining, cells were incubated with 2pgml_1 biotinylated
Herceptin or Remicade as human IgGl isotype control, for 20min on
ice, followed by washing and incubation with 2 pgml strepta-
vidin-APC. For C35 staining, cells were fixed and permeabilised
according to the manufacturer's instruction using Invitrogen
Fixation and Permeabilization kit GAS-004, and stained with
0.5 pgml-1 C35 monoclonal antibody 1F2 or mouse IgG (BD
Biosciences, catalogue no. 557732) conjugated to Alexa 647 for
45 min at room temperature. Cells were washed in FACS buffer and
analysed on FACSCalibur. Samples were run in triplicate and
averaged; ratio of median fluorescence intensity was plotted.
Three-dimensional cultures
Three-dimensional cultures have been used to study the behaviour
of MECs in the presence of reconstituted basement membrane
(Debnath and Brugge, 2005). This assay is particularly useful in
observing oncogenic potential, by measuring morphological
changes of the acinar structures formed in the culture. Such
changes include enlarged acinar structures, local invasion and lack
of lumen formation (Debnath and Brugge, 2005). We previously
studied the effects of ITAM-containing proteins using 3D cultures
(Katz et al, 2005; Grande et al, 2006), accurately predicting their
contribution to tumour formation in vivo (Ross et al, 2006).
Cells (5 x 103 cells per chamber) were cultured on Matrigel (BD
Biosciences) cushions following the precise protocol published
previously (Debnath et al, 2003) using the usual cell culture media
with the addition of 2% Matrigel. The structures were analysed, at
a magnification of x 20, on a Leitz (Microscope Co., Glasgow, UK)
Dialux 20 equipped with an Insight 4 video camera and SPOT
software (Diagnostic Instruments, Sterling Fleights, MI, USA).
Quantification of structure size was carried out using a 10 x 50 pm
grid reticule (Fisher Scientific, ThermoFisher, Fluntsville, AL,
USA), with 20-50 structures counted from each chamber. The
inhibitors BAY61-3606 and piceatannol (Merck, Nottingham, UK)
and trastuzumab/Herceptin (Roche Diagnostics, Penzberg,
Germany) were added as follows (Figures 5 and 6):
(5a) T47D cells treated for 14 days with the Syk inhibitors
BAY61-3606 (100 nM) or piceatannol (1 pgml-1) (added twice: at
days 8 and 11).
(5b) BT474 cells treated for 13 days with trastuzumab
(20 pgmL1) and/or BAY61-3606 (50 nM) (twice: at days 7 and 10).
(6b) Y39F/Y50F ITAM mutant or wt C35-expressing cell lines
were treated for 14 days with the Syk inhibitor BAY61-3606 (50 nM,
twice: at days 8 and 11).
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For siRNA experiments, 105 cells were plated 48 h before the 3D
culture. After 24 h, the cells were transfected with 100 nM non-
targeted or Syk siRNA SmartPOOLs (Dharmacon, Cramlington,
UK), using Lipofectamine (Invitrogen). At 24 h after the transfection
cells were collected, counted and seeded on Matrigel as described
above. The effectiveness of the SmartPOOLs vs single siRNA was
measured by qPCR (all reagents from Dharmacon) after 48 h on
plastic (Supplementary Figure S3).
Statistical analysis
For comparisons of means of structure diameters, two-tailed
unpaired t-test was used. P-values were as follows:
(3c) C35, null vs C35pool: <0.0001; C35pool vs C35hi: 0.0041.
E-cadherin, C35: null vs C35pool: <0.0001; C35pool vs C35hl:
<0.0001.
(5a) None vs piceatannol: 0.0343; none vs BAY61-3606: 0.0119.
(5b) None vs trastuzumab/Herceptin: not significant; none vs
BAY61-3606: 0.0356; none vs trastuzumab +BAY61-3606:
<0.0001; BAY61-3606 vs trastuzumab +BAY61-3606: 0.0005;
trastuzumab vs trastuzumab + BAY61-3606: <0.0001.
(5d) Non-targeted siRNA vs C35 siRNA: <0.0001; non-targeted
siRNA vs HER2 siRNA: 0.0329; non-targeted siRNA vs Syk siRNA:
0.0104.
(6a) Neo vs Y39F/Y50F C35: not significant; neo vs wt C35:
0.0053; Y39F/Y50F C35 vs wt C35: 0.0026.
(6b) Y39F/Y50F C35 vs wt C35: 0.0111; Y39F/Y50F C35, none vs
BAY61-3606: not significant; wt C35, none vs BAY61-3606: 0.0111.
(6c) Neo non-targeted vs Syk siRNA: not significant; neo non-
targeted vs C35 non-targeted: 0.0011; C35 non-targeted vs Syk:
0.0018.
RESULTS
C35 protein is co-expressed with HER2 in human breast
cancer cells
C35 protein expression was analysed by quantitative immuno¬
fluorescence using the HistoRx AQUA image analysis system
(Camp et al, 2002) (1) to determine whether it is co-expressed with
HER2 in the same cancer cells and (2) to investigate whether level
of expression of protein was associated with therapeutic response
to trastuzumab (Herceptin) in a retrospective clinical cohort of 122
treated patients, 32 ofwhich were found later to be HER2 negative
(Faratian et al, 2009). Pre-treatment C35 protein levels measured
by immunofluorescence were significantly associated with HER2
copy number amplification assessed by FISH (Figure 1A and B;
mean AQUA score HER2 not amplified = 47.8 (s.d. 55.2; range
17.4-327.7), mean AQUA score HER2 amplified = 255.2 (s.d.
170.9; range 40.1-1014.9); Mann-Whitney U-test, P<0.0001).
In cancers with no HER2 amplification expression of C35
was uniformly low in all but two cases, with AQUA scores of less
than 100.
We next sought to establish whether quantitative C35 expression
was associated with response to trastuzumab as measured by the
C3510 C35hi
Figure I Clinical profile of C35 expression in human breast cancer. (A) Distribution of C35 immunofluorescence according to HER2 amplification status,
as determined by fluorescence in situ hybridisation (***P<0.00l), (B) representative examples of C35hl and C35'° immunofluorescence. Green: epithelial
cell mask (pan-keratin); red: C35. Immunohistochemistry of C35 in primary breast cancers is shown in Supplementary Figure SI. (C) Kaplan-Meier survival
curves according to optimal C35 cutpoint determined by minimum P-value method (log-rank test, P= 0.028).
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overall survival time. In univariate analysis high C35 expression
(cut point AQUA score 304; minimum P-value method) was
associated with worse overall survival (Figure 1C; log-rank test
P= 0.0285), along with stage, ER status and chemotherapy regimen
(Supplementary Table SI). However, only stage was associated
with overall survival in a Cox regression multivariate analysis.
Analysis of C35 expression in H£R2-amplified tumours similarly
did not yield a significant association with survival (Figure 1C).
Over-expression of C35 leads to EMT-mediated
cell invasion
We carried out colony formation assays in soft agar to test whether
C35 can induce MEC transformation. For this purpose, the normal
MEC line H16N-2, which has been used previously for cell
transformation assays (Burwell et al, 2007; Rhodes et al, 2009), was
retrovirally transduced with wt C35. Colonies expressing high
levels of C35 consistently formed enlarged structures in soft agar,
whereas empty vector-expressing controls did not (Figure 2A). In
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Figure 2 C35 expression in mammary epithelial cells leads to colony
formation in soft agar. Quantification of soft agar assays in (A) H16N-2 cells
expressing empty retroviral construct (null clone) or C35 (clones A4, B3,
B5 and C3) and in (C) MDA-MB-231 cells (null or C35 transfectant pools).
(B) Foci formation (marked by arrows) assay results are shown for null.C5
and the C35.C3 (high expressing) clones.
expressing high levels of wt C35 protein also showed foci
formation when grown on plastic (Figure 2B; data not shown).
In the breast cancer cell line MDA-MB-231, which normally
expresses very low levels of C35, similar to those in the H16N-2
parental line (Evans et al, 2006), C35 expression was able to
transform the MDA-MB-231 cell line at levels exceeding the
transforming potential observed in the H16N-2 cell line
(Figure 2C).
We previously reported that ITAM-containing proteins such as
MMTV Env can induce an invasive phenotype in human MECs
(Katz et al, 2005), likely to be caused by an EMT (Katz et al, 2005;
Grande et al, 2006). It has also been shown that C35 promotes
migration and invasion in prostate cancer cell lines (Dasgupta
et al, 2009). To determine whether C35 expression also results in a
similar behaviour in MEC, we used an invasion assay that used
collagen lattices closely resembling breast stroma in vivo (Amjad
et al, 2007; data not shown). The stroma-like lattices were
generated by rat collagen I, contracted by seeding breast
fibroblasts into the collagen gel. After the lattices contracted,
MECs were seeded on top and invasion was induced by a nutrient
gradient (Figure 3A). Although vector only (null) cells did not
significantly invade the lattice, expression of C35 induced invasion.
The C35 transfectant pool, which had variable levels of C35
expression, invaded mostly in large clusters of cells (Figure 3B).
Three high-expressing clones showed complete transition to
spindle cell phenotype, with single cells invading deep into the
lattice (Figure 3B; Supplementary Figure S2). We chose one high-
expressing clone, C35.C3, for further molecular characterisation
(Figure 3C). Gradual loss of E-cadherin was apparent, occasionally
in the C35-expressing pool and entirely within the C35hl clone
(Figure 3B and C). Finally, all three major transcription factors
known to be involved in EMT were examined. Slug expression was
not detected and the level of Snail expression did not change in any
C35-expressing cells. In contrast, Twist protein expression
correlated positively with C35 expression (data not shown).
We carried out whole-genome expression array analysis to
examine which transcripts correlate with C35 expression in the
collagen invasion assays (raw gene expression files are publicly
available from the caBIG-supported Edinburgh Clinical Research
Facility Data Repository: https://www.catissuesuite.ecmc.ed.ac.uk/
caarray/). Of the top 100 ranked differentially expressed genes by
SAM (Tusher et al, 2001), the majority of the genes were down-
regulated (62 of 98 probes, 63%, excluding a duplicate and a
discontinued probe). First, we examined using KEGG analysis
pathways activated or deactivated by C35 expression. The KEGG
pathway that was most significantly over-represented by the most
consistently differentially expressed genes by SAM analysis was
cell communication (P= 4.33E—08, FDR = 5.43E—05). The genes
responsible were KRT15, GJB2, COL17A1, DSG3, KRT13, KRT6A,
KRT6B, KRT14, KRT16, KRT8 and LAMA3. Using the DAVID
Bioinformatics database (Huang et al, 2009), we found that the
processes highlighted by this pathway are cell-cell contact
(adherens junctions, tight junctions, desmosomes) and ECM-
receptor interactions, including focal adhesions. Interestingly, gene
expression of PLAU (uPA), MMP9, VEGFA and VEGFB did not
correlate with C35 levels. This suggests involvement of a different
set of activated signalling pathways in MECs compared with
prostate cancer cells (Dasgupta et al, 2009).
When the most consistently differentially expressed genes were
compared with those identified in two molecular subtypes of
breast cancers linked recently to EMT, claudin low (Herschkowitz
et al, 2007) and metaplastic breast cancers (Hennessy et al, 2009),
a number of interesting results were discovered. Of the 23
commonly changed genes, 5 (22%) were among most changed
by C35 expression: E-cadherin (CDH1), claudin-7 (CLDN7), MAL2,
EpCAM (TACSTD1) and HAI-2 (SPINT2). Validation by quanti¬
tative PCR confirmed that all five genes were down-regulated by
high expression of C35 in the invasion assays (Figure 4). Cells
© 2010 Cancer Research UK British Journal of Cancer (2010) 103(3), 401 -410
C35 in breast cancer




































Null C35 pool C35hi
Figure 3 C35-expression leads to invasive phenotype, associated with epithelial to mesenchymal transition. (A) Schematic illustration of the invasion
assay set-up in a collagen gel containing fibroblasts overlaid with epithelial cells. (B) H16N-2 cells expressing empty vector (null, left panels), C35-expressing
pool (middle panels) and C35hi-expressing cells were stained by immunohistochemistry for C35 and E-cadherin. Note specific areas of E-cadherin loss











































Figure 4 Genes down-regulated in C35-induced transformed phenotype. C35-induced down-regulation of CDHI, CLDN7, KRT8, MAL2, TACSTDI
and SPINT2 was observed in cells grown on plastic and in the invasion assays. Biological triplicate mRNA expression data are shown for empty vector,
C35 expressing pool and C35h'-expressing clone (C35.C3).
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expressing high levels of C35 also down-regulated eight cytokeratin
genes (out of 98 top ranked, 8%), also consistent with loss of
epithelial phenotype. These included keratin-8 (KRT8, Figure 4),
which is often down-regulated in EMT-like breast tumours
(Herschkowitz et al, 2007; Hennessy et al, 2009). Both loss of
cell-cell contact and down-regulation of cytokeratins have been
linked with EMT and are thought to enable cancer cell invasion
(Levayer and Lecuit, 2008).
C35-induced cell transformation is dependent on the
function of its ITAM
Previous studies have used 3D cell culture, in which MECs are
grown on reconstituted basement membrane (Matrigel) and form
spherical structures resembling the terminal ductal lobular units in
the breast. These cell cultures show many in vivo properties of
MECs. This model has been extensively used to study oncogenic
phenotypes (Debnath and Brugge, 2005). C35 contains an ITAM, a
motif found in glycoproteins of oncogenic retroviruses, that is
linked to epithelial cell transformation through the protein
tyrosine kinase Syk (Katz et al, 2005; Lu et al, 2006; Wang et al,
2006). Syk binds to the ITAM through its tandem SH2 domains
and activates multiple growth signalling pathways, including PI3K,
PLCy, Ras/MAPK and NF/cB, among others (Underhill and
Goodridge, 2007).
We determined the C35 and HER2 status of three breast cancer
cell lines, as well as Syk expression. BT474 and SKBr3 lines
harbour HER2 and C35 gene amplification and show high levels of
mRNA expression of these genes (Supplementary Figure S4). T47D
cells have no HER2 gene amplification and they express moderate
levels of C35 (21-fold less than SKBr3 cells, 4-fold more than
MCF10A cells). T47D cells are sensitive to Syk inhibition, by
piceatannol or BAY61-3606 treatment (Yamamoto et al, 2003;
Figure 5A), similar to that of the H16N-2 C35-expressing line in 3D
culture (Figure 6B). Therefore, the response of H£R2-amplified
cells to Syk inhibition was determined. BT474 cells were chosen as
they form non-polarised but well-defined 'mass' 3D structures
(Kenny et al, 2007), similar to those generated by T47D cells.
Treatment with Syk inhibitors, or Syk siRNA, reduced the size of
BT474 3D structures (Figure 5D). This effect was unlikely due to
changes in HER2 expression (Figure 5C). Syk inhibition combined
with Herceptin (trastuzumab) resulted in even smaller
structures, similar in size to those seen with immortalised, but
non-transformed, cell lines (Figure 5B).
We generated FI16N-2 cell transfectant pools expressing the wt
C35 protein or its Y39F/Y50F ITAM mutant. When grown in
reconstituted basement membrane (3D culture), MECs expressing
ITAM-containing proteins showed a transformed phenotype. This
phenotype included enlargement of the acinar structures and was
dependent on functional ITAM in these proteins (Katz et al, 2005;
Grande et al, 2006). Consistent with these previous observations,
when cultured in 3D, C35-expressing cells formed enlarged
structures in comparison to empty vector-expressing cells (f-test,
P— 0.0053). Immunoreceptor tyrosine-based activation motif
mutant C35-expressing cells formed similar structures to those
of vector-expressing cells (Figure 6A).
Growth of C35-expressing H16N-2 cells was sensitive to Syk
inhibition in 3D culture (Figure 6B) similar to other cell lines
expressing ITAM-containing proteins (Katz et al, 2005; Grande
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Figure 5 Inhibition ofC35 and Syk reduces mammary epithelial cells acinar structure size. (A) Quantification of 3D structure size in T47D cells at day 14
after treatment with the Syk inhibitors BAY6I-3606 or piceatannol. (B) Quantification of structure size in BT474 cells at day 13 after treatment with
Herceptin (trastuzumab) and/or BAY6I-3606. (C) Knockdown of C35 by siRNA in BT474 cells (left panel) has no effect on HER2 surface expression
(right panel) as determined by flow cytometry. (D) Quantification of structure size of BT474 cells treated with non-targeted, C35, HER2 or Syk siRNA,
at day 6 of 3D culture,
© 2010 Cancer Research UK British Journal of Cancer (2010) 103(3), 401-410
E»
C35 in breast cancer

















Neo Y39F/Y50F C35 WT C35
200 n
150-
















Neo + NT Neo + Syk C35 + NT C35 + Syk
Figure 6 C35 expression in normal mammary epithelial cells leads to cell transformation in 3D cultures. (A) H16N-2 acinar structures (at day I I)
expressing empty vector (Neo), Y39F/Y50F ITAM mutant or wild-type (wt) C35 protein. (B) Quantification of structure diameter in Y39F/Y50F ITAM
mutant or wt C35-expressing cell lines at day 14 after treatment with the Syk inhibitor BAY6I-3606 (50 nM, twice: at days 8 and I I). (C) Quantification of
structure size of Neo and wt C35-expressing H16N-2 cells treated with non-targeted, Syk siRNA, at day 6 of 3D culture.
and C35 (Figure 6C). We also observed down-regulation of Syk
mRNA in H16N-2 expressing the Y39F/Y50F ITAM mutant,
compared with those expressing wt C35 (data not shown). This
observation supports the view that Syk interacts with functional
ITAM-containing C35.
DISCUSSION
HER2/ErbB2 amplification is a frequent and well-studied event in
breast and other cancers. The genetic fragment being amplified is
commonly known as the HER2 amplicon. The smallest region of
amplification of the HER2/ERBB2 amplicon on human chromo¬
some 17ql2 contains 14 core genes, of which STARD3, TCAP,
PNMT, PERLD1, ERBB2, GRB7, GSDML and C17orf37IC35 are
over-expressed when amplified (Kauraniemi and Kallioniemi,
2006; Marchio et al, 2008). The function of HER2, in breast cancer
in particular, has been subject to intense research efforts,
culminating in the design of both small molecule inhibitors and
monoclonal antibodies in treatment of HER2+ patients (Bublil
and Yarden, 2007). Recent efforts have concentrated on under¬
standing how co-amplification of HER2 with the non-core
amplicon gene Topoisomerase II (TOP2A) may affect response to
chemotherapy (Pritchard et al, 2008). Much less is known about
the functional importance of the core genes co-amplified with
HER2. One of the best studied of these core genes is GRB7.
Co-expression of Grb7 and HER2 facilitates HER2 signal
transduction and functions synergistically for tumour formation
(Stein et al, 1994; Bai and Luoh, 2008). Tumours co-expressing
high levels of Grb7 and HER2 have a worse outcome than those
with only higher levels of HER2 (Nadler et al, 2010), in line with
the clinical data presented here. Both GRB7 and another core gene,
STARD3, contribute to the growth of HER2-amplified cell lines
in vitro (Kao and Pollack, 2006).
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Here, we show that primary breast cancers have high levels of
C35 protein expression when harbouring HER2 gene amplification,
and that over-expression of C35 and HER2 protein is correlated in
both breast cancer cell lines and primary tumours, in agreement
with previous findings (Evans et al, 2006). It is estimated that
tumours can express 70-100 times the normal breast tissue C35
transcript level (Evans et al, 2006). Cell lines expressing high levels
of C35 showed high invasive behaviour in vitro. The overall
phenotype is consistent with EMT, including down-regulation of
E-cadherin and up-regulation of Twist. Interestingly, more gene
transcripts were down-regulated than up-regulated among the 100
most changed transcripts. This raises the possibility of common
suppression mechanism of transcription, downstream of C35
expression. A study in a pancreatic cancer cell line has suggested
that the protein inhibitor specific for HGF activator-1 (HAI-1), an
HAI-2 homologue, may activate an EMT programme in these cells
by up-regulating the transcription factor SIP-l/ZEB-2 and conse¬
quently repressing E-cadherin (Cheng et al, 2009).
We found that tyrosine mutation in the ITAM of C35, or Syk
kinase inhibition, is sufficient to abolish the potential of C35
protein to cause enlargement of acinar structures in 3D cell
culture. Studies in DLBCL lines have shown that some, but not all
tumours, expressing ITAM-containing proteins may respond to
Syk inhibition (Chen et al, 2008). Evidence in this study using
C35-expressing MEC lines has supported this strategy in vitro. Syk
expression and activation are also modulated by extracellular
matrix, through integrin signalling (Zhang et al, 2009). Syk
promotes cell-cell contact on plastic (Zhang et al, 2009) and its
genetic knock-down promotes cell mobility and invasion (Sung
et al, 2009; Zhang et al, 2009). Syk may also have a tumour
suppressor function in breast cancer through its kinase activity in
the nucleus (Coopman et al, 2000; Sung et al, 2009). A plausible
mechanism is that the interaction of C35 with Syk mimics global
knock-down of Syk by changing its localisation away from
© 2010 Cancer Research UK
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integrins (Zhang et al, 2009) or the nucleus (Coopman et al, 2000).
When activated in the cytoplasm, Syk functions as a promoter of
cell growth (Zhou and Geahlen, 2009), consistent with the function
postulated in this study. Our study results indicate that recently
described Syk inhibitors (Braselmann et al, 2006; Chen et al, 2008)
may be effective in C35 over-expressing breast cancer cells and
thus have therapeutic value.
Other therapeutic approaches may be developed to take
advantage of these findings in the treatment of human breast
cancer, including the development of inhibitors of C35 interaction
with proteins other than Syk, such as the novel ITAM-interacting
protein Shb (Matskova et al, 2007). The Src kinase Lyn is unlikely
to be involved in C35-induced EMT, because Lyn mRNA levels are
reduced by approximately five-fold in C35hl cells, in comparison
with both null and C35 transfectant pool cells.
In conclusion, we show here that the HER2 amplicon contains a
second oncogene, C35, in the context of breast cancer. Our
observations suggest that targeting C35 as well as HER2 may be
beneficial for patients with HER2-amplified breast cancers.
C35/C17orf37 has recently been included in an expression
signature predicting metastatic risk in node-negative breast cancer
after chemotherapy (Jezequel et al, 2009). This signature does not
include HER2, therefore suggesting a possible autonomous role for
C35, and warrants further investigation.
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Abstract
The epithelial to mesenchymal transition (EMT) is a developmental program in which epithelial cells down-regulate their
cell-cell junctions, acquire spindle cell morphology and exhibit cellular motility. In human breast cancer, invasion into
surrounding tissue is the first step in metastatic progression. Here, we devised an in vitro model using selected cell lines,
which recapitulates many features of EMT as observed in human breast cancer. By comparing the gene expression profiles
of claudin-low breast cancers with the experimental model, we identified a 9-gene signature characteristic of EMT. This
signature was found to distinguish a series of breast cancer cell lines that have demonstrable, classical EMT hallmarks,
including loss of E-cadherin protein and acquisition of N-cadherin and vimentin expression. We subsequently developed a
three-dimensional model to recapitulate the process of EMT with these cell lines. The cells maintain epithelial morphology
when encapsulated in a reconstituted basement membrane, but undergo spontaneous EMT and invade into surrounding
collagen in the absence of exogenous cues. Collectively, this model of EMT in vitro reveals the behaviour of breast cancer
cells beyond the basement membrane breach and recapitulates the in vivo context for further investigation into EMT and
drugs that may interfere with it.
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Introduction
Breast cancer related deaths are primarily due to metastatic
progression [1]. Understanding the mechanisms that underlie this
multistep process is essential to improving clinical outcome. T he
transformation of normal breast epithelial cells to metastatic
cancer is the result of multiple epigenetic and genetic changes,
leading to deregulated interactions with the microenvironment [2].
During this process, inhibition of proliferation, cell survival,
migration and differentiation is lost leading to the acquisition ofan
invasive phenotype. The ability to breach the basement membrane
(BM) is a critical event in cancer progression and a prerequisite for
metastasis. Having breached the BM, cells may then enter the
lymphatic system, spread and attempt to establish themselves as
distant tumor foci [3].
The trans-differentiation of cells from an epithelial to a
mesenchymal phenotype is an essential part of normal embryo-
genesis and development [4]. Increasing evidence also supports a
role for epithelial to mesenchymal transition (EMT) in the
progression of many cancer types including breast, with critical
roles in invasion and metastatic dissemination [5,6]. EMT involves
loss of cell-cell junctions and re-organization of the actin
cytoskeleton, resulting in loss of apical-basal polarity and
acquisition of a spindle-like mesenchymal moq:>hology [7J. At
the same time, there is also decreased expression of epithelial-
specific proteins, including E-cadherin, which may account at least
in part for the altered properties ofmigrating tumor cells [8,9]. An
important event in EMI' is switching in expression from E-
cadherin to N-cadherin [10]. In most cases this is associated with
transcriptional repression of E-cadherin [9]. Several specific
repressor factors have been identified including Snail, Slug,
Zebl, Zeb2 and Twist [ 11], all ofwhich are zinc finger containing
proteins that can bind with so called E-boxes within the CDH1
gene promoter. N-cadherin is believed to promote cellular
invasion by binding to and enhancing signalling by growth factors
and is over-expressed in many invasive and metastatic human
breast cancer cell lines and tumors [10,12,13].
Comparative analysis of mouse mammary carcinoma models
and human breast tumors identified a novel human molecular
subtype, termed 'claudin-low' cancers. T hese cancers are char¬
acterised by low to absent expression of genes involved in tight
junctions and cell-cell adhesions, including claudins, occludins and
E-cadherin [14,15]. In addition, these moderate-high grade
invasive ductal carcinomas are morphologically distinct from
lobular carcinomas despite their low expression of E-cadherin
[14]. Similarities between claudin-low tumors and EMT in vitro
have been documented, however these features have not
previously been compared and analysed directly. Furthermore,
while the contribution of the extra-cellular matrix to the
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promotion of tumor progression is now appreciated [2], most
current in vitro models do not take into account the contribution of
stromal collagen into which cells undergoing EMT invade. The
predisposition of tumours to undergo EMT can be enhanced by
genetic alterations. For example, C35 is a 12KDa membrane-
anchored protein found on the HER2 amplicon that is over-
expressed in around 11% of breast cancers [16]. Cellular
transformation associated with acquisition of an EMT phenotype
can be induced in mammary epithelial cells transfected with a C35
expression construct resulting in increased invasion into stromal
collagen, down regulation of E-cadherin and up regulation of the
transcription repressor Twist [17]. This implies that collagen-
invading C35-expressing cells can be used to model aspects of
EMT in cancer cells.
Testing new treatments that may prevent EMT or tumor spread is
challenging: conventional clinical trials may have difficulty in
addressing the issues because of the ethical problems of leaving
tumor in situ, or the limitation ofa study to only very late stage disease.
Robust models that can identify possible predictive biomarkers are
essential. In this report, we describe a tmique invasion assay, in which
cell lines with known molecular pathology undergo spontaneous
EME when invading away from the basement membrane into
collagen. We propose that this in vitro model ofdefined breast cancer
cell lines can provide an improved representation of invasive breast
cancer in vivo, compared to existing EMT models.
Materials and Methods
Gene expression analysis, RNA extraction and qRT-PCR
Microarray data was analysed using packages within Biocon-
ductor [18] (http://www.bioconductor.org) that implement R
statistical programming. Gene expression data was normalised
using quantile normalisation within the BeadArray package [19]
and differential gene expression assessed using Significance
Analysis of Microarrays (SAM) [20] within the siggenes package.
The dataset from Hershkowitz and colleagues 114] was down¬
loaded from the UNC Microarray Database (https://genome.unc.
edu/). RNA from the collagen invasion assays was labelled using a
lllumina TotalPrep RNA amplification kit (Ambion) according to
manufacturer's instructions. Triplicate samples from invasion
assays (1500 ng cDNA per assay) were hybridised to Illumina
BeadChips and whole genome gene expression analysis performed
using the Illumina HumanRef-8 v3 Expression BeadChip and
BeadArray Reader.
RNA from cell lines cultured on plastic was converted to cDNA
prior to PCR using a QuantiTect Reverse Transcription kit
(Qiagen). Gene expression patterns for invasion assays (biological
triplicates) and cell lines cultured on plastic (technical triplicates)
were examined using the QuantiTect SYBR Green PCR kit
(Qiagen) and a Corbett RotoGene 3000. Primers for CDH1 were:
forward 5'-CGGAGAAGAGGACCAGGACT-3', reverse 5'-
GGTCAGTATCAGCCGCTTTC-3'; for CLDJV7: forward 5'-
AAAATGTACGACTCGGTGCTC-3', reverse 5'-AGACCTGC-
CACGATGAAAAT; for TBP: forward 5'-GGGGAGCTGTGA-
TGTGAAGT-3', reverse 5'-CCAGGAAATAACTCTGGCTCA-
3'; for ACTB: forward 5'-CCTTCCTGGGCATGGAGTCCT-3',
reverse 5'-GGAGCAATGATCTl GATCTT-3'. QuantiTect
Primer Assays (Qiagen) were used for KRT8, CRB3, ALAR VELD3,
IRF6, ALAL2, TACSTD1 and SRINT2. PCR program was identical
for all genes: 95°C, 15 min; (94°C, 15 s; 56°C, 30 s; 72°C, 30 s)x50
cycles; 72°C, 5 min. Standard reference human cDNA was from
Clontech, random primed. ~50 ng RNA equiv/mL was used for
quantification of mRNA expression. Final normalisation was
performed against the geometrical mean ofACTB and TBP levels.
Gene promoter analysis
Using the presumptive promoter region for the 9 genes (a 2 kb
region upstream of the presumptive transcription start site using
Ensembl 52, Jan2009, based on NCBI 36 assembly), we looked for
over-represented 6- and 7-mers oligos using oligo-analysis [21] from
the RSAT-tools package (http://rsat.scmbb.ulb.ac.be/rsat/) [22].
The program counts all oligonucleotide occurrences within the
sequence set, and estimates their statistical significance. A
calibration is done using the entire genome promoter regions as a
background model (Ensembl 52, Jan2009, based on NCBI 36
assembly). For the best 7-mers candidates, we compared the
obtained oligo sequences to the entire collection of consensus
binding sites available in Transfac professional [23] (release 2010.1)
using the compare-pattern script (RSAT-tools) and listed the
associated binding factor name.
E-value for best hit 7-mer CAGGTGC/GCACCTG
(2.6 xlO-8) represents the expected number of patterns which
would be returned at random for a given probability. The weights
in Table 1 reflect the number ofmatching positions, with a lower
weight for matches between partially specified nucleotides (the
weight for a perfect match to a 7-mer is 7). Both E-value and
weights are calculated by RSAT-tools.
Cell lines
MCF10A, Hs578T, HBL100, BT549, MDA-MB157, MDA-
MB231 and MDA-MB436 cell lines were obtained from American
Type Culture Collection. SUM159PT and SUM1315M02 cells
were a kind gift from Akira Orimo (University of Manchester).
The cells were cultured as previous described [24] at 37 deg C, 5%
C02: MCFlOAin DMEM/F12 media (Invitrogen) with 5% horse
serum (Invitrogen), 20 ng/ml EGF, 100 ng/ml cholera toxin,
0.01 mg/ml insulin and 500 ng/ml hydrocortisone (all from
Sigma); MDA-MB157, MDA-MB231, HBL100 and HS578T in
DMEM, 10% bovine serum (both from Invitrogen); SUM159PT
in Ham's F12 (Invitrogen), 5% bovine serum, insulin, hydrocor¬
tisone; MDA-MB436 in L15 (Invitrogen), 10% bovine serum;
B'1'549: RPMI-1640, 10% bovine serum; SUM1315M02 in
Ham's F12, 5% bovine serum, insulin, EGF.
Primary cell isolation for tissue culture
Fresh normal breast tissue and breast tumor materials were
incubated for 1 hour at room temperature in tissue mix consisting of
DMEM/F12, 1% fungizone, 1000 U/ml penicillin, 1000 pg/ml
streptomycin, 10 pg/nil insulin and 10% bovine serum (all from
Invitrogen). Tissue cores were then finely chopped (~ 1 ml pieces)
and put in a tissue mix/Collagenase I solution (Invitrogen; made up
with 200 pL of 200 U/ml Collagenase I to 20 ml tissue mix) for
digestion (2 hours at 37 deg C, 200 rpm). The digested tissue was
then spun for 4 mins at 60 g. The resulting pellet was plated with
fibroblast media (DMEM supplemented with 10% bovine serum,
50 U/ml penicillin and 50 mg/ml streptomycin) and the superna¬
tant spun for a further 4 mins at 600 g, 4 times. The resulting
second pellet (mammary epithelial cells) was plated with HMEC
media (CnT-22 (Cellntec) supplemented with 5% FCS).
Ethics Statement
The use of primary breast cells was approved by the Lothian
Research Ethics Committee (08/S1101/41). Materials were
obtained with written informed consent from all participants
involved in this study.
Rat tails obtained from animals at the University of Edinburgh
animal facilities scarified for other scientific purposes and did not
require ethical approval.
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Table 1. Common transcription factor binding sites in the 9-gene signature.
Best hit Weight Matrix consensus Transfac ID Factor name
GCACCTG 6.5 ASCACCTGTTNNCA M00044 Snail*
CAGGTGC 6.5 RACAGGTGYA M00060 Snail*
GCACCTG 6.5 VNRCACCTGKNC M00414 AREB6/ZEB1*
CAGGTGC 6.21 CNNCAGGTGB M00277 LM02 complex*
CAGGTGC 6 RRCAGGTGNCV M00693 E12/ELSPBP1*
CAGGTGC 6 CNGNRNCAGGTGNNGNA M00929 MyoD*
GCACCTG 5.5 YNYACCTGWVT M00412 AREB6/ZEB1*
GCACCTG 4 RRTGNMCYTNNTGAMCCNYNT M00966 VDR, CAR, PXR
GCACCTG 3.5 GCTGGNTNGNNCYNG M00947 CP2/LBP-1c/LSF
GCACCTG 3.5 RGNACNNKNTGTTCT M00957 PR/Progesterone receptt
GCACCTG 3.5 TGGCASNNNGCCAA M01196 CTF1
A list of binding sites matching to best 7-mer found in promoters of the common EMT gene signature. Three muscle initiator sequences with no further information
were excluded.
*E-box binding transcription factors. El 2 is part of the LM02 complex.
doi:l 0.1371/joumal.pone.OOl 7083.t001
SDS-PAGE
Protein lysates (50 pg/well, as determined by MicroBCA
protein assay) were resolved by SDS-PAGE after being denatured
for 1 hour at 60 deg C. The resolving gel (7.5% w/v acrylamide,
0.37 M TRIS pH 8.85, 0.1% SDS, 0.02% AMPS, 0.25%
TEMED; all from Sigma) was set between glass plates using a
Bio-Rad kit. Once the resolving gel had set, a stacking gel (3.6%
w/v acrylamide, 0.12 M TRIS pH 6.8, 0.1% SDS, 0.03% AMPS,
0.33% TEMED) was layered and a comb used to create wells for
sample loading. The loaded samples were electro-separated under
constant current (100-200 mA) using electrophoresis buffer
(25 mM Trizma Base, 0.19 M Glycine, 10% SDS). Electro-
transfer onto immobilon transfer membrane (Millipore) was
performed using transfer buffer (25 mM Trizma Base, 0.19 M
Glycine) using a Bio-Rad kit, under constant electrical potential
(~30 mV for at least 2 hours).
Western Blotting
Nonspecific binding was blocked with Li-Cor Odyssey Blocking
Buffer (Li-Cor), diluted 50:50 in PBS, for 1 hour at room
temperature. Primary antibodies were diluted in Li-Cor Odyssey
Blocking Buffer, diluted 50:50 in 0.1% PBS-Tween20, and
incubated with the blot overnight at 4 deg C. Blots were washed
3 times for 5 mins with PBS-T before incubation with appropriate
fluorescent secondary antibodies (Li-Cor), diluted 1:10,000 in Li-
Cor Odyssey Blocking Buffer, diluted 50:50 in 0.1% PBS-
Tween20, for 45 mins at room temperature. Exposure to light
was avoided. Subsequently, membranes were washed, dried and
scanned on the Li-Cor Odyssey scanner. All washes/incubations
were carried out under constant agitation. Primary antibodies used
as follows: E-cadherin, BD, 610181, Mouse, 1:2500; Claudin7,
Abeam, Ab75347, Rabbit, 1:1000; N-cadherin, BD, 610921,
Mouse, 1:3000; Vimentin, Sigma, V 6630, Mouse, 1:1000; Zeb2,
BD, 611256, Mouse, 1:250; Slug, LifeSpan Bio, LS-C30318,
Rabbit, 1:4000; Snail, Abeam, abl7732, Rabbit, 1:4000; Tubulin,
Abeam, Ab7291, Mouse, 1:6000.
tendons were weighed and transferred to the appropriate volume
of pre-cooled acetic acid (1 g tendon to 250 ml 0.5 M acetic acid)
and gently stirred for 48 hours at 4 deg C. The tendon/acetic acid
mix was then centrifuged at 10,000 g for 30 mins and the pellet
discarded. An equal volume of 10% (w/v) NaCl was added to the
supernatant and the mix allowed to stand overnight at 4 deg C.
The collagen-rich, insoluble 'bottom layer' was taken and collected
by further centrifugation (10,000 g for 30 mins). The collagen-rich
material was resuspended in 0.25 M acetic acid at 4 deg C and
dialysed against 1:1000 acetic acid at 4 deg C for 3 days, changing
the dialysis buffer twice daily. The collagen solution was then
sterilised by centrifugation (20,000 g for 2 hours) and stored at 4
deg C. Collagen was diluted as required by the addition of sterile
1:1000 acetic acid to a stock concentration of 1.2 mg/ml.
Establishment of 3D invasion assays
200 pL cell-collagen plugs and 75 |iL cell-Matrigel plugs were
made in a u-shaped 96 well plate, with the aim of achieving
comparable size after a 24 hr incubation (day -1). A cell
concentration of 1 X106 was used for all plugs. Rat tail collagen
I, for both plugs and subsequent embedding, was prepared as per
the 'on top' assays. Growth factor reduced Matrigel was obtained
from BD and used at a 5 mg/ml. Matrigel matrix is a soluble
basement membrane extract of the Engelbreth-Holm-Swarm
tumor that gels at room temperature to form a reconstituted
basement membrane. The major components are laminin,
collagen IV, entactin and heparin sulphate membrane. After the
24 hr incubation, cell plugs were carefully removed from their 96
well plate and embedded in 1 ml of collagen in a 24 well plate
(taken as day 0), with or without fibroblasts (used at 10,000/ml).
These cultures were incubated for a further hour and then
carefully freed from the edges of the well (to allow contraction of
the collagen) and supplemented with 0.5 ml of cell-specific media.
The cultures were then left to invade. Media was changed weekly.
Gels were fixed at either 1 or 2 weeks in 10% phosphate buffered
formalin and wax embedded.
Rat tail collagen I preparation
Eresh rat tails were collected and frozen. Prior to harvesting
these were placed in 70% ethanol. Tendons were stripped from
the tails and returned to 70% ethanol to sterilise. The collected
Immunofluorescence
Immunofluorescence was preformed as described previously
117]. Briefly, antigen retrieval for all epitopes was carried out using
heat treatment under pressure in a microwave oven for 5 min in
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citrate buffer (82 ml 0.01 M sodium citrate: 18 ml 0.01 M citric
acid) pH 6.0. Slides were incubated with primary antibodies for
1 hr at room temperature. Primary antibodies were as follows: E-
cadherin, BD, 610181, Mouse, 1:1500; N-cadherin, BD, 610921,
Mouse, 1:300; Zeb2, BD, 611256, Mouse, 1:50; Slug, LifeSpan Bio,
LS-C30318, Rabbit, 1:1000; Snail, Abeam, abl7732, Rabbit,
1:700. For Snail staining, mouse anti-pancytokeratin (Invitrogen,
1:25) was added to visualise epithelial cells. Mouse primary
antibodies were incubated overnight with rabbit anti-pancytoker-
atin (Dako, 1:150). The epithelial compartment was then visualised
with Cy3 (Invitrogen, anti-rabbit; anti-mouse, both used at 1:25).
DAPI (4',6-diamidino-2-phenylindole) counterstain (Invitrogen)
was used to identify nuclei and Cy-5-tyramide (HistoRx, 1:50)
was used to detect protein 'targets'. Monochromatic images ofeach
TMA core were captured at 20 x objective using an Olympus AX-
51 epifluorescence microscope, and high-resolution digital images
were analyzed by the AQUAnalysis software [17].
Results
Identification of a common EMT signature in the breast
In order to establish an in vitro EMT signature, we identified a
set of 57 genes that strongly correlated with C35-induced EMT in
vitro using significance analysis of microarrays (SAM, [20]). These
'C35 genes' were subsequently found to be sufficient to cluster
claudin-low tumors together in a breast cancer dataset [14] (Figs. 1
and SI). In addition, a 34 gene 'claudin-low' signature identified in
murine mammary carcinoma and human breast tumors [14], was
significantly down-regulated in collagen-invading C35-expressing
cells in comparison to parental cells (range p = 0.048 to
p = 1 x 10-8; Figs. 1 and SI). Nine genes were common between
the 'C35 genes' and 'claudin-low genes' signatures (Fig. 1): CDH1,
CLDJV7, CRB3, KRT8, TACSTD1, IRF6, SPINT2, MAL2 and
MARVELD3. Five of these, CDH1 (E-cadherin), CLDN7 (Claudin-
7), TACSTD1 (EpCAM), 1RF6 and KRT8 (Keratin-8) have been
previously implicated by their low expression in claudin-low
cancers and/or in EMT in vitro [25,26,27]. SPLNT2 (Hepatocyte
growth factor activation inhibitor-2, HAI-2) is capable of
regulating a HGF-induced invasion of human breast cancer cells
[28]. Two novel genes found to be down-regulated: the apical
sorting protein MAL2 [29] and its tight-junction-associated
homologue MAR VKLU3 [30].
We determined whether the nine EMT genes share common
regulatory elements in their promoters and identified a shared 7-
mer: CAGGTGC/GCACCTG. This binding motif is targeted by
E-box transcription repressors, including Snail and ZEB families
(Table 1) raising the possibility that these transcription factors
repress all nine genes in the EMT pathway both in vitro and in vivo.
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Figure 1. Comparison of genes correlating with C35 expression and those identifying the claudin-low phenotype identifies a 9-
gene EMT signature. The 100 illumina probes most significantly differentially expressed between collagen-invading C35 and parental cells were
represented by 57 genes that were able to cluster together the 13 claudin-low tumors identified by Herschkowitz and colleagues (/eft panels). A set of
34 claudin-low genes from the Herschkowitz were all significantly down-regulated in C35-expressing cells compared to parental cells (right panels). A
signature of nine EMT-related genes is shared between the C35 and claudin-low gene lists (full lists in Fig. SI).
doi:10.1371/journal.pone.OOI 7083.g001
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COH1 CLDN7 KHT8 CRB3
Figure 2. The 9-gene C35/claudin-low signature is down-regulated in a subset of human breast cell lines. Eight cell lines exhibit low
expression of CDHI, CLDN7, CRB3, KRT8, TACSTD1, IRF6, SPINT2 and MAL2 when cultured on plastic. MARVELD3 could not be assessed due to
particularly low levels of expression. Technical triplicate mRNA expression data is shown for each line. HMEC cDNA is shown for comparison.
doi:10.1371/journal.pone.OOl 7083.g002
excluded the MDA-MB435 line from this cohort of cell lines due
to doubts as to its tissue of origin [31]. The remaining eight cell
lines show clear mesenchymal morphology when cultured on
plastic (Fig. S2). We confirmed down-regulation of eight of the
nine EMT genes by quantitative RT-PCR (Fig. 2) using normal
human mammary epithelial cells (HMECs) as a positive control.
We also validated low expression of these genes in the C35 model
([17] and data not shown).
Western blotting was used to investigate the expression patterns
of EMT-related proteins, including transcription repressors. All
lines exhibit low levels ofE-cadherin and Claudin-7 in comparison
to normal mammary epithelial cells (Fig. 3), whereas ZEB2 (SIP-
1), an E-box transcription factor that can induce EMT, is
expressed in all the cell lines with claudin-low features. Most of
the cell lines also have detectable expression ofSnail, whereas Slug
is absent in only one (MDA-MB231). Lastly, all of the cell lines
express the mesenchymal marker vimentin and seven of the cell
lines have detectable expression of N-cadherin.
A 3D invasion assay that mimics invasion into stromal
collagen
A critical event in cancer progression is the acquisition of an
invasive phenotype, and in particular the ability to breach the
basement membrane (BM) into the stromal collagen. We
developed a 3D model that attempts to mimic this process.
Histologically normal breast epithelial cells are first embedded in a
laminin-rich, BM-like Matrigel to generate a cell 'plug' which was
subsequently embedded in collagen to mimic the surrounding
extracellular matrix (Fig. 4a). This model potentially generates a
three-stage assay that allows investigation of cells: i) contained by
BM; ii) as they invade across BM; iii) as they invade more distally
into surrounding collagen. In addition, the movement of cells in a
horizontal plane can easily be followed by light microscopy, in
Identification of cell lines with 'claudin-low' features
The 9-gene signature was identified in nine breast cancer cell
lines from a previously published gene expression dataset [24] that
all expressed low levels of the EMT genes: cell lines BT549,
Hs578T, HBL100, MDA-MB157, MDA-MB231, MDA-MB435,





Figure 3. Claudin-low-like cell lines express key markers of
EMT. Western blots demonstrate the expression of EMT-related
markers at the protein level. HMEC lysates are shown for comparison.
doi:l 0.1371/journal.pone.OOl 7083.g003
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Figure 4. A novel invasion assay mimics EMT. (a) Schematic illustration of the 'plug' invasion assays. A collagen- or Matrigel-based epithelial
plug is embedded in additional collagen, with or without fibroblasts. Epithelial cells then invade in a star-burst manner into surrounding collagen, (b)
Morphological changes suggestive of spontaneous transitions between MET and EMT states are observed by light microscopy. Cell-collagen plugs
were made with HBL100, HS578T and SUM159PT cell lines. These exhibit a predominantly elongated morphology at day 0. Clear invasion into
surrounding collagen is seen by day 7 (left panels, arrows). Cell-Matrigel plugs with the same lines exhibit a rounded morphology on day 0. By day 7,
HBL100 and HS578T cells have reverted to an elongated morphology and are invading into surrounding collagen. In contrast, SUM159PT cells retain a
rounded morphology accompanied by delayed invasion (day 7) although this appears to be overcome by day 14 [right panels). Dotted lines represent
the original plug edge. Bar= 100 pm.
doi:10.1371/journal.pone.0017083.g004
contrast to the movement of cells in a vertical plane that occurs
with the collagen-based 'on top' assay [17].
Three different cell lines with low expression of the 9-gene EMT
signature (HBL100, HS578T and SUM 159PT) demonstrated
clear and reproducible invasion in this novel assay. Importantly,
all three cell lines adopt a round morphology when embedded in
Matrigel (day 0), versus the predominantly elongated morphology
that is seen in collagen (Fig. S3). By day 7, the HBL100 and
HS578T cells have reverted to an elongated morphology,
indistinguishable from that seen in collagen, and are invading
across BM and into surrounding collagen. In contrast, many
SUM159PT cells retain a round morphology, accompanied by
delayed invasion (Fig. 4b). By day 14, SUM159PT cells appear to
have overcome this inhibition and many elongated cells are now
seen leaving the Matrigel plug. Those cells that remain in the
Matrigel plug still retain a more round morphology (Fig. 5a).
MCF10A cells (a non-transformed line) were also tested in this
assay and do exhibit an invasion phenotype. As expected,
MCF10A cells appear to form polarised, growth arrested
structures [32]. These observations suggest that this model may
allow the investigation of cells as they invade across the BM.
Importantly, SUM159PT cells are the most affected by Matrigel in
terms of morphology and invasive capacity, and were therefore
selected for further investigation.
SUM159PT cells, which are an excellent metastasis model in vivo
[33,34], were selected for further EMT analysis with MCF10A cells
serving as a control, as they show uniform, membranous expression
of E-cadherin and no expression of N-cadherin. In contrast,
SUM159PT cells show no membrane-specific E-cadherin expres¬
sion but do show membranous N-cadherin expression throughout
the core of the plug (Fig. 5b). In the elongated invading cells at the
periphery N-cadherin expression appears to be down-regulated.
Stromal fibroblasts have been shown to play critical roles in some
models of invasion, remodelling the ECM and generating tracks
along which epithelial cells can follow [35], The role of normal and
cancer-associated fibroblasts (CAFs) was therefore also investigated.
No difference in invasion was evident with both normal fibroblasts
and CAE's. This lack of effect on invasion was seen when epithelial
cells were embedded in both collagen and Matrigel (Fig. S4).
Discussion
This study identifies 9 key genes shared by breast cells
undergoing EMT in vitro and EMT enriched claudin-low tumors.
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Figure 5. Changes in cells undergoing EMT while invading collagen stroma in vitro, (a) SUM159PT cell-Matrigel plugs were fixed at day 14
to monitor morphological changes during collagen invasion. Images of the whole plugs (4x magnification, left panel), core (middle panel) and plug
edge (right panel) are shown (both 40 x magnification). Note the organised, rounded morphology in Matrigel (middle panel) in contrast to the
elongated morphology as cells invade into surronding collagen (right panel), indicative of EMT. (b) E-cadherin expression in MCF10A cells is
comparable to N-cadherin expression in SUM159PT cells. Representative immunofluorescence images of E-cadherin and N-cadherin protein
expression in MCF10A (left panel) and SUM159PT cells (right panel) are shown. Expression within the plug (core) and at the edge where cells are seen
to invade surrounding collagen (arrows) is compared. Note the change in morphology as cells invade. Bar = 50 jim.
doi:10.1371/journal.pone.0017083.g005
This signature in turn was used to identify breast cancer cell lines
that are potentially useful in studying EMT in vitro. A 3D invasion
model was developed that specifically addresses the link between
EMT and invasion into stromal collagen in these cell lines, which
may be representative of a general behaviour. This novel model
was used to examine the expression patterns of cadherins in the
EMT cell lines when invading from the basement membrane
context to a collagen-rich environment.
The association of claudin-low breast cancer and epithelial to
mesenchymal transition is now well established [14,27,36] and cell
lines can be identified with gene expression profiles similar to those
of claudin-low tumors [27]. The low expression signature is also
found in these Basal B/mesenchymal/claudin-low cell lines,
identified elsewhere [27]. Importantly, our results do not single
out a particular EMT inducing transcriptional repressor, although
these are broadly expressed (ZEB2, Snail and Slug) in the cell lines.
This suggests that the induction of EMT may result from a
combination of factors, resulting in repression of common
downstream molecules. From a functional point of view, this is
consistent with loss of cell-cell contact as a prerequisite for the
detachment of invading cells from the tumor mass and their
penetration of surrounding stroma [37].
Previously published invasion models have used either pure
collagen environment [38] or non-physiological methylcellulose
[39]. More physiologically relevant basement membrane-contain¬
ing models, such as the chick chorioallantoic membrane [40] or
peritoneal basement membrane [41], are inflexible, difficult to
scale up and often have a very low yield. Our in vitro invasion
model potentially offers a deeper investigation of the nature of
EMT. The combination of basement membrane environment and
surrounding collagen stroma maintains and mimics aspects of
EMT in vivo.
The 3D model demonstrated here exemplifies how using the
same cell line simultaneously in both basement membrane
environment and in tissue-like collagen matrix may enable a
better understating of EMT. Two novel observations were made
using this model: within the basement membrane plug, N-
cadherin expression in cells with EMT signature can phenocopy
E-cadherin expression in normal mammary epithelial cells,
maintaining a tight round morphology; and surprisingly, N-
cadherin is lost as cells with EMT signature invade.
Claudin-low breast cancers are likely to represent the most
acute EMT phenotype in vivo, but other subtypes may also present
some EMT features [15,42]. The current study has extended our
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understanding of common mechanisms of EMT in breast cancer.
This study showed that the down-regulation of cell-cell contact
molecules in claudin-low cancers is accompanied by changes in
HGF signalling and apical sorting molecules. Furthermore, the 3D
model has questioned the concept of a 'cadherin switch' in vivo. We
have also observed elsewhere that in invasive ductal breast
carcinomas there is no inverse correlation between E-cadherin and
N-cadherin protein expression levels (S. Dubois-Marshall and E.
Katz, unpublished observations). This raises the possibility that
single cell invasion is cadherin-independent. This will to be
verified in future experiments examining other cadherin molecules
involved in cell motility, such as cadherin-11 [13]. Taken together,
the 3D model presented here gives an opportunity to explore these
possibilities relating to EMT as it may occur in vivo in claudin-low
breast cancers and beyond.
Supporting Information
Figure SI Comparison of genes correlating with C35
expression and those identifying the claudin-low pheno-
type. Full details of C35 and claudin-low signatures shown in
Fig. 1.
(TIF)
Figure S2 Claudin-low cell lines exhibit a mesenchymal
morphology. Eight claudin-low cell lines were identified.
Representative live microscopy images of these lines cultured on
plastic are shown. The non-transformed cell line, MCF10A, is
shown for comparison. Bar= 100 |im.
(TIF)
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Abstract Epithelial to mesenchymal transition (EMT)
occurs in embryogenesis and normal development. It has
been predominantly described in vitro and in animal
studies, but EMT is also implicated in the progression of
many cancers with proposed roles in invasion, metastasis
and resistance to treatment. It is closely associated with
loss of epithelial-specific protein expression and up-regu-
lation of mesenchymal proteins, but several pathways are
implicated in its execution. We explored what are the
expression patterns of EMT proteins in human breast
cancer. We interrogated two independent cohorts enriched
for high-grade, invasive, ductal breast cancers. We used
quantitative immunofluorescence to study the expression of
key EMT proteins. Statistical associations to define protein
profiles were based on Pearson's correlations. E-cadherin
down-regulation in breast cancer was associated with
/Tcatenin down-regulation, but not with up-regulation of
mesenchymal markers. While EMT-related transcription
repressors were expressed in some breast cancers, their
expression did not negatively correlate with E-cadherin.
Instead, an additional EMT profile was identified, com¬
posing Snail and Slug. In conclusion, EMT occurs in
human breast cancer in a manner distinct to that seen in
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vitro. Certain EMT events are uncoupled from E-cadherin
down-regulation and may constitute a novel EMT profile,
which warrants further exploration.
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E-cadherin • Breast cancer ■ Neoplasm invasion •
Beta-catenin
Introduction
The trans-differentiation of cells from an epithelial to a
mesenchymal phenotype or epithelial to mesenchymal
transition (EMT), occurs in embryogenesis and normal
development [1], Increasing evidence supports a role for
EMT in the progression of many cancer types including
breast, with critical roles in invasion, metastatic dissemi¬
nation and acquisition of therapeutic resistance [1,2]. EMT
involves loss of cell-cell junctions and re-organisation of
the actin cytoskeleton, resulting in a spindle-like mesen¬
chymal morphology [3]. EMT is associated with decreased
expression of epithelial-specific proteins [4]. Down-regu¬
lation of E-cadherin expression is possibly the most
important consequence of EMT that leads to the changed
behaviour of tumour cells [5, 6]. An important event in
EMT is the switching of expression from E-cadherin,
which becomes down regulated, to N-cadherin, which is
up-regulated [7], Other mesenchymal proteins, such as
Vimentin, are also up-regulated during EMT [8, 9].
E-cadherin down-regulation is usually caused by tran¬
scriptional repression [5]. Several zinc finger containing
repressors have been indentified, including Snail, Slug
(Snail2) and Twist [10]. These transcriptional repressors
interact with E-boxes within the CDH1 gene promoter.
Increased expression of Snail, Slug, and Twist has been
Published online: 26 July 2011 <£} Springer
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associated with poor prognostic clinico-pathological fea¬
tures and outcome in breast and other cancers [11, 12].
We recently compared claudin-low cell lines, which are
enriched for EMT genetic events, to normal human mam¬
mary epithelial cells. Claudin-low cancer cell lines display
uniform down-regulation of junction proteins (E-cadherin
and claudin-7), but more variable up-regulation of Snail,
N-cadherin and Vimentin [4],
Recent evidence indicates that there are reciprocal
interactions between E-cadherin, /J-catenin and EMT-
inducing transcriptional repressors [5], Wnt signalling,
through a nuclear /i-catenin-TCF complex, is capable of
driving EMT by up-regulating Snail in human breast can¬
cer cell lines [13]. In addition, loss of E-cadherin-/?-catenin
junctions at the cell membrane can independently drive
EMT by allowing freed /Tcatenin to relocalise to the
nucleus [14, 15].
The role of EMT in human cancer has predominantly
been inferred from in vitro studies using cell type-specific
markers [16-18]. Its importance in human cancer remains
controversial and data are sometimes conflicting [19, 20].
While EMT in human breast cancer shares common traits
with in vitro models, it may not display all the hallmarks
predicted by them. We have identified recently a genetic
EMT signature common to breast cancer in vitro models
and in vivo [4]. This signature includes the down-regula¬
tion of E-cadherin alongside other cell-cell contact mole¬
cules, but it does not include increased expression of
mesenchymal proteins or EMT repressors.
In order to gain insight into EMT in human breast
cancer at the protein level, we selected two patient cohorts
that maximised the likelihood of identifying EMT-events.
We examined invasive ductal carcinomas of no special
type (IDC-NST). We found that E-cadherin protein
expression was associated closely with /Tcatenin expres¬
sion level. However, E-cadherin down-regulation in breast
cancer was not associated with the up-regulation of other
EMT markers, such as N-cadherin. A distinct EMT profile
containing Snail and Slug was identified in both patient
cohorts.
Materials and methods
Patient cohort selection, exclusion of special type
cancers and tissue microarray construction
We quantitatively determined expression of EMT-related
proteins in the common type of human breast cancer,
invasive ductal carcinoma/no special type breast cancers
(IDC-NST). Down-regulation of E-cadherin is more com¬
mon in invasive lobular cancer (ILC) than in IDC-NST
[21]. ILC and IDC-NST are molecularly distinct [22] and
therefore down-regulation of E-cadherin is likely to occur
through distinct mechanisms in each type.
The first patient cohort (set 1) was enriched for HER2+
breast cancers [18], The HER2+ sub-group usually contain
a minimal number of invasive lobular cancers (ILCs) [23].
This study population consisted of 122 patients with pri¬
mary breast cancer who, subsequently to the analysis
specimens, were treated with trastuzumab in the Edinburgh
Breast Unit, as previously described [18].
The second patient cohort (set 2) was enriched for large,
high-grade breast cancers that had already given rise to
lymph node metastases. The presence of these poor prog¬
nostic features maximised the chance of identifying EMT
events [24]. This study population was derived from an
original population of 521 patients with primary breast
carcinomas treated in the Edinburgh Breast Unit from 1999
to 2002 [25, 26]. Patients with paired lymph node metas¬
tases were selected (143 patients) for tissue microarray
(TMA) construction.
Construction of these sets and acquisition of linked
clinical data was approved by the Lothian Research Ethics
Committee (08/S1101/41): all cases were anonymised once
data linkage had occurred. Tumour areas were selected for
TMA construction on H&E slides and 0.6 mm2 cores were
placed into three separate TMA replicates for each sample,
as previously described [27].
The characteristics of the patient cohorts used to construct
the two TMA sets in this study are summarised in Tables 1
and 2. HER2 and ER scores were reported by us previously
for all of these cases [18, 25], The scores were given during
the clinical process using Allred classification scoring.
Immunofluorescence
AQUA methodology has been described elsewhere [18].
Briefly, antigen retrieval for all epitopes was carried out using
heat treatment under pressure in a microwave oven for 5 min
in citrate buffer pH 6.0. Slides were incubated with primary
antibodies for 1 h at room temperature. Primary antibodies
used: E-cadherin (intracellular), BD, 610181, Mouse, 1:1500;
N-cadherin, BD, 610921, Mouse, 1:300; Vimentin, Sigma,
V6630, Mouse, 1;400; Fibronectin, Abeam, ab2413, Rabbit,
1:10,000; Slug, LifeSpan Bio, LS-C30318, Rabbit, 1:1000;
Snail, Abeam, abl7732, Rabbit, 1:700; /J-catenin, BD,
610153, Mouse, 1:500. The specificity of all antibodies was
verified previously by Western blotting [4].
Rabbit primary antibodies were incubated overnight
with mouse anti-pancytokeratin (Invitrogen, 1:25) to
visualise epithelial cells. Mouse primary antibodies were
incubated overnight with rabbit anti-pancytokeratin (Dako,
1:150) and rabbit anti-pancadherin (Cell Signalling, !:50).
The epithelial compartment was then visualised with Cy3
(Invitrogen, 1:25). DAPI (4',6-diamidino-2-phenylindole)
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Tumour grade Tumour grade
1 1 (0.8) 1 (0.9) 1 4 (2.8) 3 (2.7)
2 18 (14.8) 11 (10.4) 2 72 (50.3) 49 (44.1)
3 99 (81.1) 93 (87.7) 3 67 (46.9) 59 (53.2)
NK 4 (3.3) 1 (0.9) NK 0(0) 0(0)
Prognostic index Tumour size (mm)
>5.4 59 (48.4) 53 (50.0) <20 (Tl) 49 (34.3) 44 (39.6)
3.4-5.4 46 (37.7) 40 (37.7) 21-50 (T2) 84 (58.7) 62 (55.9)
<3.4 2(1.6) 1 (0.9) >50 (T3) 9 (6.3) 4 (3.6)
NK 15 (12.3) 12 (11.3) NK 1 (0.7) 1 (0.9)
Node stage Nodes
Negative 26 (21.3) 24 (22.6) Negative 1 (0.7) 1 (0.9)
Positive 85 (69.7) 75 (70.8) Positive 142 (99.3) 110 (99.1)
NK 11 (9.0) 7 (6.6) NK 0(0) 0(0)
HER2 status HER2 status
Positive 82 (67.2) 73 (68.9) Positive 18 (12.6) 18 (16.2)
Negative 32 (26.2) 30 (28.3) Negative 109 (76.2) 83 (74.8)
NK 8 (6.6) 3 (2.8) NK 16 (11.2) 10 (9.0)
ER status ER status
>3 71 (58.2) 60 (56.6) >3 90 (62.9) 69 (62.2)
<3 39 (32.0) 36 (34.0) <3 53 (37.1) 42 (37.8)
NK 12 (9.8) 10 (9.4) NK 0(0) 0(0)
Nine cases were excluded due to <50% available data. A further 7
cases were excluded (ILC 5, no/insufficient tumour 1, no E-cadherin
data available 1), leaving 106 cases for statistical analysis
Seventeen cases were excluded due to <50% available data. A further
15 cases were excluded (mixed NST/1LC 3, ILC 9, other special types
3), leaving 111 cases for statistical analysis
counterstain (Invitrogen) was used to identify nuclei and
Cy-5-tyramide (HistoRx, 1:50) was used to detect protein
'targets'.
AQUA automated image analysis
Monochromatic images of each TMA core were captured
at 20x magnification using an Olympus AX-51 epifluo-
rescence microscope. These high-resolution, digital images
were individually, manually quality checked to exclude
aberrant imaging artefacts from analysis. All areas of
normal mammary duct and ductal carcinoma in situ (DCIS)
were excluded to ensure that only invasive cancer was
included in the analysis. Images were then analysed using
AQUAnalysis software, as previously described [18].
Statistical analysis methods
Cases with <50% of all available AQUA scores were
excluded from further analysis. Cases lacking in TMA
cores stained and scored for E-cadherin were also
excluded. AQUA scores for each array were log2 trans¬
formed and mean centred. The mean of the three replicates
for each protein target were used for further analysis. For
each replicate, zero is the mean after transformation. After
averaging across the three replicates, zero is not necessarily
the mean of the entire dataset. Associations between vari¬
ables were calculated using Pearson's correlation coeffi¬
cients and differences in means with one-way ANOVA
using SPSS software (vl4). The resulting P-values were
adjusted for multiple-testing using the conservative Bon-
ferroni correction (uncorrected P < 0.0014).
Results
Human breast cancer has a wide range of E-cadherin
expression, highly correlated with /i-catenin
Two patient cohorts containing large numbers of high-
grade invasive breast cancers LI8, 25] were used to gain
insight into possible EMT events and establish whether




Fig. 1 Human breast cancer has a wide range of E-cadherin protein
expression, a Comparable, dynamic ranges of E-cadherin expression
are seen in both TMA sets. AQUA scores for each array were log2
transformed and mean centred (0 represents the adjusted mean for
each individual TMA slide). The mean of three TMA replicates is
shown, b Representative immunofluorescence images (from set 2)
illustrating varying E-cadherin protein expression (left panels, with
pan-cytokeratin mask; right panels, without pan-cytokeratin). Note
the membranous staining of E-cadherin. Cytokeratin green; DAPI -
blue; E-cadherin red. Normalised AQUA scores are given (arbitrary
units). Bars 50 pm in all images
range of membrane/cytoplasmic E-cadherin expression was
seen in both sets (Fig. la). In set 1, an 18-fold range of
expression of E-cadherin was seen. A corresponding
11-fold range was seen in set 2. No correlation between
E-cadherin expression and estrogen (ER) or HER2 receptor
status was observed (data not shown). Qualitative assess¬
ment of immunofluorescence images showed that E-cad-
herin staining remains membranous across all breast
tumours (Fig. lb), similarly to its distribution in the normal
breast (Supp. Fig la). In all cases, diffused E-cadherin
staining could be detected also in the nucleus, although its
functional importance is unknown (not shown).
Tumours with high cytoplasmic /i-catenin expression
were identified (Fig. 2a). Nuclear /i-catenin expression,
although less distinct, was also observed and positively
correlated with cytoplasmic expression (Table 3; Supple¬
mentary Tables 1-2 contain all correlations in this study,
corrected for multiple testing). A positive correlation
between E-cadherin and /(-catenin protein expression was
seen in both patient sets (Fig. 2b and Table 3). This
established that in human breast cancer there is an EMT-
related profile in which concomitant down-regulation of
E-cadherin and /i-catenin occurs.
High expression of N-cadherin and other mesenchymal
markers in human breast cancers
Having identified tumours with relatively low E-cadherin
expression, we examined whether these tumours show
evidence of a 'cadherin switch'. Tumours with high cyto¬
plasmic N-cadherin expression (Fig. 3a) were identified.
Nonetheless, no correlation between E-cadherin and
N-cadherin expression levels was found in either set
(Supplementary Tables 1-2). The lack of a consistent
cadherin switch in human breast cancers is in agreement
with our findings in cell line 3-dimensional cultures [4],
Vimentin and fibronectin are mesenchymal markers that
are up-regulated in EMT in the context of breast and other
cancers [1], As with N-cadherin, tumours with relatively
high cytoplasmic Vimentin and fibronectin expression were
identified (Fig. 3b-c), but no correlation with E-cadherin
expression observed (Supplementary Tables 1-2). Immu¬
nofluorescence images show stromal and epithelial staining
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Fig. 2 E-cadherin and /i-catenin protein expression are highly
correlated in human breast cancer, a Representative immunofluores¬
cence images (from set 2) illustrating tumours with high (left panel)
and low (right panel) expression of /)-catenin. Inset shows nuclear
staining in individual cells (arrows). Cytokeratin green; DAPI blue;
fl-catenin red. b Plots comparing membrane/cytoplasmic and nuclear
/f-catenin expression levels to E-cadherin in both TMA sets (all
P < 0.01 by Pearson's correlation, see Table 3)
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Tabic 3 Significant correlations between protein markers of EMT
Protein marker r value Protein marker
E-cadherin 0.476 (set 1) /1-catenin (cytoplasmic)
0.749 (set 2)
E-cadherin 0.501 /1-catenin (nuclear)
0.724




All reproducible correlations (significant after Bonferroni correction)
observed between protein markers of EMT
for these markers as expected. Epithelial fibronectin
expression was focal in high expressing tumours (Fig. 3c).
No correlation was observed between N-cadherin, Vimentin
and fibronectin expression in these tumours (Supplementary
Tables 1-2). These findings suggest that up-regulation of
mesenchymal markers is unlikely to be a common event and
that tumours that up-regulate one protein marker do not
necessarily up-regulate other markers.
High expression of Snail and Slug in human breast
cancers
Quantitative analysis of transcription repressors was per¬
formed to determine their correlation with E-cadherin
expression and other EMT markers. Tumours with high
nuclear Snail and Slug expression were identified (Fig. 4).
Snail expression is predominantly nuclear, whilst Slug
expression is mostly cytoplasmic (Fig. 4a-b). Cytoplasmic
expression of EMT transcription repressors, including
Slug, has been reported anecdotally in previous studies,
although the functional importance of this is unknown [28].
This expression pattern of Slug is not seen in ovarian
cancers (Supplementary Fig 1).
No correlation of E-cadherin expression with either Slug
or Snail was observed (Supplementary Tables 1-2). In
addition, protein expression of Slug and Snail did not differ
significantly between ER— and ER+ tumours (not shown),
as suggested using immunohistochemical methods [29],
Correlations between markers of EMT identify two
distinct profiles in human breast cancer
Protein markers of EMT with reproducible, significant
correlations across both patient sets are shown in Table 3.
Univariate analysis showed no significant correlations
between the markers of EMT investigated in this study and
patient survival (not shown). Down-regulation of E-cad-
herin significantly correlates with down-regulation of
/(-eatenin (Fig. 2b). In a second EMT event profile, the
expression of Snail correlates with Slug (Fig. 5). These
observations were reproducible in both sets (Supplemen¬
tary Tables 1-2). Interestingly, in Set 1, Snail correlated
Fig. 3 High expression of
mesenchymal proteins is found
in human breast cancer.
Representative
immunofluorescence images
(from set 1) illustrating tumours
with high (left panels) and low
(right panels) expression of
a N-cadherin, b Vimentin and
c fibronectin. Corresponding
E-cadhcrin expression is shown
in each case. Note the stromal
(short arrow) as well as
epithelial (long arrow)





N-cadherin = 2.03 E-cadherin = 0.55 N-cadherin =-0.88 E-cadherin = -0.63
Vimentin = 1.57 E-cadherin = 0.73 Vimentin = -0.82 E-cadherin = 0.34
Fibronectin = 0.75 E-cadherin = 0.26 Fibronectin = -1.41 E-cadherin = -0.36
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Fig. 4 High expression of Snail
and Slug in human breast
cancer. Representative
lmmunonuorescence images
(from set 1) illustrating tumours
with high (left panels) and low
(right panels) expression of
a Snail and b Slug.
Corresponding E-cadherin
expression is shown in each
case. Note the clear nuclear
expression of Snail whilst Slug
is predominantly cytoplasmic.
Cytokeratin green; DAPI blue',
Snail/Slug red
Snail = 0.66 E-cadherin = 0.57 Snail = -2.14 E-cadherin = -0.50





Fig. 5 Correlations between protein markers suggest a second EMT
profile in human breast cancers. Plots illustrating the correlations
between Snail and Slug as identified in Table 3
with /(-catenin (cytoplasmic and nuclear) expression. Slug
correlated with N-cadherin and Vimentin protein expres¬
sion (Supplementary Table 1). This may reflect unique
roles for these EMT transcription factors in HER2+ breast
cancers.
Discussion
EMT is believed to be a mechanism that allows cells to
acquire an invasive phenotype [2], There is accumulating
evidence that EMT may not be a single, conserved pro¬
gramme [19]. Partial or incomplete EMT phenotypes, where
advanced carcinomas display some mesenchymal features
whilst retaining characteristics of well-differentiated epi¬
thelial cells, have been described in several studies [30]. A
recent systems analysis has suggested that in partial EMT in
vitro, loss of epithelial components is more uniform than the
gain of mesenchymal components [31], Until now, EMT
features were foundmainly in ER- subtypes of breast cancers
and in some mouse models [9]. Basal-like cancers contain
higher levels of N-cadherin and Vimentin, but only some
down-regulate E-cadherin. Notably, /Tcatenin expression is
more prevalent in this sub-type [32]. Two other sub-types,
namely claudin-low and metaplastic breast cancers display
strong down-regulation of E-cadherin and other junction
proteins, but more variable up-regulation of markers such as
EMT transcription factors [4, 8, 33], The current study is a
more global analysis of EMT proteins in invasive human
breast cancers, building on previous studies showing
that cytokeratin-expressing breast epithelial cells may
co-express mesenchymal proteins such as Vimentin [8, 9],
We examined EMT in human breast cancer by investi¬
gating the expression of key protein markers and the
associations between them. We tested two hypotheses:
(i) IDC-NSTs expressing low levels of E-cadherin undergo
cadherin switch to N-cadherin and (ii) that this is driven by
known transcriptional repressors of E-cadherin. We also
investigated /1-catenin nuclear translocation in these can¬
cers as an alternative mode of EMT.
Two EMT profiles were identified in invasive breast
cancers. Each of these profiles presents some of the EMT
events as seen in vitro. Using quantitative immunofluo¬
rescence analysis, we identified a dynamic range of
E-cadherin protein expression across two patient cohorts.
Our findings suggest that co-expression of E-cadherin and
/Tcatenin at cellular junctions is maintained in the majority
of human breast cancers [34]. A significant, positive cor¬
relation between E-cadherin and /i-catcnin was seen, but
without an apparent patient outcome association. Positive
correlations between E-cadherin and /j-catenin in human
breast cancer with no correlation to outcome have been
described using immunohistochemical methods [35]. These
and our findings are in contrast to a different report in
which a significant correlation between loss of /Tcatenin
and poor clinical outcome [36], The lack of cadherin
switch in this profile is consistent with our previous
observations in cell line models [4].
"£) Springer
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The correlation between Snail and Slug suggests that a
transcriptionally driven EMT mechanism may also be in
place in human breast cancer. This profile is uncoupled
from down-regulation of E-cadherin, unlike what is found
in cell line models [4], This suggests that EMT does occur
in vivo but in a manner distinct from that suggested by in
vitro studies. A number of studies support our findings. In a
series of human breast invasive ductal cancers with asso¬
ciated lymph node metastases, both Snail and Slug were
significantly over-expressed at the mRNA level. Impor¬
tantly, expression of Snail or Slug did not preclude sig¬
nificant E-cadherin expression [28]. Twist expression could
not be reported here due to the poor specificity of com¬
mercially available antibodies. In cell lines, Twist expres¬
sion induced up-regulation of both Snail [37] and Slug
[38], as well as down-regulation of E-cadherin and
jS-catenin protein expression [38],
In conclusion, our observations of EMT events in breast
cancer manifest in two distinct profiles. These validated
profiles give first comprehensive insight into EMT in
human breast cancer. This should enable more fitting
applications of EMT knowledge gained in vitro in the
clinical setting.
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